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Part I Introduction
Human brain research has gained tremendous momentum in recent years and unquestionably will 
continue emerging as a result of our ability to record, image and modulate brain processes. As our 
knowledge about fundamental brain processes increases, clinical neuroscience advances at a rapid pace. 
As a result, it might often be necessary to step back for a while to give room to both carefully reflect on 
how the field is developing and critically appraise knowledge gains and their therapeutic applications.
Section I: Clinical aspects of modulating behaviour and affect through 
Deep Brain Stimulation
SUMMARY:
The papers which are part of this cumulative dissertation have in common that they discuss deep 
brain stimulation (DBS) for investigating clinical and ethical aspects of neuromodulation interven-
tions with a particular emphasis on assessing complex behavioural and affective changes. First, I will 
outline the intervention itself combined with the clinical relevance of this type of intervention and a 
preview on technological developments. Secondly, I outline the significance of DBS for basic research 
and clinical neuroscience together with some recent notions on how unwanted behavioural and affec-
tive side-effects might emerge. Finally, I briefly outline the connection between the basal ganglia (i.e. 
the neuroanatomical loci most frequently used in DBS interventions) and their role in establishing 
certain behaviours and emotions. In summary, I argue that given the clinical relevance DBS holds and 
the still unknown mechanism of action, DBS has revealed more about how the brain works than how 
DBS works and this particularly through successful electrophysiological research. Besides other im-
portant investigations, such research brought back to the fore the importance of electrophysiological 
processes in human brain research. Given the emphasis on electrophysiology, performed research in 
recent years contributed to new disease models emphasising the network architecture of the human 
brain. Next, I argue that the difficulty of stimulating a given target with the requisite precision is one 
key contributing factor leading to the existence of complex changes. The last paragraph finally bridges 
empirical neuroscience with morality in that it outlines the neurophysiological importance of the basal 
ganglia in our ability to achieve executive control, a key function in the context of moral behaviour.
1.1 Deep Brain stimulation: Procedure
Iconic figures such as Walter Hess and Jean Siegfried from Berne and Zurich respectively, repre-
sent two prototypes who have been actively involved in DBS development. While Jean Siegfried 
treated patients suffering from chronic pain in 1976 with DBS and performed a first intervention for 
movement disorders in a dyskinesia patient in 1982, Walter Hess performed experimental brain sti-
mulation in cats already in the 1940’s. Walter Hess, who was later awarded the Nobel Prize in Medicine 
(1949), was director of the physiological institute of the University of Zurich. Although thalamotomy 
represented an established target in the treatment of tremor, the idea to use stimulation as a therapeutic 
modality did not emerge until Benabid’s preliminary report in 1987 (Benabid et al., 1987) on stimu-
lation of the Vim (ventral intermediate nucleus of thalamus). Benabid and the Grenoble group inclu-
ding Pierre Pollak, who now works in Geneva, pioneered chronic stimulation of the STN for PD 
and reported their first patient in 1994 based on the findings from animal experimentation (Benabid 
et al 1994, Pollak et al 1993). Hence, the roots of DBS can be traced back to France and Switzerland.
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DBS represents a symptomatic therapy and currently is offered as escalation therapy only. It compri-
ses a high-precision method in which a patient is implanted one or two electrode leads into a specific 
brain region, usually located in the basal ganglia. Electrodes are inserted into the brain via burr ho-
les in the skull using neuroimaging-guided stereotactic neurosurgery. Leads typically contain several 
contacts and are connected via a subcutaneously implanted pulse generator (IPG) in the clavicular or 
abdominal region containing the systems battery and computer that drives stimulation. Despite a lack 
of proven (patho-)physiological-based evidence, typically used parameters in clinical settings for the 
treatment of Morbus Parkinson include frequencies of 130 Hz, pulse widths of 60-90 µs and intensi-
ties of 1 to 4 Volts. Stimulation of neuronal tissue at any frequency evidently excites various neuronal 
elements, including (mostly) myelinated axons in vicinity of the electrode. After the induction of an 
action potential, it may flow in orthodromic and antidromic directions. It is likely that the therapeutic 
effect has more to do with stimulating the axons than with the stimulation of neurons within the 
target. Apart from hardware related complications (e.g. lead migration or fracture), risks of this type 
of intervention (such as infections, haemorrhage) are comparable to other brain surgeries, less risky 
compared to tumor resections and repeated minor surgery is required for IPG replacement only. In 
addition, DBS is said to be a reversible and adaptable procedure. The integration of precision medicine 
of this sort into the therapeutic landscape requires multidisciplinary teams of highly qualified experts.
1.2 Clinical relevance of deep brain stimulation
During the last 25 years, tens of thousands of patients have been treated with DBS (Lozano & Lips-
man, 2013) suffering from the most debilitating symptoms of a multitude of disorders. Early lesion 
studies in humans and laboratory animals aiming at interrupting putative circuits together with sti-
mulation experiments marked the origin for the development of DBS. Since the beginning of the tre-
atment of mainly tremor-dominant Parkinson patients through thalamic high-frequency-stimulation 
(HFS) till today, knowledge gained from DBS as both a probe and modulator of the underlying neural 
circuitry resulted in a new way of describing and understanding (neuro)-pathologies. Likewise, the 
rapid development reached a non-undisputed (Hariz et al., 2013) broadening of therapeutic spectrum 
ranging from the treatment of neurological disorders, such as chronic pain, epilepsy and movement 
disorders (mainly essential tremor, dystonia and Parkinson’s Disease) to neuropsychiatric disorders, 
such as obsessive compulsive disorder and depression, to name a few. DBS unquestionably is a remar-
kable therapy and has been shown to be more effective than best medical treatment for some disorders. 
Unlike pharmacological treatment, for some patients suffering from different disorders of the brain, 
the improvement with DBS is present at the click of a switch. The nearly instant improvement of many 
neurological disorders, for neurologists, provides a gratification not usually afforded in this discipline.
1.3 Prospects of technological deployments
In order to minimize stimulation-induced adverse events (described in „Section II: The ethics of 
behavioural and affective changes following DBS“), the following future technological advances are 
under way: First, closed-loop devices are believed to symbolize next-generation DBS devices. They 
are characterized by their capability to detecting errors through feedback and by automatically ad-
justing the critical parameters in response to changes in the brain. Hence, they can correct stimula-
tion on their own depending on electrophysiological or neurochemical imbalances (Abbott, 2006; 
Potter et al., 2014, Rolston et al., 2010). Secondly, the potential of field-steering for shaping the 
stimulation to target anatomy by overcoming conventional annular DBS electrode configurations 
provides a promising mean. Generally, two main approaches, both aiming at field steering, are being 
pursued: (1) segmented DBS electrodes based on mechanically assembled leads and (2) DBS elec-
trode arrays. Finally, and because neurons and glia communicate at a micron to submicron level, 
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the development of (PPy-coated) carbon-nanofiber-electrodes, if achieved in the near or far future, 
will permit greater sensitivity in recording electrical activity and greater safety, precision and hence 
efficacy in stimulating brain tissue. Vascular malformations and tumors located very distal to the 
major arteries of the circle of Willis are nowadays catheterized routinely. Electrodes within blood 
vessels supplying nervous system tissue can record and stimulate electrical activity as effectively as 
electrodes in the parenchyma adjacent to the blood vessels (Llinas et al., 2005). The idea of newly 
fabricated nanofiber-electrodes which have already been tested in vitro and to a minimal extent 
in vivo, is to enter the brain’s capillary system minimally invasively and precise placement of the 
electrodes (dozens or hundreds, if desired) anywhere in the brain. Because red blood cells have a 
diameter in the µm-range, it is even possible to enter the parenchyma without the risk of bleeding 
from capillary wall puncture (Andrews et al., 2012). However, this  idea is still largely hypothetical.
1.4 Balancing the brain
After the initial usage of ventriculography 25 years ago with which help one is able to only visualize 
two landmarks in the three-dimensional brain, the anterior - and posterior commissure, the enormous 
progress in visualizations provided by MRI techniques together with the development of stereotactic 
frames (Hariz et al., 2010) paved the way for individualized lead implantation and DBS as a means for
modulating the brain.
Over the last three decades, a large number of patients have been helped by DBS, yet a compre-
hensive scientific understanding of the underlying mechanisms of action is still missing. As a mat-
ter of fact, DBS has revealed more about how the brain works than about how DBS works and 
has proven that current notions of pathophysiology, particularly of basal-ganglia disorders, are sim-
ply wrong (Montgomery, 2007): recent studies showing that both pathways, the direct and indi-
rect cortico-basal ganglia pathways which were believed to exert opposing effects, are activated du-
ring the initiation of action, the stopping of action and the initiation of a behavioural sequence 
(Jahanshahi  et al., 2015) depart from the linear “push-pull”, direct-indirect dichotomy. Also, ac-
cording to the GPi Rate Theory, overactivity of the GPi is assumed to cause the motor dysfuncti-
on of PD and that decreased GPi activity frees ventrolateral thalamic neurons from inhibition ge-
nerating involuntary movements such as dyskinesia. However, studies show that DBS of the STN 
and GPi drives GPi activity (Montgomery & Gale, 2008) and that this increased activity facilita-
tes movements in patients with PD. Stimulation of neuronal tissue at any frequency evidently ex-
cites various neuronal elements, including (mostly) myelinated axons in vicinity of the electrode. 
After the induction of an action potential, it may flow in orthodromic and antidromic directions. 
Because DBS provides the exceptional opportunity to probe brain function and dysfunction, as 
evidenced by the previously outlined example of e.g. Montgomery and Gale, it provides a substrate 
for investigational research by e.g. recording from implanted electrodes. It is possible to record elec-
trophysiological changes (altered firing rates and patterns, pathologic oscillatory activity and increa-
sed inter-neuronal synchronization) of neurons in the basal ganglia and related regions in thalamus 
and cortex by e.g. single-cell recording techniques. Moreover, changes in joint spiking activities at a 
neural population level can be observed by deploying local field potentials (LFPs), electroencepha-
lograms (EEGs) or electrocorticograms (ECoGs) (Galvan et al., 2015). It can also be coupled with 
neuroimaging, and genetic profiling studies. Many hypotheses about network dysfunctions contri-
buting to pathological states emerged as a result of such investigations (e.g. increased oscillatory po-
wer in the beta frequency band in PD, Hammond et al., 2007). In PD, the loss of diencephalic 
dopaminergic cells may lead to unbalanced basic oscillations between cortex and subcortical regions. 
In light of this, DBS serves as an important tool for rebalancing resting state network activity in 
brain disorders (Kringelbach et al., 2011). Hence, DBS represents an important tool both for allevia-
ting human suffering and for obtaining novel insight into the nature of fundamental brain function.
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It has long been a lost notion, that the brain is to a great extent an electric device and as a result 
has properties uniquely instantiated in the electrical activities distinct from those of neurotransmit-
ters (see L. Galvani, or Giovanni Aldini who published an influential book that reported expe-
riments in which the principles of Luigi Galvani and Alessandro Volta were used together for 
the first time over 200 years ago). While neuro-(psycho)-pharmacology was and still is a dominant 
force in the investigation and treatment of brain diseases, the introduction of DBS contributed to 
the notion that electrophysiology plays a crucial role both for the understanding of the interven-
tion itself, but also for the investigation and characterization of distinct electrophysiological fin-
gerprints of diseases of the brain. As a result, from initial hypotheses stating that e.g. psychiatric 
disorders are caused by chemical imbalances (e.g. monoamine hypothesis of depression), to more 
complex theories that involve brain circuit interactions and plasticity, research aimed at unraveli-
ng the mysteries of brain disorders and has allowed the development of network models of disea-
se (e.g. Llinas (1999) coined the concept of “network-dysrhythmia” or McIntyre & Hahn, 2010 
who highlighted the notion of the interplay of pathological oscillations in a network). In fact, the 
emphasis on the neuron doctrine introduced by Cajal by emphasizing the individual neuron may 
have contributed negatively to the exploration of recurrent network models with emergent properties 
(Yuste, 2015). Still, quantitative outcome metrics and biophysical markers are needed for a better 
definition and more accurate classification of brain disorders on the basis of their etiological and 
pathological aspects. As important is the need to carefully document neurobehavioural outcomes.
Undesired behavioural side-effects, in the meantime, are construed as emanating from the complex 
interplay of drug-reduction, electric current spreading into the neighboring  tissue and the progression 
of the disease. In fact, the often observed sequelae involving apathy, mania, speech problems (among 
others) may result from not stimulating targeted circuits with the requisite precision, overstimulating 
them, or from expanding effects to other circuits. Focused stimulation is challenging because many 
brain functions and the physical and mental capacities they mediate involve distributed and interac-
ting neural pathways that send projections to and receive projections from each other. For example, 
the subthalamic nucleus in the basal ganglia is one of the areas stimulated to restore motor control in 
Parkinson’s disease (PD). Yet the subthalamic nucleus, and with it the basal ganglia, as will be outlined 
below in some more detail, consists of a complex network involving not only a motor circuit but also 
associative and limbic circuits mediating cognitive and emotional processes. For example, the compul-
sive behaviour of some PD patients receiving DBS may be explained by unintended excitatory effects 
on the limbic circuit (Castrioto et al., 2014). Particularly the recent notion of re-entrant network 
loops reflects both the complexity of positively influencing a certain function without influencing yet 
another function but also shows that theoretically, DBS can modulate output function at any point 
of the loop. Recent results clearly demonstrate that once believed, highly segregated circuits are in fact 
interconnected to a higher degree. This is exemplified by referring to the once believed segregation of 
D1 and D2 medium spiny neurons (MSN) which faded into thin air after demonstrating extensive 
cross-talk (Calabresi et al., 2014, Kupchik et al., 2015). The D1-D2 distinction refers to the direct 
and indirect basal ganglia pathway concept (as outlined above). It is believed to adequately describe 
the promotion and inhibition of movements in a highly segregated fashion and still is the most often 
used model for (1) describing the emergence of PD, a hypokinetic movement disorder, as well as 
(2) pinpointing potential therapeutic effects of DBS. Hence, the notion of a modular organization 
of the brain has probably to be replaced by more recent dynamic network models. According to the 
modular organization, specific areas in the brain perform specific functions. Although these functions 
are being integrated to cause a final behaviour, the integration is fragmentary and often sequential. 
In the meantime, there are other conceptualizations such as the Systems Oscillators theory which 
appears to be more precise and less contradictory in describing brain function. This theory refers to 
the brain being composed of sets of loosely coupled interconnected networks of oscillators made 
up of reentrant activity in closed feedback circuits. After this notion, physiological and behavioural 
functions are distributed throughout the network rather than restricted to a specific structure that 
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implies a given function. Hence, a desired function can be targeted by DBS anywhere within such a 
network. In sum, current knowledge rather leads away from one-dimensional, sequential push-pull 
theories (e.g. of simple over- and underactivity) for the sake of conceptualizations which point at 
nested or interconnected oscillators representing many different frequencies (Montgomery, 2007).
However, it is important to add that the above delineation which involves the conception of net-
work-diseases bears the danger of exclusively focusing on objective electrophysiological and neuroche-
mical measures of brain activity which may ignore the phenomenological aspect of having a neurologi-
cal or psychiatric disorder. It is persons rather than neural circuits that have and suffer from diseases of 
the brain (Glannon & Ineichen, 2016). Thus, the medical, psychological and social needs generated by 
these diseases are in the sum vital parameters that should be considered at any time of the therapeutic 
process. To narrow down the network-physiology of disorders of the brain is a necessary but not a suf-
ficient undertaking. What it means to live with a neurological or psychiatric disorder is often expressed 
by a multitude of other factors including behavioural and affective reactions. Such reactions are a central 
component of the therapeutic but also the investigational process aiming at explaining a brain disorder.
1.5 The Basal Ganglia: From neuroanatomy to behaviour and affect
As implied previously, the basal ganglia are the primary target for DBS interventions. In what 
will follow, I briefly outline how the basal ganglia can exert behavioural and affective function.
The basal ganglia are subcortical nuclei consisting of the nucleus caudate, putamen, substantia nigra 
(SNr and SNc), the subthalamic nucleus, the globus pallidus (GPi and GPe) and the nucleus ac-
cumbens together with the greater part of the olfactory tubercle and the rostral part of the substantia 
innominata (Nieuwenhuys et al., 2007). Besides being connected to motor cortical areas (motor cor-
tex, supplementary motor area (SMA), premotor cortex, cingulate motor area and frontal eye fields), 
the basal ganglia connect to a lot of non-motor areas of the cortex and subcortical structures, inclu-
ding the superior colliculus, the pedunculo-pontine nucleus (PPN), the periaqueductal or central 
grey (PAG), the amygdala, the dorsal raphe nuclei, the pontine nuclei and the medullary reticular 
formation. Traditionally, the basal ganglia have been considered to be important for producing beha-
viours mainly by their inhibitory action in motor domains. Hence, they are implicated in disorders of 
movement such as PD, but also in Tourette Syndrom (Ts) or obsessive compulsive disorder (OCD). 
However, the role of the basal ganglia has expanded from motor-based conceptualizations to co-
gnitive and emotional domains. The basal ganglia orchestrate output through neuronal inhibition, 
disinhibition and facilitation, processes that allow flexible interactions and which are the essence of 
executive control. At least in the classic model, the output nuclei (GPi and SNr) hold the cortex and 
superior colliculus under tonic inhibition to prevent inappropriate (i.e. maladaptive) movements and 
can phasically release this inhibitory control to allow movements (Jahanshahi et al., 2015) if MSNs 
are in the physiological upstate and enough dopamine is present (Da Cunha et al., 2015). Exe-
cutive control, for example, is important to override habitual or prepotent responses. It constitutes 
appropriate and context-specific inhibition and facilitation which is relevant to our ability to control 
our emotions, focus our attention, exert self-control and engage in behavioural regulation necessary 
for social interaction. Therefore, adaptive behaviour owes as much to taking appropriate action as 
to inhibiting or suppressing contextually inappropriate or socially unacceptable behaviour. Hence, 
the basal ganglia are important nuclei in facilitating or inhibiting certain behaviours. Notably, the 
inhibitory action is difficult to observe and hence perhaps underestimated (Jahanshahi et al., 2015).
Apart from the previously described connections, it is noteworthy to add that the nucleus accumbens 
(NAc) receives strong dopaminergic inputs from the ventral tegmental area (VTA) and is part of the 
medial forebrain bundle, a target which is used for the treatment of refractory depression via DBS. The 
NAc furthermore is well characterized as a hedonic hotspot. Hence, these structures are implicated in 
motivation and the support of goal-directed behaviours and can trigger addictive behaviours. Secondly, 
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important connections comprise the amygdalostriatal projection (implicated in fear-responses and hen-
ce also implicated in MDD) which is distributed to all parts of the caudate-putamen complex and the 
numerous connections of the basal ganglia with the hippocampus (associated with procedural learning 
and working memory) and the mesencephalic raphe nuclei (a serotonergic center implicated in MDD).
Parkinson’s disease is also a disorder of executive control and DBS mainly targets nuclei 
in the basal ganglia. Hence, the dysexecutive syndrome which is described as a dysfuncti-
on in executive functions such as planning, abstract thinking, flexibility and behavioural con-
trol, often manifests in patients suffering from PD. Given the above described influences of 
the basal ganglia which reach far beyond mere motor control, complex behavioural and per-
sonality changes are likely to occur following basal-ganglia-DBS surgery and stimulation.
Lack of context-appropriate inhibitory control leads to impulsivity which includes risk taking, reflec-
tion impulsivity and aversion to delayed gratification and is implicated in many neuropsychiatric dis-
orders. Thus, impulsivity can form the basis of one typ of complex behavioural and personality-related 
changes following DBS interventions. Hence, inhibition (and more specifically proactive as opposed 
to reactive inhibition) allows for self-regulation of emotion, behaviour and thoughts. Pathological 
non-motor inhibition, in contrary, is common in attention deficit hyperactivity disorder (ADHD) and 
OCD. Among others, a range of impulse-control disorders (ICDs) including pathological gambling 
and hypersexuality have been described as attributable to dopamine agonists in patients suffering from 
PD. Such behaviours reflect impaired behavioural regulation based on changes in mesolimbic dopami-
ne pathway. Consistent with the proposed role of the STN in inhibitory control, damage to the STN, 
the most common DBS target for PD patients - through infarction or tumor -, can result in behaviou-
ral disinhibitions such as hypersexuality, hyperphagia, logorrhoea and disinhibition of mood, impul-
sivity and aggression. STN-DBS in some studies resulted in mirthful laughter (Krack et al., 2001), in 
acute sadness and crying when stimulating a lower contact residing in the SN (Bejjani et al., 1999) or 
in the onset of new ICDs after surgery (Moum 2012, Lim 2009). However, while DBS can worsen or 
cause the development of ICDs in some cases, it can also be an effective (indirect) treatment (Broen et 
al., 2011). In sum, DBS of the basal ganglia in general can produce changes in cognition, emotional 
state and self-regulation. Such effects are attributable to both failure of inhibition such as impulsive, 
perseverative or disinhibited behaviours and excessive inhibition. Failure of inhibition include frontal 
lesions, trichotillomania, mania, Ts, OCD, ICD and hemiballism, chorea and dyskinesias whereas 
excessive inhibition comprise akinesia (including freezing), abulia and apathy (Jahanshahi et al., 2015).
In fact, executive control (or self-regulation) is an important topic in evolutionary anthropolo-
gy and also in models trying to describe the genealogy of morality. Apart from the notion that the 
capability of inhibiting certain instincts might be a true Specificum Humanum, it is adaptive to 
possess the ability to, in cases of competing goals, not only give room for the stronger instinct but 
to be able to consider prospect of success and the like. Sometimes, it might be better to wait for 
a while and to follow another, yet less important goal in the meanwhile. In the tradition of Ar-
nold Gehlen, an important figure in philosophical anthropology, this phenomenon was termed 
the Hiatus of self-control (Gehlen, 1966, p.35f). Being able to inhibit certain goals for the sake of 
other executive plans - possibly only experienced in a modus of anticipation -, implies the develop-
ment of a complex sense of time including anticipation and foresight. In fact, not only future ac-
tions have to be anticipated but also the motivational moods and motives which help coordinating 
the respective action. As a result, executive control can be conceptualized as a defining characteristic 
of morality. To put aside own desires, particularly if perceiving that intentions and goals of others 
might be harmed, can symbolize a defining property of morality. Also Wallace (Wallace, 1994) ar-
ticulated that free autonomous agents must possess the powers of „reflective self-control“. This very 
idea, that autonomous agency involves the capacity to stand back from and evaluate one’s first-or-
der desires is widely shared by philosphers of both a Humean and a Kantian cast (e.g. Bratman, 
2000 or Kennett, 2001). Finally, self-regulation relates closely to the definition of Moral Intel-
ligence, a psychologically informed framework outlined at the end of part II of this introduction.
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In sum, DBS, by interfering with the predominantly inhibitory basal-ganglia action leading to 
disinhibition of various nodes in the network and by exerting effects on concomitant medication, 
is thought to exert effects on behaviour and affect which might well extend to a moral domain. It 
is for this reason that the development of an instrument for measuring moral competencies is de-
cisive (see „C. The problem of conflicitng outcome interpertations following DBS intervention“).
Section II: The ethics of behavioural and affective changes following 
DBS
SUMMARY:
In the second part of this introduction, I shift the focus to the ethical analysis of complex chan-
ges. I argue that the general topic can be framed by a process logic which involves an intervention, 
potentially leading to complex changes which may lead to conflicting outcome interpretations ulti-
mately leading to suboptimal clinical outcomes. The first construct involves an ethical intervention 
assessment, which is central to ethics analysis in general and can be structured by incorporating two 
general principles namely beneficence and non-maleficence. Next, I provide examples of complex be-
havioural and affective changes and argue that the intervention assessment is non-trivial, as complex 
changes can result from a potentially ongoing neurodegenerative process, drug reduction, stimulation 
and their interrelation. The evaluation of complex changes which transcend mere side-effects and 
hence extend towards a moral domain is likewise non-trivial due to the relativistic nature of mora-
lity (i.e. moral jugments often depend on context and time and hence can be framed according to 
inner-societal disagreement and evaluation instability over time). I next argue that complex changes 
are especially problematic if undermining the autonomy of the patient. As a result, and when dealing 
with conflicting outcome interpretations (i.e. between patients, their relatives and clinical experts), a 
relational understanding of autonomy becomes important. Hence, I discuss the importance of giving 
the patients and their surroundings the necessary time to prepare for changes that are to be expec-
ted within a context of shared-decision making. Given the fact of occurring ICDs post-DBS, the 
discussion requires an analysis of potentially dysfunctional psychological competences such as abili-
ties relating to moral sensitivity, decision making or behavior, which are hardly the basis of current 
assessment processes. Hence, after having outlined the promising basis of DBS for efficacy testing 
as well as the importance of evaluating psychological competences, I argue for the importance of de-
veloping psychologically informed instruments in order to measure pre-post DBS effects which are 
meaningful for patients and their surroundings. The fact that autonomy, besides other abilities, also 
requires moral competencies stipulates the previously formulated need of new instruments in order 
to quantify the latter. I refer to a recently developed framework termed Moral Intelligence and 
end the introduction by attributing explanatory power to our newly built instrument when dealing 
with conflicting outcome interpretations and the circumscription of complex changes following DBS. 
After Henrik Walter, “good philosophy needs a dab of speculation, which, however, should be firmly 
anchored in historical and empirical knowledge.” He further states that “we can consider neurophilosophy 
as a discipline that moves in on the mind-brain problem from two opposite directions. Either we begin on 
the empirical side and happen upon philosophical questions, or we set out with philosophical puzzles and 
need empirical findings to solve them” (Walter, 2001). Hence, the appropriate strategy is neuroethical re-
search translated, bi-directionally, between empirical (pre)-clinical neuroscientific research and normati-
ve philosophical reflection. However, my approach is closer in spirit to the first method Walter describes. 
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Contrary to empirical research, the thoughtful inquiries into the ethics of neuromodulation repre-
sented in numerous publications nicely demonstrate the many areas in which ethical analysis can 
contribute to clarity of thought – not by removing doubt but by introducing it (Radden, 2004). 
The following section on normative considerations of the ethics of behavioural and affective ch-
anges following DBS interventions is structured along the process logic visualized in Figure 1. It 
aims at providing a simplified overview of the three main components which will be discussed below.
Disease,
Intervention
(Drugs or DBS)
Complex
behavioural and/or
aective changes
Conicting
outcome
interpretations
(A) (B) (C)
Fig1. Framework for structuring the normative part of this dissertation. Both a disease or any type of intervention 
targeting the central nervous system (CNS) (A) can lead to complex behavioural and/or affective changes (B) which not 
rarely are the cause for conflicting outcome interpretations (C) and hence influence the general assessment of the inter-
vention.
After having provided information on component (A) and (B) from an empirical point of view in 
Part I of this introduction, I shall now proceed to its normative assessment.
A. Intervention-assessment
The evaluation of any type of intervention targeting the human CNS, but also many of the questions 
which will be addressed in this cumulative dissertation later on, fall within the field of Neuroethics 
(NE). NE can be defined broadly as the study of ethical issues pertinent to knowledge about the central 
nervous system. It pursues two aims: evaluating the ethical consequences of findings, methodologies and 
tools used in neuroscience (Part II of this introduction), and analyzing the consequences of knowledge 
gained in neuroscience on human moral agency to our understanding of ethics (Illes & Raffin, 2002, 
Roskies, 2002) („1.5 The Basal Ganglia: From neuroanatomy to behaviour and affect“). Hence, the field 
represents a branch of bioethics concerned with ethical issues arising from investigating, monitoring and 
modulating the central nervous system. There are many neuroscience-society tension points which foster 
and justify the relevance of NE (e.g. pharmacological enhancement, lie detection using neuroimaging, 
use of biomarkers to predict human behaviour or mental disorders, free will and personal responsibility). 
NE tries to bridge empirical brain sciences, normative ethics, philosophy of mind, law and social sciences.
Generally, the assessment of whether and to what extent the procedures and drugs aiming at helping 
patients suffering from diseases of the brain can benefit or harm them is a key issue of NE. Actions benefit 
the patient when they satisfy their interests and they harm patients if they defeat their interests. Hence, 
assessing the severity of prospective side-effects together with the potential for symptom relief is necessary 
to evaluate whether a course of action is obligatory, prohibited or permissible. In the context of an inter-
vention-evaluation, the principles of beneficence and non-maleficence are of particular importance and 
often represent a straight-forward way for assessing whether to endorse a certain treatment strategy or not. 
The principle of non-maleficence, one of the two core bioethical principles which can be traced 
back to the Hippocratic Oath, refers to primum non nocere (first, do no harm) and includes 
the promise to abstain from doing harm, is particularly important in this context. Hence, the topic 
of dealing with side-effects itself unequivocally represents a source for ethical investigation. The ad-
herence to the principle of non-maleficence first and foremost implies that one is able to assess ne-
gative effects. Hence, there is a direct link to the problem of measuring complex unintended effects. 
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This measurement problem of component B (Fig1) („B. Complex behavioural and affective changes“) 
which complicates the assessment regarding the underlying risk-benefit ratio, will be discussed at the 
end of this introduction in the context of component C (Fig1) („C. The problem of conflicitng out-
come interpertations following DBS intervention“) dealing with conflicting outcome interpretations. 
For now it is enough to say that if one is unable to measure potential changes with the requisite pre-
cision, consequently one is unable to decide whether the current practice complies with the general 
duty of non-maleficence. Additively, this complexity is likely to increase because some side-effects 
are controversially evaluated by different stakeholders (e.g. patient and his partner) (see component 
(C), Fig 1 „C. The problem of conflicitng outcome interpertations following DBS intervention“).
The duty of beneficence, a second core bioethical principle, could be described as the duty to pro-
mote the good of others and reflects a general duty of any medical intervention. This duty must 
be balanced against the duty of non-maleficence in order to verify whether a positive risk-benefit 
ratio results. In the context of the principle of beneficence, the following ethical questions emerge: 
Firstly, and as implied in the first part of this introduction, the feeling of beneficence (e.g. happi-
ness, well-being, absence of pain) has itself a neuronal basis and can be modulated by DBS and or 
medications (Synofzik et al., 2012). This implies that the assessment of potential beneficial effects 
of a DBS intervention can become heavily obscured and could point at the need for an a-priory 
definition and consensus on what “beneficence” means in a particular treatment approach. Second-
ly and in what will be discussed later, DBS can result in complex behavioural changes (see com-
ponent (B), Fig 1 „B. Complex behavioural and affective changes“) which are evaluated positively 
by the patient, but which can have consequences on the beneficence of his/her social surrounding.
B. Complex behavioural and affective changes
Characterizing complex behavioural & affective changes
Based on the first part of this introduction, we can summarize the following: Even if not ac-
cepting a reductive-materialists theory, most scholars would agree nowadays that the brain 
plays an exceedingly important role in the formation of who we are as a person. This is not res-
tricted to the notion that the brain holds the capacity to produce a myriad of different beha-
viours. As a result, it is evident that changes in the brain can result in aberrations of relevant be-
haviours. Behavioural changes may result from sudden injuries, slowly progressing diseases and 
some may even result from therapeutic interventions intending to counteract brain disorders.
While some patients show aberrant behaviours due to accidents (e.g. accidents which cause 
frontal lesions, exemplified by the classic prototype involving the story of Phineas Gage sho-
wing a clear relationship between brain and moral behaviour), others may show devia-
tions of what we would consider normal, socially acceptable behaviours because of neurolo-
gical and psychiatric disorders, like Parkinson’s disease or autism spectrum disorder. Novel 
therapeutic deployments such as deep brain stimulation may represent a way out of such pro-
blems but pose themselves the risk of inducing unwanted behavioural side effects (see Fig1).
It is not surprising that it represents a complex task to investigate psychosocial and behavioural 
consequences of such a complex intervention. From an ethical point of view, the assessment of psy-
chosocial and complex behavioural consequences is an important undertaking when assessing the 
legitimacy (see „A. Intervention-assessment“) of such interventions. Complex behavioural and affec-
tive changes can include apathy, hypomania, compulsive behaviours such as gambling and hyper-se-
xuality, egocentrism, obstinacy, violence, lying or depression apart from other fine-grained changes 
which may reach far into the domain of personal convictions, values and sensitivities. It has been 
shown that DBS can result in impatience, irritability, distractibility, attention problems, problems 
in ordering complex actions and thoughts, anticipation and planning (Müller, 2010) and in prema-
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ture responding in high conflict situations (Frank et al., 2007). The previously mentioned complex 
changes have in common that they are characterized by motor and affective components (I delibe-
rately exclude cognitive components because current and past research dealing with side-effects al-
ready broadly explored the latter (e.g. language or memory problems)). Whilst the first can include 
reduced/increased motor drive, the latter can involve anhedonia, depressed mood or increased emoti-
onal tone. Such changes are often particularly meaningful for patients and their relatives because they 
represent defining elements of the treated patients’ personality and hence influence social coexistence.
An important difference which is relevant in this context is the distinction between intended and 
unintended behavioural and affective changes. Contrary to the neurological context, in psychiatry, 
the mere intention of changing one’s “personality” is at the core of the therapeutic aim. Hence, the 
problem of how to deal with intended as opposed to unintended changes will gain relevance when psy-
chiatric conditions are object of DBS interventions (e.g. who decides which complex changes should 
occur, how controllable are these, etc.). In what follows, we shall focus on unintended behavioural 
and affective changes. The primary and direct aim of DBS in the neurological context is to specifi-
cally improve agency (i.e. motor or executive control). However, as elaborated in the first part of this 
introduction, the procedure in general lacks a high level of specificity due to interacting circuitries. 
Hence, theoretically, DBS might influence agency and “personality” in general relatively unspecifi-
cally. In addition, improved motor control (agency) provides access for new opportunities due to 
regained motor skills and might in turn indirectly influence the psyche of the individual being treated.
Apart from the possible restitution towards a normal psychophysiology, changes in personality traits 
or behaviour can occur after DBS surgeries both in the adaptation phase (i.e. first 12 months) and 
in the long-term treatment phase. In cases of undesired, non-inherent disease related changes, sti-
mulation parameters and medication need to be adjusted post-operatively. Behavioural side-effects 
often reflect a complex interaction between drug and stimulation parameters but changes in general 
are likely also the result of an ongoing neurodegenerative process e.g. in the context of PD. Also, the 
reduction of dopaminergic medications after surgery in PD, for example, has been identified as a 
possible cause for behavioural and affective problems: Forced reduction of dopaminergic medications 
can lead to apathy and depression. On the other hand, dopamine agonists often cause impulse con-
trol disorders and related behavioural disturbances (hypersexuality, pathological gambling, excessive 
shopping, etc.). Finally, stimulation may induce behavioural changes (see Part I of this introducti-
on). In particular, increased impulsivity by STN-DBS or DA-agnoists may interfere with deliberate 
actions. Additional contributing factors include lead location, preoperative neuropsychiatric status, 
postoperative psychosocial (mal)-adaptation and premorbid personality traits. More general adverse 
effects such as increased tonic muscle contractions (when stimulating the internal capsule) or balance 
problems when stimulating the brachium conjunctivum also include effects associated with intracra-
nial surgery, such as intracerebral haemorrhage, edema and infection, which are within the range of 
typical neurosurgical complications. As mentioned, they also include mania (e.g. due to current lea-
kage into the neighboring VTA), depression, apathy and compulsive behaviours such as gambling and 
hyper-sexuality (Müller & Christen, 2011; Christen et al., 2012). One particular aspect that reaches 
beyond conventional motor and non-motor aspects of PD and that has received less attention in the 
context of DBS is moral behaviour (see below). As will be elaborated, problems in social adjustment 
raise ethical questions that relate to competences and abilities of the patient with ethical relevance (e.g. 
agency, autonomy, socially acceptable behaviour) and that relate to consent capacity after DBS (Leent-
jens et al., 2004) and conflicting outcome interpretation due to (e.g.) unmet patient expectations or 
when the changes are evaluated positively by the patients, but negatively by their social surrounding. 
Those aspects may require decision procedures in case of social conflicts (Müller & Christen, 2011).
Even though deep brain stimulation seems to favour a hard neuro-essentialist perspective, which 
refers to reducing behaviour strictly to basic brain processes, subjective reports of motor, cognitive, 
affective or volitional impairment may be reliable indicators of abnormalities in brain regions at least 
partially mediating these physical and mental capacities. They unequivocally represent important sour-
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ces for evaluating the success of a brain intervention. Notable, abnormalities which reflect subtle perso-
nality and behavioural changes are often meaningful both for patients and their surroundings. Hence, 
there is a need to try accurately depicting such changes in such a way that counteracts a too reductioni-
stic understanding but emphasises the holistic nature of complex changes relating to patients and their 
relatives. Besides that, how a patient reports symptoms, how a clinician responds to the report and how 
the patient responds in turn to the clinician are fundamental components of the therapeutic process.
In summary, the many contributing factors such as the natural disease progression, changes in medica-
tion, socio-economic circumstances and stimulation effects make it difficult to pinpoint causal elements 
for behavioural and personality-like changes observed after DBS interventions. Given the fact that sub-
tle behavioural and personality-related changes are themselves hard to assess, an ethical discussion of 
the named changes must lead to a discussion of how to overcome this measurement problem. This will 
be the topic when discussing conflicting outcome interpretation and the need for new measurements 
(component (C) „C. The problem of conflicitng outcome interpertations following DBS intervention“). 
In order to better understand reactive problems after DBS, in-depth psychological assessments of the 
patients and their surrounding may reveal explanations related to the individual psycho-social situati-
on. In line with the previously said, there is a need to carefully documenting and publishing side-effects 
that reach beyond simple outcome measures, potentially with the help of new and refined instruments.
Evaluating behavioural & affective changes
Apart from the context dealing with neuro-enhancement or psychiatric conditions, beha-
vioural and affective changes are normally unintended. Such risks are to a greater degree li-
kely to occur in case of neurosurgical or pharmacological interventions targeting the brain. 
Medical treatments with the potential of changing the patients’ biological foundation of behavi-
our and affect in such a way that the treated patient may change either abruptly or slowly and as 
a consequence deals differently with others, warrants additional ethical reflection. Thus, the need 
for weighting whether possible benefits for patients justify the risk of unintended and undesirab-
le changes in their personality which may negatively affect their surroundings, becomes evident. 
Furthermore, the issue relates to the basic problem that there is disagreement on what counts as 
socially (in)acceptable behaviour. Because morality is often embraced by relativism, moral issues are 
evaluated controversially and the controversies depend significantly on cultural and societal differences. 
Additionally, such evaluations may transform over time: First, within a society, there are actions that 
are undisputedly either moral or immoral, whereas other actions are less clear in that respect (e.g. in re-
spect of (1) murdering innocents or (2) sexual practices such as child-marriage, homosexuality and the 
like). Second, across societies and during history, the moral condemnation of some behaviours seems to 
be stable (e.g. murdering innocents), whereas others undergo remarkable changes (e.g. slavery). Thus, 
moral evaluations of given actions differ both with respect to inner-societal disagreement and evalua-
tion instability over time (Christen & Müller, 2015). For a scientific investigation of brain disorders 
and their interventions that may cause aberrations of moral behaviour, a universalistic ethical appro-
ach would be optimal, because many ethical theories consider universalizability to be a distinguishing 
feature of moral judgments and a substantive guide to moral obligation: Moral imperatives should be 
regarded as equally binding on everyone. Additively, ethical theories often regard universalizability as 
a prerequisite in order that a norm can be called moral. As DBS related side-effects include behaviours 
for which no universal opinion can be expected (e.g. hypersexuality, evidenced by the high degree of 
variance of prevalence), the notion of universalizability is fraught with problems. The problem of defi-
ning socially (in)acceptable behaviours reaches far into the practice of establishing diagnostic criteria. 
This is epitomized by the role of values in psychiatry which notions directly enter the definitions of 
what constitutes a disease within the diagnostic and statistical manual of mental disorders (DSM) pre-
vailing at a given time. Hence, psychiatry ever since adopted the role of making an explicit statement 
about what morally acceptable ought to be. Otherwise, diagnosis and treatment would be impossible. 
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Some scholars claim that mental illness is defined by reference to evaluative norms by contrast with 
physical illness, which is defined as deviation from structural or functional integrity (Thornton, 2007). 
As implied previously, it might not even be clear how moral behaviour should be conceptualized. The 
term moral generally refers to a given set of norms and values which exists in a given society. Conse-
quently, behavioural and affective changes of patients undergoing DBS interventions can, depending 
on the prevailing context, hold a moral dimension. As a result, the question of which complex beha-
vioural or affective changes have ethical relevance which reach beyond mere side-effects (see principle 
of non-maleficence), emerges. Ethical relevance is attributable to those changes which implicate mo-
ral aspects, that is, changes which hold a social component and/or changes which can conflict with 
prevailing values or norms existing in a given culture. Such changes include, but are not limited to, 
changes influencing psychosocial aspects of patients postoperatively and their relation to third parties, 
behaviours that result e.g. in excessive sexual drive, or changes that might induce harmful consequen-
ces for the patients’ surrounding. If adopting a broader definition upon which morality is defined by 
its social component (that is, morality is genuinely social), behavioural and affective changes following 
DBS modulation nearly always imply a moral dimension because they most often exert consequences 
on the coexistence of patients and their relatives and society as a whole, e.g. in the form of psychoso-
cial maladjustments (but see „C. The problem of conflicitng outcome interpertations following DBS 
intervention“, Fig 1, discussed below). Finally, the link between executive control, DBS with its aim 
to influence it and morality has already been made in the last section of Part I of this introduction.
Why are complex unintended changes problematic?
Brain disorders impose internal constraints on behavioural control (agency) and autonomy. Likewi-
se, unintended effects on behaviour and affect can undermine the autonomy of patients because they 
relate to competences (e.g. decision making capacity) and the authenticity of patients. Hence, DBS can 
restore or impair autonomy by e.g. resolving alienation in OCD or by inducing mania in PD. It can 
also impair the experienced autonomy when patients feel remote-controlled. Autonomy is an import-
ant guiding principle in NE because a properly functioning brain is a decisive precondition for being 
able to act as an autonomous agent. According to Beauchamp and Childress, acting autonomously 
involves the ability to act 1) intentionally, 2) with understanding and 3) without controlling influences 
(e.g. coercion or manipulation) (Beauchamp & Childress, 2013). The requirement of absent cont-
rolling influences in definitions of autonomy not only includes external manipulation but also internal 
coercion potentially resulting from a diseased brain, secondary to medications or resulting from a neu-
romodulation intervention (Müller & Walter, 2010). Any intervention into the central nervous system 
is commonly evaluated as unethical if it reduces the patient’s biological prerequisites of autonomy, when 
being perform against the patient’s will, when causing suffering (see „A. Intervention-assessment“) or 
when deteriorating the behaviour of the patient in such a way that rights of other persons will be 
concerned. Importantly, the prerequisites of autonomy include mental capacities but also moral com-
petencies (see „C. The problem of conflicitng outcome interpertations following DBS intervention“). 
Regarding the competency component, assessing consent capacity before, during or after DBS 
interventions is an ethical requirement resulting from respect for autonomy. As a result of patho-
logical brain conditions, it is often unclear to what extent a patient is able to provide informed 
consent for a treatment which intends to change this condition. It is in the nature of things that 
this problem extends to interventions in psychiatry, where patients often lack such competencies 
and where the mere intention of changing one’s “personality” is at the core of the therapeutic aim.
In order to uphold the key derivative ethical aim originating from respect for autonomy, na-
mely the notion that the patient’s perspective is fundamental, advance directives should be in pla-
ce to manage states of temporarily losing the decisional competence (Müller & Christen, 2011) 
e.g. in the case of stimulation-induces mania. If the patient is judgmentally able (i.e. demonstra-
tes decision making capacity), physicians would face legal problems if thinking of discontinu-
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ing therapy. In such cases, a contract between patient and physicians might be a good solution.
C. The problem of conflicitng outcome interpertations following DBS intervention
Towards a relational understanding of autonomy
DBS interventions may in some cases lead to complex behavioural and personality-related changes also 
in the context of movement disorders (as a side-note, PD is nowadays conceptualized as a neuropsych-
iatric disorder). An additive problem associated with respect for autonomy (see previous paragraph on 
consent capacity) is the ethical relevance and practical handling of conflicting outcome interpretations 
between different stakeholders (e.g. patient, relatives, medical experts) with respect to changes in mo-
ral/social behaviour of the patient. Hence, the term relational autonomy has been coined to emphasis 
the notion of a “relational” understanding of autonomy, arguing that decision making should consider 
not only the individual perspectives of patients, but also those of their families and members of the he-
alth care team as well as the perspectives that emerge from their interactions (Epstein & Street, 2011). 
Such a relational understanding attempts to explain both the positive and negative implications of so-
cial relationships for individuals’ autonomy, de-emphasizes independence while emphasizing trust and 
facilitates well-nuanced distinctions between forms of clinical communication that support and that 
undermine patients’ autonomy. In this context, the concept of shared minds (Epstein & Street, 2011) 
has been articulated in order to investigate when, why and how individuals involve trusted others in 
sharing information, deliberation, and decision-making through the sharing of thoughts, feelings, 
perceptions, meanings, and intentions among two or more people. Resulting from conflicting outcome 
interpretations, the phenomenon of a satisfaction gap (i.e., disagreement between physicians and pati-
ents relating to the treatment success) – potentially secondary to an expectation mismatch, prevailing 
motor function problems despite DBS intervention, apathy and speech problems and personality chan-
ges, among others – is not uncommon in treated patients. The often observed satisfaction gap may also 
point towards an insufficient sensitivity for complex side-effects (for which no measurements exist) on 
the part of medical professionals and misconceptions of the patients regarding their pre-operative state.
Because of these difficulties, patients qualifying for DBS are confronted with a very difficult decisi-
on of weighing benefits and risks of the intervention against other alternatives. The difficulty is great 
because of an underlying measurement problem (i.e. the frequency of complex side effects is difficult 
to estimate) and an evaluation problem (i.e. the retrospective assessment can significantly differ bet-
ween patients, their relatives and physicians). Psychosocial problems postoperatively emerge either 
because the patients gained autonomy and rejected their spouses whereas the spouse did not want to 
quit her role of a caregiver or because the spouses expected more personal responsibility of the pati-
ents, whereas those did not want to quit their role as sick persons and demonstate severe problems in 
proving themselves in the world of healthy persons  (i.e. Burden of Normality problem) (Gilbert, 
2012, Wilson et al., 2001). Sometimes, postoperative improvements are objectively not optimal and 
sometimes, there is the problem of satisfaction gaps. Hence, there is a need to transparently inform 
patients about those difficulties and to include patients, their families and caregivers into the decision 
making process long before surgery is performed. Numerous causes might exert difficulties in social 
adjustment such as the adjustment to the new self with a brain pace-maker and suddenly radically 
improved motor signs, the adjustment to an abruptly changed situation with the significant other and 
close family whose roles as a caregiver may suddenly change or the adjustment to a new situation at 
work and with leisure activities. As a result, it is important to give patients and their surroundings the 
necessary time to prepare for the changes that are to be expected in their lives and as a result to include 
patients and their relatives early into the shared decision making process (Schüpbach & Agid, 2008).
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The importance of psychological competencies and their assessment
The process of shared decision making however, additively requires a discussion of morally rele-
vant behaviours (such as ICDs) which themselves depend on psychological competencies. The un-
derlying psychological competences which might be dysfunctional after complex affective changes 
however, are hardly the basis of the current assessment process. In turn, new instruments that are 
able to quantify and depict such competencies might be highly relevant for an improved (i.e. up-
dated) shared decision making. Such a particular psychological competency is moral sensitivity, the 
ability to recognize morally salient aspects in a given situation. Out of theoretical consideration, it 
might be possible that DBS constrains the sensitivity of an individual in such a way, that makes it 
impossible for the patient to recognize that a given person might be harmed by certain actions, even 
though he is generally of the opinion that one should abstain from harming others. The inability to 
implicitly recognize the harming nature of certain action following DBS intervention could symbo-
lize a basis for explaining complex behavioural and affective changes. Notably, there is a difference 
between the inability to subconsciously recognize that a given value might be harmed and the deli-
berate convictions somebody holds. It is such subtle changes in psychological competencies which 
soak through the clumsy neuro-psychological assessments which are being used nowadays. Hence, 
conflicting outcome interpretations emphasize the need for trying out new avenues aiming at tho-
roughly uncovering more subtle changes following diseases, medication and or DBS intervention. 
As outlined, currently there is a lack of sensitive instruments which adequately depict such changes. 
Standardized questionnaires and tests are available, but they may not reflect sufficiently the behavi-
oural changes and their effects in real life. New avenues for the better circumscription of behavioural 
and affective changes which may explain causal elements for the emergence of conflicting outcome 
interpretations may involve instruments which rely on newer insights of moral psychology. Hence 
and in the following, I outline why DBS is suitable for investigating behavioural and affective ch-
anges, followed by discussing the methodological problems of trying to assess complex changes. Fi-
nally I emphasize the role of moral psychology and its potential for developing suitable instruments.
DBS as a suitable means for investigating behavioural and affective changes
DBS is suitable for efficacy testing in randomized, double-blind, controlled trials and partially the 
testing of acute effects (by switching the device on and off). It is even possible to perform sham-stimu-
lations in order to measure placebo effects. Apart from a purely scientific demand, it additively repre-
sents an ethical requirement to optimize study designs in order to capture objective therapeutic effects. 
However, statistically significant efficacy represented in the very abstract improvement captured by 
rating scale scores is only a necessary but not a sufficient condition. Hence, the quality of life of pati-
ents independent of motor functions comprising e.g. psychosocial factors has long been overlooked. 
Psychosocial maladjustment in this context can be expected after rapid symptom modification in any 
chronic life-determining disease. Quantitative outcome measures have to be complemented by either 
qualitative measures or by psychologically informed innovative instruments. As outlined previously, 
any causal factor (e.g. stimulation, drugs, disease and their interplay) leading to unintended side-effects 
is by nature non-trivial to identify. Therefore, highly individualized approaches are needed. It is im-
portant to note that even though DBS is said to be reversible, non-efficacy results in severe despair in a 
multitude of patients which strongly depends on the medical care team (Synofzik & Schlaepfer, 2011).
Methodological problems of trying to assess complex changes
As outlined in paragraph A (Intervention-assessment), unintended side-effects represent import-
ant ethical factors for the evaluation of novel therapies in general. However, the ethical evaluation 
of side-effects is associated with two fundamental methodological problems: First, some side-effects 
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are difficult to measure and to quantify exacerbating the assessment of the incidence of certain si-
de-effects. Second, the impact of some side-effects on the patient’s life is difficult to classify, especi-
ally in comparison with the impact of the diseases’ natural progression. Hence, assessing the severi-
ty in order to evaluate whether a course of action is obligatory, prohibited or permissible in some 
cases is very difficult. As a result, any novel therapy is confronted with a measurement problem of 
this sort. In order to shape the ethical analysis, Müller & Christen (2011) have introduced an 
analytic scheme that classifies therapy side effects along two gradual, qualitatively described dimen-
sions (measurement complexity of side-effect vs relative life impact of the side-effect weighted by 
its incidence in the natural disease history). It implies a higher ethical sensibility for complex side 
effects but also, by incorporating the “relative life impact”, accounts for the consequences of not in-
tervening apart from the fact that side-effects are genuinely ethically relevant. The scheme should 
not be misunderstood as an objective and general classification of the salience of side-effects because 
whether certain side-effects can be tolerated, compensated for or cause suffering depends strongly on 
the individual patients’ attitudes and life situation (social situation, professional activity, psychologi-
cal condition, among others). The fact that several effects with small life impact may cumulate to an 
effect with a high life impact further highlights the importance of individually attributing life-impact 
scores. Thus, the scheme might serve as a tool in the patient briefing and in shared-decision making. 
As a site note and with regard to psychiatric disorders and the involved harm-benefit assess-
ments, numerous core problems arise. Among others, objectively evaluating beneficial or ne-
gative effects of the therapy depends more strongly on subjective evaluations. Also, cases with 
predictable side effects that clearly outbalance therapeutic effects are probably rather rare in 
this context. If DBS will play an important role in psychiatry, we certainly cannot expect that 
the side-effects spectrum will become smaller compared to that implicated by the alternatives.
The role of moral psychology and its potential for developing suitable instruments
As outlined above, DBS aims at modulating a complex system which effects are not always fore-
seeable and which can extend into the social or moral context. Morality can be defined very bro-
adly as a set of norms, principles, values and virtues that are governed by an orientation towards 
the good. It reflects respect and concern for oneself and other entities (persons, animals, environ-
ment). Additively, it is embedded in a justification structure. It is this sort of complex behaviou-
ral changes, including social and moral aspects, which are to a greater degree ethically problematic 
and for which assessment, psychologically informed instruments are highly needed. The field with 
the richest knowledge on how agents reason, decide and act morally is still moral psychology. In 
the following, the framework termed moral intelligence (MI) (Tanner & Christen, 2014) might 
represent an appropriate mean for investigating psychological competencies that may relate to a re-
vised shared decision making. MI is defined as the capability to process moral information and to 
manage self-regulation, a key-feature already outlined above (see paragraph: the basal ganglia: from 
neuroanatomy to behaviour), in any way that desirable moral ends can be attained. It refers to the 
set of skills that moral agents need in order to align their behaviour with the moral ends they have 
set for themselves, using the broad understanding of “morality” defined above. Hence, this approach 
emphasizes psychological skills which are important to constitute moral behaviour. MI is composed 
of five key elements: a moral compass, i.e. a set of moral schemata whose content is responsible 
for orienting the subject’s behaviour (Narvaez & Lapsley, 2005), moral commitment, as the abi-
lity to activate and or sustain motivation for the inclusion of moral considerations in the process 
of perception, decision-making and action, moral sensibility, as the ability to recognize morally 
salient aspects in a given situation, moral problem solving as the ability to bring morally salient 
features to the decision making process and to arrive at a decision consistent with the subjects’ moral 
compass and finally moral resoluteness as the ability to carry out own decisions despite of barriers.
In the context of this dissertation, one aim was to operationalize moral sensibility in order that 
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it can be measured. Hence, after having successfully developed the instrument, a major future step 
will involve the translation of this tool for the clinical landscape in order to investigate subtle ch-
anges in patients’ sensitivities regarding different moral and non-moral values. The inclusion of an 
instrument of this sort might enable us to deeper investigate complex changes after DBS interven-
tions. It is thereby most likely, that different neural systems are mediating sensitivities related to e.g. 
harm versus honesty in a distinctly different way and that the underlying neural mediators may be 
entirely different. A specific disease may thus impair one aspect of moral sensibility stronger than 
others but the relevance of this difference will depend on the situation in which this competence 
is needed. Moreover, a neurological or psychiatric disorder is likely to influence other competen-
cies (also non-moral ones) as many regions in the brain have multimodal and re-entrant functions.
Because it is neither useful for a healthcare professional who is interested in investigating mo-
ral behaviour to work with a very broad concept of moral behaviour (e.g. moral behaviour its-
elf ) nor with a highly complex and fine-grained understanding of moral behaviour (e.g. impair-
ment of honesty-related moral resoluteness), the need for developing instruments achieving a 
reasonable compromise is utterly important. Hence, the aim is to have an instrument at ones’ di-
sposal which includes a sufficiently but not too complex set of constructs that describe compe-
tencies relevant for moral behaviour (such as the MI model). Correlational studies which inclu-
de lead-position variations in different neuroanatomical targets, increased knowledge about the 
brains’ network architecture combined with psychological data on value sensitivity might there-
fore turn out to be fruitful for more thoroughly investigate the mechanisms of complex changes. 
After having outlined the centrality of psychological competencies required that desirable moral ends 
can be attained, we are now able to circumscribe such competencies in relation to the previously described 
concept of „self-control“ (see last part of part I of this introduction). In order to act in reference to values 
and norms, the individual must possess moral concepts and have the capacity to recognize and apply moral 
reasons appropriately in his practical deliberation. Secondly, such an individual must be able to control 
her behaviour in accordance with these same reasons. It is quite likely that such capacities come in de-
grees. While most persons suffering from a psychiatric illness will have acquired ordinary moral concepts, 
disordered thinking, delusions, depressed mood but also drugs and other medical interventions may re-
duce or remove the ability to recognize or weigh relevant moral considerations and to judge accordingly.
The role of an instrument measuring moral sensitivity in clinical practice
Finally, I will briefly outline the role of an instrument measuring moral sensitivity in clinical practice.
Generally, the deployment of an instrument of this sort is conceivable for the referral practice in 
DBS interventions and as an outcome-measure in order to measure pre-post DBS effects. Con-
cerning the deployment in referral practice, it is important to examine whether moral sensitivi-
ty (MS) represents a defining competency in sustaining primary competencies such as decision 
making capacity. If MS demonstrated to preserve or substantiate one’s ability to act independent-
ly, with (self )-understanding and authenticity, then it would only be logical to include the inst-
rument in referral practice in order to have a decisional grounding to potentially exclude patients 
from such interventions. If MS demonstrated to be decoupled from such abilities, it might be less 
pressing to include it in the referral process. This however would presuppose having a keen idea 
how DBS might affect MS which relates to the question whether it should be used as an outco-
me-measure (see below). Also, the acknowledgment of MS as a primarily relevant competency might 
shift the general risk-benefit assessment in direction of preservation of MS. Finally, both the po-
tential inability to pinpoint causative factors reducing MS and given the fact that MS is conceived 
as a competency which can be trained, the specific handling of this construct seems challenging.
Concerning the deployment of the instrument in the outcome-assessment, one would be very tempted 
to make use of it. For the investigation of meaningful pre-post effects following DBS is an important un-
dertaking, investigating changes in MS would be necessary in order to not only assess the legitimacy of this 
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intervention but also contributing factors which might explain complex changes and conflicting outcome 
interpretations. Based on the direction of test-results, either a revision of stimulus parameters and/or elec-
trode location (in case of marked changes), or in-depth validation on the sensitivity of the instrument at 
stake would be needed. Alternatively, DBS might not interfere with MS and the underlying competencies.
It might be a good strategy to slowly approach these questions by e.g. investiaing pre-post effects 
relating to MS before the evaluation of whether the outcomes may have an impact on referral practice 
and the content alignment of exclusion criteria.
As I have outlined previously, the perspective of the individual patient is fundamental. Hence, I end the 
second part of this introduction with an emphasis on the individual patient. The care of patients suffering 
from severe neurological or psychiatric disorders is often challenging. Based on the previously outlined 
problem of psychosocial changes, disabilities that directly affect social interactions with others pose chal-
lenges to family and caregivers to a greater extent than purely physical disabilities. The challenge is even 
greater if patients demonstrate questionable moral behaviours (e.g. egocentrism, obstinacy) or even im-
moral behaviours (e.g. violence, lying). In most cases, people suffering from a neuropsychiatric disorder 
are not responsible for their diseases. However, they are significantly disadvantaged and suffer from stig-
matization apart from their disease. Hence, it represents a moral duty to support them medically but also 
their reintegration. If the neuromodulatory therapy shows the need for balancing between therapeutic 
and unwanted effects and indicates that the optimal balancing can look differently depending on diffe-
rent perspectives (patient, close relatives, medical experts), the ethical assessment is even more complex. 
In summary, when examining ethical questions dealing with behavioural and affective changes following 
DBS, difficult “measurement problems” have to be resolved. In fact, standardized questionnaires may not 
sufficiently reflect behavioural changes and their effects in real life. Hence, there is a need for developing 
new instruments which are able to enrich the behavioural and affective assessment in order to uncover 
changes that are meaningful for patients, their surroundings and society. Such changes likely encompass 
alterations which hold a moral component. As a result, implementing recent insights of moral psycholo-
gical research in the development process of new instruments is likely to represent a promising solution.
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Approaching the research question of investigating clinical and ethical 
aspects of complex behavioural and affective changes following DBS 
interventions
The strategy for approaching the research question incorporating clinical and ethical as-
pects of complex behavioural and affective changes after DBS, including the interventi-
on (DBS) and the targeted diseases (component A), complex behavioural and affective chan-
ges (component B), as well as conflicting outcome interpretations (component C), included:
1. First, a quantitative understanding of the field of DBS including clinical and ethical as-
pects. Hence, we performed a statistics driven approach implementing a network analy-
sis in order to gain an overview of primarily patient relevant issues (such as most often di-
scussed side-effects, anatomical targets and indications) in DBS publications since 1992.
2. Next, an increased understanding of the prevailing global practices based on expert evaluations 
with an emphasis on patient relevant parameters was approached (e.g. finding elements which 
might be causative for conflicting outcome interpretations, fears of patients and their like-
lihood estimation, estimating the occurrence of complex changes in behaviour, among others).
3. Moreover, and in appreciation of the technological influences on the likely emergen-
ce of personality-related changes following DBS together with the decisional pow-
er the device industry has, we critically scrutinized the technological status quo as a me-
ans for an ethical evaluation of important aspects of the technology-development.
4. Finally, and after gaining important insights into the interplay of the device-disease-drug 
and complex changes-relation as well as the need for new and better instruments for mea-
suring such changes, we developed a psychologically informed instrument which might 
prove valuable in the context of assessing complex behavioural and affective changes.
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Part II Research
Publication 1: Mapping the field through a quantitative understanding
Synopsis
Taking advantage of recent developments in network analysis, statistics of interconnections and 
graph theory, we analysed abstracts of 7000 deep-brain-stimulation-papers published between 1991 
and 2014. With an emphasis on patient relevant categories such as DBS indications, anatomical tar-
gets and side-effects, we confirmed known trends e.g. regarding the emergence of psychiatric indica-
tions. As outlined in the introduction, the emergence of both neurological and psychiatric disorders 
stipulates the need for adequate pre-post assessments with an emphasis on behavioural and personali-
ty changes.
The data also reflect an increased discussion of complex issues such as the topic “personality” 
which is connected tightly to the topic “ethics”. In addition, a mismatch concerning an apparently 
increased interest in depression as an important indication and an unsatisfactorily low description of 
side-effects was evident. Hence, we outlined the need for the accurate and careful observation and 
measure of psychosocial and personality-related changes which is backed by our data analysis. We 
argued that in order to minimize problematic behavioural and personality-related side-effects, DBS 
should get more individually tailored. In this context, we also advocated for the eagerness to evaluate 
results beyond short-term quality of life. 
Finally, we found a robust connection between hardware-related issues and an ethical context.
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The enormous increase in numbers of scientific publications in the last decades requires
quantitative methods for obtaining a better understanding of topics and developments
in various fields. In this exploratory study, we investigate the emergence, trends, and
connections of topics within the whole text corpus of the deep brain stimulation (DBS)
literature based on more than 7000 papers (title and abstracts) published between
1991 to 2014 using a network approach. Taking the co-occurrence of basic terms
that represent important topics within DBS as starting point, we outline the statistics
of interconnections between DBS indications, anatomical targets, positive, and negative
effects, as well as methodological, technological, and economic issues. This quantitative
approach confirms known trends within the literature (e.g., regarding the emergence
of psychiatric indications). The data also reflect an increased discussion about complex
issues such as personality connected tightly to the ethical context, as well as an apparent
focus on depression as important DBS indication, where the co-occurrence of terms
related to negative effects is low both for the indication as well as the related anatomical
targets. We also discuss consequences of the analysis from a bioethical perspective,
i.e., how such a quantitative analysis could uncover hidden subject matters that have
ethical relevance. For example, we find that hardware-related issues in DBS are far more
robustly connected to an ethical context compared to impulsivity, concrete side-effects or
death/suicide. Our contribution also outlines themethodology of quantitative text analysis
that combines statistical approacheswith expert knowledge. It thus serves as an example
how innovative quantitative tools can be made useful for gaining a better understanding
in the field of DBS.
Keywords: deep brain stimulation, text analysis, network analysis, co-occurrence of terms, bibliometrics,
bioethics
INTRODUCTION
A characteristic of modern knowledge production is the enormous increase of the number of
scientific publications (original papers, reviews, conference abstracts, editorial material, etc.) that
is made accessible through digital technology. In neuroscience alone, it is estimated that more
than 100,000 papers a year are added to a text corpus that contains many millions of publications
(Grillner, 2014). This information overload poses a substantial challenge for researchers to keep
pace with the developments in their own fields; and it is well-known that the biomedical sciences are
especially vulnerable in this regard, since they are strongly oriented toward text-based knowledge
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sources (Hölzer et al., 2006). This problem certainly also holds
within the field of Deep Brain Stimulation (DBS) (Hariz et al.,
2013), that has experienced a substantial growth of publications
since the late 1990s (Müller and Christen, 2011). In this paper
we propose a way to handle this challenge by using quantitative
text analysis that combines statistical approaches with expert
knowledge.
Quantitative approaches using bibliometrics, scientometrics,
and text mining have gained popularity, as they may serve
as navigational prospects and orientation aids. They enable
researchers to identify relevant topics, trends, and publications
in a fast-growing text corpus. Among other methods, network
approaches, and data visualization techniques that aim to identify
connections between topics within a given text corpus are being
used (Popping, 2000, 2003; Ryan, 2007) and have shown to
be useful to grasp important concepts within a text of any
length. While being applied in a wide field, such approaches
have a long tradition in enabling researchers exploring possible
configurations of the unknown, shared visual representations
which may open new ways for channeling collective attention,
envisaging innovative interpretations and help us to make sense
of data at different scales (Okada et al., 2014). The ultimate
advantage of network analyses and their visual representation
in general is recognized from a wide and diverse field. Ideally,
the results of such a methodological approach will verify
conjectured trends within the field, enrich the discourse, and
support unconventional ideas or interpretations of the ongoing
scientific development. In the following, we will explore the
techniques of sized graphs in combination with sophisticated text
preprocessing in order to find features in the network structure of
the DBS text corpus which otherwise would be difficult to detect.
In general, a graph visualizes relations of a given set of data
and is composed of nodes and edges. Nodes typically represent
items or concepts whereas edges connect nodes according to
some association rules. Graphs are widely used for e.g., analyzing
social networks where people represent the nodes and edges
represent relationships between people. To convert information
(e.g., of text) into a visual representation can facilitate the
handling and perception of hidden structures from large data
sets. By following paths and detecting clusters of closely related
nodes, one may detect unique features of a given data set.
However, if the data set exceeds a certain level of magnitude, the
task of exploring, and navigating becomes increasingly difficult.
More specifically, there is extensive work on representing textual
data as graphs and the subsequent application of network text
analysis (e.g., Losiewicz et al., 2000; Grbic et al., 2013; James et al.,
2013; Guan et al., 2014) for gaining an increased understanding
of influential concepts, text’s meanings, and structure. Network
Abbreviations: ALIC, Anterior limb of internal capsule; BC, Betweenness
Centrality; DBS, Deep Brain Stimulation; ECT, Electro-convulsive therapy; ET,
Essential tremor; GP, Globus pallidus; GPi, Globus pallidus internal segment;
MDD, Major depressive disorder; STN, Nucleus subthalamicus; Nacc, Nucleus
accumbens; OCD, Obsessive-compulsive disorder; PD, Parkinson’s disease; PPN,
Pedunculo-pontine nucleus; QoL, Quality of life; SCS, Spinal cord stimulation; SG,
Subgenual cingulate; TS, Tourette syndrome; tDCS, Transcranial direct current
stimulation; VNS, Vagus nerve stimulation; Vim, Ventral intermediate nucleus; Zi,
Zona incerta.
analysis is therefore also suitable for linguistic comparative
analyses which focus on semantic relations between words, often
framed through the co-occurrence of terms (i.e., relevant terms
that more often appear in the same text are more likely to share
some semantic connection). By making use of the large number
of published DBS papers as well as a statistics driven quantitative
approach, a potential subjective bias may be diminished.
In the following, we will use graph analysis and visualization
techniques for investigating (1) most influential topics, (2) their
mutual connections as well as (3) the temporal development
of topics by retrieving the titles and abstracts of all published
publications from 1991 to 2014 in the field of DBS (see
Material and Methods for more specific information). We
expect to be able to reproduce known phenomena (e.g., an
increase in discussing psychiatric disorders in the DBS literature,
well-described anatomical targets for the treatment of various
disorders, or known treatment methods for various disorders)
which might become obvious in different ways (e.g., direct
connections or by reference to how e.g., anatomical targets
are being discussed). Additively, we are interested in detecting
how specific topics (e.g., lesioning-methods, personality, and
bioethics) develop over time and/or how they interrelate with
other topics. The original text corpus was composed of more
than 10,000 DBS publications, based on which 7154 texts (titles
and abstracts) containing more than 400,000 potentially relevant
words have been selected for analysis. Using the co-occurrence of
key terms as association rule, we conducted graph visualization
techniques, community analyses and quantitative metrics to get
insight into how DBS has been discussed during the last 23 years.
The results of this analysis are then reflected by referring
to issues that dominated the DBS literature. Beside others, we
are interested in how some topics that have been identified as
ethical focal points in the international practice of DBS (Christen
et al., 2014) are represented in this quantitative approach. In this
way we explore the potential of such quantitative approaches for
identifying subject matters that are of relevance from a bioethical
perspective. The study will conclude by a discussion of limitations
of quantitative approaches as heuristics to deal with information
overload.
MATERIAL AND METHODS
Textual data is complex due to syntactic (verb forms, declination,
etc.), semantic (homonymy, synonymy, etc.) and pragmatic
(context-dependency etc.) variation. Therefore, any quantitative
analysis based on textual data has to ensure appropriate
preprocessing of text data such that it can be correctly used
for statistical processing. In the following, we first describe text
preprocessing to generate the final word set that was then used for
trend and co-occurrence analysis, before we outline the network
analysis and visualization methodology. The aim of the study was
to obtain a comprehensive set of DBS publications as a set for
quantitative analysis. We restricted ourselves to papers published
since 1991, as earlier papers on DBS are rather sparse and do not
yet contain in all cases the string “deep brain stimulation” as a
simple identifier for a text that can be attributed to the DBS text
corpus.
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Text Preprocessing
Text preprocessing contained three steps as outlined in Figure 1.
The starting point was a search in the Web of Science Core
Collection database (the search was performed on December 5th
2014)1. We used the search string “deep brain stimulation” in
the “topics”-field, restricted to the time range 1991 to 2015. We
excluded the “Proceedings Citation Index,” because entries in this
database only contain the title of contributions without abstract.
This resulted in a set of more than 10,000 contributions and a text
corpus of almost 1.2 million words. In a first preprocessing step,
we deleted special characters (e.g., “(” or “?” including number
signs) as well as the search string itself (because it is unspecific),
we transformed all letters into lower case and wemerged frequent
word pairs (e.g., “informed consent” to “informedconsent”). This
last step was based on a word-pair statistics over the whole text
set to identify very frequent pairing of words (a cutoff value
of about 80% was chosen). We identified frequent word pairs
by selectively looking through potential word-pairs and decided
whether they should be merged based on our experience with the
DBS vocabulary (in total, 130 word pairs were merged).
In a second preprocessing step, we deleted standard stop
words2 like “the,” “is” etc., and we performed a lemmatization,
i.e., we transformed all nouns, verbs, and adjectives into their
ground form using standard lookup tables3; for example the
plural “brains” is replaced by “brain” or the past tense “came”
is replaced by “come”—the latter step served for removing the
amount of variability. We refrained from stemming (another
standard procedure in text processing), because a stemmer
operates on a single word without knowledge of the context,
and therefore cannot discriminate between words which have
different meanings depending on the text. Finally, we computed
the text length distribution and we deleted all short texts4. The
remaining text corpus consisted of 7154 texts and 597,474 words,
22,034 of which were distinct words.
Finally, a third preprocessing step was necessary due to
area-specific stop-words and terms that were not contained
in standard lemmatizing lists. We first deleted all words that
were present in less than 0.1% of the texts (i.e., that are
contained in maximal seven texts), because these rare words are
not suitable for statistical text analysis. Then, two raters (the
authors) independently assessed which words are considered to
be unspecific. If both raters independently rated the same words
as unspecific, they were deleted (1308 in total). In a similar
way, we identified 1380 replacement-pairs for area-specific
lemmatization5. In this way, we generated a set of 7154 texts that
1WoS, Thomson Reuters, access through https://webofknowledge.com/
2Available at: https://code.google.com/p/stop-words/
3Available at: http://www.lexiconista.com/datasets/lemmatization/
4The text length distribution displayed a peak for very short texts (e.g., editorial
material that is only present in the WoS database with its title). In the mean, there
were 36 texts per bin, the standard deviation was 57. Thus, the distribution was cut
where there were more than 36 + 57 = 93 texts per bin, which was the case for
texts that contained 11 or less words).
5In some cases, we also replaced verbs or adjectives with nouns; e.g., “painful”
was replaced with “pain,” because the number of words of one category was
considerably lower compared to the number of words of the other category.
FIGURE 1 | Scheme outlining the generation of the final text set for
network analysis.
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FIGURE 2 | Distribution of publication years of all texts of the final set
(7154 texts), indicating a steep growth in the number of DBS texts
since the late 1990s.
consisted of 411,655 words, consisting of 2591 distinct words.
This set was used for the quantitative analysis.
Figure 2 provides an overview of the text corpus in terms
of publication years which shows the quantitative basis for our
analysis and reflects the substantial growth of publication within
the field of DBS. Text size distribution and term frequency are
shown in Supplementary Figure 1.
Text Analysis
The text analysis consisted of an expert evaluation part and a
statistical part. The expert evaluation (performed by the authors)
aimed to identify terms that are characteristic for issues and
topics that are widely discussed in the field of DBS. For issue
identification, we also referred to earlier publications from us, i.e.,
we included issues and topics which were identified as relevant
based on an analysis of DBS conference contributions (Christen
and Müller, 2011) and a large review covering the literature on
DBS in the Nucleus subthalamicus (Christen et al., 2012). “Issues”
refer to overarching themes (such as anatomical localization),
“topics” refer to defined subject matters within an issue (such
as specified anatomical localizations), and “terms” refer to the
actual words that appear in the text. As outlined in Table 1, seven
issues containing 73 topics were chosen for further analysis, based
on the authors estimation of relevance (some topics could be in
more than one issue; e.g., pain as indication or side-effect). Topics
sometimes are composed of different terms (e.g., “accumbens”
and “nucleusaccumbens”). In that case, the terms describe the
same topic.
In addition, we analyzed ethical issues as a single topic
characterized by the terms “ethic,” “moral” and “social” because
we were interested in investigating on how ethical aspects are
being discussed in the literature. In total, we had 74 topics and
162 terms. For these topics, we performed a trend analysis, i.e., we
counted the appearance of terms belonging to different topics in
all texts of a single year starting from 2000 (due to the low number
of texts in the 1990s that contained topic terms). We always
normalized the trend data with the total number of publications
per year for detecting trends within the whole DBS publication
body.
Furthermore, we calculated the pairwise co-occurrence
C(X,Y) of two topics X and Y as:
C(X,Y) =
∣∣T(X,Y)
∣∣
min({|X| , |Y|})
Where
∣∣T(X,Y)
∣∣ denotes, how often the terms characteristic for
topic X and Y appear in the same text and |X| respectively |Y|
denotes, in how many texts these terms appear in the whole
set. C(X,Y) is between 0 (the terms of two topics never occur
in a same text) and 1 (the terms always occur in same texts).
The co-occurrence is used as similarity metrics for the network
analysis.
For visualizing the co-occurrence matrix, we used Gephi,
an open source software for analyzing graphs and networks6.
In the resulting graph, the thickness of the edges reflects the
co-occurrence, i.e., a higher probability that two terms appear
in the same text is reflected by a thicker and more saturated
connection.
The sizes of the nodes (= topics) reflect their betweenness
centrality (BC), which is equal to the number of shortest
paths from all vertices to all others that pass through
that node. The betweenness centrality BC(X) of topic X is
defined as:
BC(X) =
∑
X �=Y �=Z
σY,Z(X)
σY,Z
Where σY,Z is the number of shortest paths between topics Y
and Z, and σY,Z(X) is the number of shortest path between those
two topics that pass through X. For example, if there are three
different shortest paths between two nodes and a third node is
part of two of them, then the BC of this third node and for
this specific configuration is 2/3. As a result, nodes with higher
BC are more influential, because they functions as junctions for
“communication” within the network (Freeman, 1977; Brandes,
2001). Terms with high BC are therefore hypothesized to play the
most important role in establishing the meaning for the text and
its interpretation.
We visualized the whole network of all topics as well as
the networks that only contained topics of two issue classes
(we performed six specific visualizations in total: anatomical
targets-indication, indication-side effects, anatomical targets-
side effects, technological issues-indication, economic issues-
indications, positive-effects-anatomical targets. In the following,
we display the three of them that yielded the most interesting
results.
In some cases, we also looked at Page rank values of each
node in order to make a statement about the importance of the
term. Page rank is an algorithm that was originally developed
to measure the relative importance of web pages. It formed the
basis for ranking results when using the Google search engine
and was named after Larry Page (Brin and Page, 1988; Page
et al., 1999). Today, Page rank is a common tool in network
analysis aiming at assessing linked documents based on their
6Available at http://gephi.github.io/
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TABLE 1 | Issues and associated topics, characterized by terms that were contained in the final set.
Issue Topics associated with issue (in brackets: terms that characterize the topic)
Anatomical localization 15 topics:
{accumbens, nucleusaccumbens}, {alic, limb}, {amygdala}, {caudatenucleus}, {centromedian, centromedianparafascicularcomplex},
{cingulatecortex}, {cingulum}, {globuspallidus, globuspallidusexternus, globuspallidusinternus, pallidus}, {hippocampus}, {pallidum},
{pedunculopontine, pedunculopontinenucleus}, {stn, subthalamicus}, {subgenual, subgenualcingulate, subgenualcingulatecortex}, {vim},
{zonaincerta}
DBS indication 20 topics:
{addiction, alcoholism, smoke}, {alzheimer}, {anorexianervosa, eatingdisorders, obesity}, {anxiety}, {ataxia}, {bradykinesia}, {chorea,
huntington}, {clusterheadache, headache}, {depression}, {dyskinesia}, {dystonia}, {epilepsy}, {essentialtremor, tremor}, {hypomania, mania},
{memory}, {obsessivecompulsive, ocd}, {parkinson}, {schizophrenia}, {sclerosis}, {tourette}
Positive effects 3 topics:
{qualityoflife, wellbeing}, {alleviation, relief, remission}, {enhancement}
Negative effects 18 topics:
{safety}, {aberrant, adverse, adverseevents, complication, decline, deterioration, distress, impairment, perseverative, sequela, sideeffect},
{apathy}, {ataxia}, {character, personality}, {death, die, suicide}, {dysarthria}, {dyskinesia}, {fluency, language, speech}, {hemorrhage,
hemorrhage}, {hypersexuality}, {hypomania, mania}, {impulsecontrol, impulsivity}, {infection, inflammation}, {memory}, {pain}, {psychosis},
{psychosocial}
Methodological issues 15 topics:
{ablation}, {radiosurgery, ultrasound, gammaknife}, {capsulotomy}, {cingulotomy}, {pallidotomy}, {subthalamotomy}, {thalamotomy},
{psychosurgery, lobotomy, leucotomy}, {computertomography, diffusiontensorimaging, eegfmri, electrocorticography, electroencephalography,
fmri, magnetoencephalography, mri, tomography, transcranialsonography, ventriculography, pet, spect}, {spinalcordstimulation},
{transcranialdirectcurrentstimulation}, {transcranialmagneticstimulation}, {vagusnervestimulation}, {electroconvulsivetherapy}, {dopamine,
dopaminereplacementtherapy, duodopa, ldopa}
Economic issues 3 topics:
{commercial, cost, costeffectiveness, economic, expensive, financial, inexpensive, market, socioeconomic, expenditure}, {industry,
manufacture, manufacturer, medtronic, kinetra}, {effectiveness}
Technological issues 3 topics:
{battery, cable, device, electrode, hardware, implantablepulsegenerator, lead, pacemaker, recharge, rechargeable, stimulator, wireless},
{closedloop, responsiveneurostimulatorsystem}, {program}
Remind that Lemmatizing in step 3 has mapped most of the different manifestations of topics (e.g., abbreviations) on a single term (e.g., the abbreviation “PD” on “parkinson”). The
topics ataxia, dyskinesia, (hypo)mania, and memory are present in two issue classes.
connectivity structure. The principle of this measure can be
explained as follows: the more links (in our case connections)
refer to a site (in our case to a node/topic), the more weight a
given site receives. As a consequence, the more weight a given
site/node acquires, the bigger its importance. If one interprets co-
occurrence of topics as a measure of “linking” two topics, then
the page rank value would determine the order of “search results”
in the network determined by the topics chosen by us. Since we
are only rarely referring to page rank, we refrain from describing
the mathematical basis of this algorithm in detail and refer to the
original work by Brin and Page, to a brief description by Chen
et al. (2007 p. 9) and to an in-depth review by Langville and
Meyer (Brin and Page, 1988; Langville and Meyer, 2004; Chen
et al., 2007).
Graphs were represented by use of a Force Atlas 2 algorithm
(Jacomy et al., 2014). This algorithm is used to spatialize the
network: nodes repulse each other similar to charged particles
whereas edges attract their nodes like springs. The specific
spatial distribution of each node therefore depends on the nodes’
connections to other nodes. As a result, the specific coordinate
of one single node cannot be interpreted on its own but has
to be analyzed in combination with other nodes (Jacomy et al.,
2014). Since edges are weighted, we added the “Edge Weight
Influence” δ (δ = 3.0, a pre-programmed selection option)
to the visualization in order to prevent edge weights to be
ignored.
RESULTS
Trend Analysis over Time
The trend analysis of potential anatomical DBS targets over
time suggests a crosscurrent tendency: while the discussion of
psychiatric DBS indications such as addiction, major depressive
disorder (MDD), schizophrenia, Tourette syndrome (TS), and
obsessive-compulsive disorder (OCD) (among others) are
increasingly being discussed, the discussion of conventional,
motor-related indications such as Parkinson’s disease (PD)
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and essential tremor (ET) recedes (see Figure 3A). Dystonia,
on the other hand, shows a surprisingly stable pattern over
time. In confirmation of the above, the trends for anatomical
DBS targets mainly match the ones depicted in the DBS
indication analysis: while traditional anatomical targets used in
movement disorder therapy decline over time—globus pallidus
(GP), ventral intermediate nucleus (Vim), subthalamic nucleus
(STN) –, a marked increase of “psychiatric” targets—e.g., nucleus
accumbens (Nacc) or subgenual cingulate (SG)—is visible (see
Figure 3B). Interestingly, the increase of psychiatric targets is less
pronounced than the one for psychiatric indications, suggesting
that psychiatric indications have become per se an emerging
topic within the DBS literature. The above described pattern is
again partly backed when including the trend analysis for lesion
methods (including radiosurgery, capsulotomy, gammaknife,
pallidotomy, to name a few) specifically: the discussion of such
alternative techniques in the context of motor disorders decreases
substantially. Interestingly, there is no trend in the case of
psychiatric indications (see Figure 3C).
In line with these results is the fact that overall, the trend
analysis for negative effects shows an increased emphasis in
discussing “psychiatric” phenomena (including anhedonia,
hypomania, personality, and impulsivity among others)
whereas phenomena associated with traditional, motor related
indications (apraxia, ataxia, dysarthria, among others) are
consistently less often discussed. Surgery related issues (such
as hemorrhage, infection, and ischemia, to name a few) are
quite stable. The data also confirm earlier findings (Müller and
Christen, 2011) that general terms which indicate side-effects
non-specifically such as “aberrant,” “adverse,” “complication,”
“distress,” “impairment,” “sequel,” “sideffect” (among others), are
also less often mentioned.
FIGURE 3 | Trend analysis for selected topics. (A) Movement disorders vs. psychiatric indications; (B) DBS targets for movement disorders vs. targets for
psychiatric indications; (C) mentioning of lesion methods in papers also mentioning movement disorders vs. psychiatric indications.
Frontiers in Integrative Neuroscience | www.frontiersin.org 6 October 2015 | Volume 9 | Article 52
Ineichen and Christen Analyzing 7000 DBS texts
Finally, technological terms associated with new stimulator
systems such as “closed loop,” “responsive neurostimulator
system,” “rechargeable,” and “wireless” have partly displaced
the discussion about conventional technological and hardware-
related terms which themselves are less often discussed (e.g.,
“battery,” “cable,” “electrode,” “implantable pulse generator,”
“lead,” “pacemaker,” and “stimulator”; data not shown).
Analysis of Whole Data Set
General Structure of the Graph
Overall, the aggregated graph (except the issue ethic which
was analyzed separately) consists of 73 nodes and 1908 edges
(Figure 4). We observe the average shortest path length to be
pretty small (1.3) (Jackson, 2008) (i.e., we can move from one
point in the network to another point quite easily, the graph is
therefore well-interconnected). The graph furthermore shows a
high number of influential nodes besides a high value of average
degree (i.e., a quite diverse text corpus). In general, degree is a
measurement of connectedness in graph theory whichmeans that
a specific node in a given network with high degree consequently
has many neighbors in that network. A high average degree
therefore means that the graph is highly interconnected. Because
of this high average degree, no contextual clusters have been
identified using the community detection algorithm of Blondel
et al. (2008).
Thematic Structure of DBS Publications
The betweenness centrality (BC) analysis reveals that apparently
five main topics dominated the DBS field in terms that they
occupied an exceedingly central space within the whole text
corpus. Those are effectiveness, safety, side-effects, and hardware
related issues apart from PD, the main indication for DBS
FIGURE 4 | Network of all 73 topics (except ethic). Color-code: Blue: indications; purple: anatomical targets; yellow: methods; green: positive effects; red:
negative effects; brown: economic issues; gray: technological issues.
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(equal BC values; see Figure 4 and Table 1 in Supplementary
Materials). Moreover, those topics are adjacent to most of the
words in the network and therefore function both as local hubs
(i.e., a node with many connections) and as important junctions
within the whole text corpus.
Apart from the five main topics, the topics including positive
effects (alleviation, relief, remission), MDD, imaging methods,
dopamine, quality of life (QoL), STN, dystonia, OCD, anterior
limb of the internal capsule (ALIC), pain, enhance(ment),
epilepsy, death, ET, and imagingmethods (with decreasing values
across sequence) also show high betweenness centrality. Concrete
side-effects appear at place 25 and 27 (dyskinesia and infection).
The topics personality (place 41), psychosocial (place 56)—
both inherently difficult variables –, subthalamotomy, alternative
therapies [such as electro-convulsive therapy (ECT), vagus nerve
stimulation (VNS), spinal cord stimulation (SCS), or transcranial
direct current stimulation (tDCS)] and hypersexuality [which
itself occurs quite rarely (in 19 abstracts only)] (place 72) receive
especially low BC.
A Google’s page rank analysis revealed the following
sequence of importance: PD, hardware related terms, side-effect,
STN, MDD, effectiveness, dopamine, ET, imaging-methods,
GP, OCD, safety, dystonia, and positive effects (alleviation,
relief, remission). The BC values of neuroanatomical targets
indicates a higher BC value for ALIC than for GP and a
higher one for Nacc than for Vim. However, this sequence
changes when conducting Page-rank analysis: highest values
are accredited to the STN, GP, ALIC, Vim, and Nacc.
Also, the lesional approaches (pallidotomy, subthalamotomy,
and thalamotomy) receive dramatically more weight (in the
middle field) when performing Page-rank (among lowest if
conducting BC).
Analysis of Specific Topics
Next we performed a co-occurrence analysis incorporating the
five terms (effectiveness, safety, side-effect, PD, and hardware)
with highest BC (see Table 2 in Supplementary Materials for
detailed information on all co-occurrence-values). Firstly, the
topic effectiveness is most often mentioned in combination
with the topics PD and hardware. Likewise, the second
topic safety is most often discussed in the context of PD
and hardware. Third, we were interested in the topic side-
effect, which shows to be, apart from PD, the topic with
most above-threshold co-occurrences (co-occurrences > 0.3,
determined by the authors based on distribution of the
data; see Table 2 in Supplementary Materials). It is most
often mentioned with hardware- and motor-related side-effects
but also includes side effects of the psychiatric/psychological
domain: infection, hemorrhage, dysarthria, apathy, speech,
psychosis, memory, mania, dyskinesia, psychosocial, anxiety,
hypersexuality, subthalamotomy, STN (among others, with
decreasing values across sequence). Fourth, the main indication
PD, is discussed to a greater extent with hypersexuality
(or more accurately; whenever there is a text including
the term “hypersexuality,” “parkinson” is most often also
present), bradykinesia, subthalamotomy, and apathy. Please
note that the term “hypersexuality” appears quite rarely
(in 19 abstracts only). The results therefore have to be
complemented and analyzed in combination with how often a
term actually occurs within the texts (for frequency distributions
see Supplementary Figure 1B). The last and fifth key-
topic with highest BC includes hardware-related issues which
is discussed most often with industry, hemorrhage, new
systems (terms: “closed loop,” “responsive neurostimulation
system”), program, infection, PD, and general economic-
topics (terms “cost,” “commercial,” “economic,” “financial”
among others).
Analysis of Interactions between Different
Issues
In order to investigate on potential interactions of different
issues, we conducted a co-occurrence analysis. First we outline
the co-occurrence of topics related to the issues indications,
anatomical targets, and side-effects.
Interaction between Indications and Side-effects
As for the combination of indications and side-effects (Figure 5),
the strongest co-occurrence connections yielded the following
results. The topic PD is most commonly discussed with
hypersexuality (as already stated above). Moreover, PD is
often discussed with apathy, dyskinesia, mania, impulsivity,
speech (and dysarthria), psychosocial, death/suicide, and
psychosis. ET, on the other hand, is most often discussed
with dysarthria. Of note is the fact that neither MDD nor
dystonia is strongly connected to any concrete side-effect.
Additionally, and as a side note, an intracategorial analysis
shows most often co-occurring side effects to be impulsivity and
hypersexuality.
Interaction between Indications and Anatomical
Targets
The combination of indications and targets (Figure 6) showed
strongest co-occurrence connections between PD and the STN,
followed by the pedunculo-pontine nucleus (PPN), the zona
incerta (ZI) and lastly with the GP. ET, on the other hand, is
clearly connected with the Vim. MDD is most often linked to
the SG, the cingulate cortex, and Nacc, while the indications
bradykinesia and dyskinesia show most frequent connections to
the STN. Finally, OCD is most often discussed with the Nacc and
schizophrenia with the hippocampus.
Interaction between Side-effects and Anatomical
Targets
Finally, the strongest co-occurrence connections between the
issues side-effects and anatomical targets (Figure 7) yielded the
following results: The STN is most often discussed with apathy,
mania, speech, dysarthria, impulsivity, death, and hypersexuality.
We found no robust co-occurrence between neuroanatomical
targets relevant for the treatment of psychiatric disorders and
concrete side-effects (such as infection and the like). Also no
marked co-occurrence of side-effects and anatomical targets
other than the STN were observed.
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FIGURE 5 | Network-Analysis for the issues indications (blue nodes) and side-effects (red nodes).
Additive Relationships
Additively, we were interested in potential connections between
topics from economic issues, technological issues, and positive
effects.
The topic industry is most often discussed with PD, imaging
methods, safety, and ET. Interestingly, terms like “costs,”
“economic,” “commercial” and the like are markedly linked to
the indication PD solely. The issue positive effects including the
topics alleviation, relief, and remission are most often associated
with PD, pain, and dopamine. The terms “quality of life” and
“wellbeing” on the other hand are most often connected to PD,
side-effect-related terms, psychosocial, and apathy while most
prominent connections with regard to the topic enhance(ment)
are PD, hardware, and STN. In particular, the strong connection
between QoL and psychosocial is important because it may
highlight an increased interest in psychosocial issues in the
context of QoL. Finally the topic program is most often discussed
with PD and STN whereas the topic of new-devices (terms:
“closed loop” and “responsive neurostimulation system”) is most
often connected to PD and epilepsy.
When integrating how methods other than DBS are discussed
within the DBS-literature, one finds the following outcomes:
Concerning indications, PD is most often connected to
subthalamotomy, dopamine, and pallidotomy. OCD on the
other hand is robustly connected to capsulotomy and to a
minor degree to cingulotomy whereas ET is mentioned most
often in combination with thalamotomy. Finally, MDD is
most often discussed with ECT, cingulotomy and still quite
often with tDCS whereas epilepsy is most often discussed
with VNS.
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FIGURE 6 | Network-Analysis for the issues indications (blue nodes) and anatomical targets (purple nodes).
Regarding side-effects, dopamine is apparently most often
discussed in combination with hypersexuality, impulsivity,
psychosis, apathy, and dysarthria. Psychosurgery on the other
hand, is mostly discussed in the context of cingulotomy
whereas pain (here probably meant as indication) most often
with SCS.
Associations with the Topic “Ethic”
There is a rich discussion which deals with ethical aspects in
the context of DBS. Ranging from personality changes and side-
effects (Christen et al., 2012) to topics taking up the debate of
human enhancement (Synofzik and Schlaepfer, 2008; Schermer,
2013) and research ethics (Fins et al., 2011), the discussion is
clearly multifaceted. Hence, ethical questions are a constant topic
of debate. Therefore, we were interested in how ethics-terms
interrelate with other terms of the text corpus. We therefore
investigated the co-occurrence of the topic ethics with all other
topics (see Figure 8). Apart from the rare topic psychosurgery
(present in only 52 texts) and the very frequent topic PD (present
in 3544 texts) which yielded the strongest co-occurrences, the
ethics-topic is most often linked to personality, psychosocial, side
effect, hardware, MDD, and hypersexuality. Of note is the very
rare connection between ethical issues to the GP (in only 3% of
the total possible co-occurrences) compared to the STN (in 14%
of the total possible co-occurrences).
DISCUSSION AND CONCLUSION
We will first outline some of the findings which underpin
the validity of our approach directly followed by discussing
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FIGURE 7 | Network-Analysis for the issues negative effects (red nodes) and anatomical targets (purple nodes).
findings acquired from the trend analysis over time and then
guide the discussion toward the graph analysis based on BC
and co-occurrence. Finally, we will outline pertinent ethical
questions.
Findings Corroborating the Validity of Our
Approach
We detected a multitude of findings which underpin the validity
of our approach, some of which we highlight in the following.
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FIGURE 8 | Interrelation of the topic ethics to all other topics with at least 5% co-occurrence (for color code see caption of Figure 4).
Chronic pain for example, is a well-described indication
suitable for spinal cord stimulation (Wolter, 2014). The findings
including indications and lesion methods also confirm known
connections as evidenced in the case of ECT, a well-known
therapeutic option for the treatment of MDD, besides others.
The relationship of epilepsy and closed-loop systems might
also underpin the robustness of our methodological approach
by bearing in mind that epilepsy characterizes a promising
indication for the application of closed loop devices (Armstrong
et al., 2013; Krook-Magnuson et al., 2013; Paz et al., 2013;
Nagaraj et al., 2015). Regarding anatomical targets and side-
effects, we highlight a distinct connectivity between the STN
and impulsivity which has been described elsewhere (Zavala
et al., 2015). Regarding the detected intracategorial connection
between impulsivity and hypersexuality, a recent publication
confirms a tight connection between the two topics (Kor
et al., 2013). Hence, a multitude of identified co-occurrences
incorporating the different issues such as indications and
corresponding lesion methods, or indications and anatomical
targets among others, serve as validation of our method.
Trend Analysis
When analyzing the data set including DBS-indications and
relevant anatomical targets, one can identify a clear shift
away from motor-related neuroanatomical targets (GP, Vim,
STN) (even though numerically still predominant) toward an
emphasis on anatomical targets which are especially relevant in
psychiatric indications (Nacc, amygdala, hippocampus, SC) (see
Figures 3A,B). Such a tendency is indicative for the broadening
of the therapeutic spectrum of DBS. A multitude of scientific
publications highlighted this circumstance already (e.g., Hariz,
2012; Hariz et al., 2013; Christen et al., 2014, to name a few).
Even though we cannot make a qualitative statement about how
such topics are being discussed (i.e., the discussion may be
framed in a supportive, critical, or neutral way), the identified
increase may represent the seen utility in DBS for the treatment
of psychiatric indications. Questions about suitability of such
complex disorders for the therapeutic application of DBS and
the difficult search of anatomical loci for the treatment of such
indications (e.g., for MDD (among others): Nacc, ALIC, and
SG) may also be indicative for such an increase. Additionally,
the data highlights no standard locus for the treatment of MDD
(e.g., Hariz et al., 2013 for the unspecific use of neurostimulation
targets in the context of MDD, TS, and OCD; or Da Cunha
et al., 2015; Kocabicak et al., 2015). Finally, the trend analysis
incorporating negative effects (data not shown) completes the
picture; while motor side effects are less frequently discussed,
complex issues such as personality are increasingly the topic of
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the current debate. In the context of psychiatric disorders, such
phenomena seem to be prevalent to a greater extent.
The trend analysis involving lesion based therapy approaches
revealed that lesion approaches recede in the context of motor-
related disorders and are quite stable in the case of psychiatric
disorders. This might demonstrate—and under the assumption
that medication based therapy is still the most frequently used
therapeutic approach—that (1) lesions are still considered to
be an effective and reliable means for patients refractory to
drug-therapy and (2) that DBS was not (yet) able to replace
lesion-based therapy approaches in psychiatry. When talking
about an observed decline of the discussion of topics related to
lesion approaches, one has to emphatically point out that this
reflects how lesions are being discussed within the DBS-literature
only. This means that we are limited in our interpretation
of observations related to lesion methods and look with a
narrow “DBS-perspective” on relationships which are discussed
in these articles. Moreover, lesion approaches are still considered
therapeutic competitors and as suchmight receive little attention.
We have outlined elsewhere (Christen et al., 2014, but see
also Müller et al., 2015) the importance of ensuring alternative
therapeutic approaches which of course would not quantitatively
carry much weight when extracting abstracts from numerous
DBS-publications.
Network Analysis
Thematic Structure of DBS Publications
Our results suggest that the topics PD, side-effect, hardware,
safety, and effectiveness play a conducive role within the DBS
literature and this to a greater degree than other terms because
the relation of their influence to the total number of connections
was calculated to be highest (reflected in BC). One could say
that the backbone of any publication in the context of DBS
is composed of issues about safety, side-effects, effectiveness,
hardware, and PD. These junctions act as mediators within the
discursive field of the textual graph. The broader backbone of a
publication in the field of DBS can be inferred to be generated
through the mentioning of the remaining major topics: relief,
MDD, imaging methods, dopamine, QoL, STN, dystonia, OCD,
ALIC, pain, enhance(ment), epilepsy, death, ET, and TMS. This
furthermore means that by analyzing the top 20 terms and by
allocating those to the major topics, it is evident that indications
are most numerously represented (n = 7), followed by negative
effects (n = 4), methods (n = 3), and anatomical targets
(n = 2). As the discussion in the DBS literature is shifting
toward new and more specific questions, specific anatomical
targets tend to be less often associated with more general topics.
The strong representation of indications again reflects the trend
of broadening the therapeutic spectrum in the context of DBS.
Personality and Psychosocial Issues in DBS
Publications
The growing discussion about personality (trend analysis) is not
yet reflected in BC because the topic personality shows one
of the lowest BC-values. This can be explained by referring
to the low frequency of the topic itself within the whole
text corpus and may likely change as such issues have to
be addressed in the context of measuring pre-post-effects in
the case of psychiatric neurostimulation. The circumstance
of personality and psychosocial issues receiving low BC may
indicate that their associated concepts represent genuinely vague
and difficult variables and consequently are not utterly useful
for clinical research. As validated instruments to objectively
and qualitatively measure changes in the personality and the
psychosocial dimension are often missing or criticized for not
accurately measuring the topic under investigation, such much
needed concepts cannot easily enter clinical research (Dimitrov
and Rumrill, 2003). The fact that psychiatric indications are
increasingly being addressed by means of brain-stimulation, the
need for the accurate and thorough observation and measure
of psychosocial and personality-related issues (and also in the
context of movement and other disorders, Pham et al., 2015)
is obviously most important. Therefore, with more accurate
insights into the neuronal circuitries exerting maladaptive effects
on many disorders despite high complexity and limited means
of investigation (Rossi et al., 2015) and the eagerness to evaluate
results beyond short-term quality of life (Ooms et al., 2014),
indications for DBS should get more individually tailored (Galati
and Stefani, 2015). Additively, the accurate and longitudinal
measure of psychosocial issues has already been proposed also in
the context of movement disorders (Schüpbach and Agid, 2008).
Combined with the fact that the topic QoL is robustly connected
to the topic psychosocial, as well as the fact that a limited number
of scales for the measurement of personality- and psychosocial-
related issues do exist, the introduction of such instruments
combined with the eagerness to improve such instruments, is
greatly needed.
Economic Issues
The restriction of the discussion incorporating economic issues
to PD only, also poses questions. Given the increase of
psychiatric indications, economic considerations should be in
place and extended toward other indications in order to
adequately address socio-economic issues. The often observed
co-occurrence between the topic economic and ethic further
emphasizes this point.
Centralities of Neuroanatomical Targets and Their
Implications
The BC-values of neuroanatomical targets indicate a higher one
for ALIC than for GP and a higher one for Nacc than for Vim.
This may serve as another evidence for the growing importance
of neuropsychiatric topics in the literature of DBS. However, this
sequence changes when conducting Page-rank analysis: highest
values are accredited to the STN, GP, ALIC, Vim, and Nacc. Since
Page-rank puts an emphasis on the number of connections (e.g.,
“links”), the traditionalmotor targets STN andGPwould be listed
before ALIC within a given search result. Given the fact that GP
and Vim represent historically older topics in DBS and based on
the higher Page-rank values, the two are more densely linked
with other topics. However, ALIC and Nacc already are more
central concepts within the DBS-literature, presumably acting as
mediators of information to a greater extent than GP and Vim.
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MDD and Alternative Therapeutic Approaches
The execution of a Page-rank analysis also changes the sequence
of the most important topics: PD clearly is attributed the highest
value and MDD makes it into the “top 5.” In sum, one can
state that depression is the most discussed psychiatric indication
in the DBS literature. In light of MDD’s importance within the
DBS literature, it is from a bioethical point-of-view important to
emphasize that this indication has not yet received approval from
the U.S. Food and Drug Administration (FDA) as a standard
therapeutic treatment. Patients therefore should be well-
informed about the ongoing search of optimal neuroanatomical
targets, the challenging support without standardized guidelines
of patients along the whole treatment and beyond as well as the
complexities associated with the appropriate conduct of clinical
trials (Jimenez-Shahed, 2015) and the vulnerability of patients
(Bell et al., 2014).
When looking specifically at alternative therapeutic
approaches such as SCS, tDCS, ECT, and VNS, it becomes
obvious that they receive especially low BC. This circumstance
can be explained by highlighting that we specifically selected
scientific publications involving DBS. Presumably, those
publications have a low interest in advocating for alternative
therapeutic approaches. Furthermore, the co-occurrence analysis
shows that within the DBS-literature, ablative therapeutic
approaches such as pallidotomy, subthalamotomy, and
thalamotomy are most frequently discussed in combination
with terms from the topic side effect. While ablative therapeutic
strategies appear to a greater degree to be negatively connoted,
the latter also symbolize the still most direct competitors to
DBS, as already outlined within the trend-analysis. Interestingly,
the lesional approaches (pallidotomy, subthalamotomy, and
thalamotomy) receive dramatically more weight (in the middle
field) when performing Page-rank (among lowest BC). In
analogy of the previous hypothesis, lesion approaches might
be underestimated if incorporating BC only and seem to be
interlinked to a greater extent.
Discussion of Issue-comparisons
The specific comparison involving indications and side-effects
indicates that the description of side effects is clearly dominated
by the ones closely associated with PD, the indication for which
most publications exist (n = 3544, followed by essential tremor,
n = 901). This does not mean that PD is the DBS indication
where most side effects occur, but that side effects are most
frequently described in the context of PD. As outlined above,
the strong connection between PD and hypersexuality only
reflects that within the few papers dealing with hypersexuality,
the term “parkinson” is almost always present. Since the topic
hypersexuality is very infrequent, this result has to be taken
with caution. On the other hand, one also has to take into
account that our data consist of abstracts only, i.e., terms need
to have some importance within a paper in order to appear
in the abstract. Side effects of other indications, especially
neuropsychiatric, are to a far lesser degree discussed. Depression
for example co-occurs only to a minimal extent with personality,
death, and psychosocial issues. As highlighted previously, side
effects in the context of psychiatric disorders are expected to
be (1) much harder to be identified and (2) still have to be
published as such newer indications have only recently been
added to the therapeutic spectrum. OCDwith its unconventional
entry into the therapeutic landscape via a humanitarian device
exemption (Fins et al., 2011) is also quite rarely discussed in
the context of concrete side effects [probability of co-occurrence:
hypersexuality (11%), impulsivity (8%), and infection (5%)].
Again, there is a duty to longitudinally follow patients in order to
constantly monitor potential side-effects, besides the great need
for introducing new measures in order to fully capture potential
changes also in the psychosocial/psychiatric domain (Lilleeng
et al., 2015).
The comparison involving indications and neuroanatomical
targets highlights a further interesting result: apart from being
discussed most often with the STN, PD is also quite strongly
connected to the PPN, even more than to the GP—the other
standard target for stimulation apart from the STN. PPN-
stimulation was initially promoted for the treatment of balance
impairments as well as refractory gait freezing and has been
shown to be used as surgical target relatively unspecifically (“the
PPN-area”) and this despite largely unknown clinical usefulness
(Hariz et al., 2013). The high centrality of the PPN together with
such a critical stance toward its usefulness and lack of clinical
evidence further corroborates an apparent tension.
Finally, when comparing side-effects and anatomical targets,
we observe again a dominant description of side-effects in
combination with the STN—one of the most widely used
anatomical targets for the treatment of movement disorders.
The most frequent co-occurrence of the GP is its connection
to apathy, but this happens only in 7.5% of cases in which a
possible co-occurrence is possible. This, potentially driven by
stimulation of ventral and medial subterritories of the STN
(for STN-subterritories see Tremblay et al., 2015; for actions
beyond motor control see Zavala et al., 2015), reflects a described
dominance of side-effects in the context of STN rather than
other (e.g., GPi) DBS targets. Moreover, this could indicate
that side-effects emanating from predominantly ventral STN-
stimulation have overshadowed the description of side-effects
of other anatomical targets such as the GP. Alternatively,
the STN may be intrinsically more prone to (behavioral or
affective) side effects due to its circumscribed connectivity to
limbic areas. There is evidence for a clearer separation of
motor and non-motor functions in the GPi compared to the
STN (Wichmann and DeLong, 2011; Da Cunha et al., 2015).
Additionally, ALIC, an anatomical target with marked BC, is
rarely found in combination with specific side effects. This
imbalance may be problematic or may be the result of the already
mentioned problem of capturing side-effects in the context of
psychiatric disorders. However, if DBS for the neuropsychiatric
domain further expands, the accurate description combined
with the nuanced measurement of psychological changes poses
a bioethical obligation and responsibility for any researcher
involved. It might be an interesting endeavor to once try to
capture the implicit perception of professionals in the field of
DBS regarding such issues. The numerical imbalance of how
e.g., anatomical targets are discussed in relation to side-effects
together with the concrete framing of such issues within the
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most often read articles in the literature supposedly induce
unconscious preferences which do not necessarily display the
situation in an accurate way based on (pre-)clinical evidence.
Bioethical Issues
As the field of bioethics is comparably subjected to a vast
increase of publications, quantitative methods for obtaining a
better understanding might be as important as for neuroscience.
Such an approach is moreover suitable for identifying potential
mismatches between what is currently being discussed and what
might be important ethical topics which are less tangible or more
vulnerable for being overlooked.
Motor-targets and Their Connection to Ethics
Apparently, ethical issues are to a greater extent discussed in
combination with the STN rather than the GP. Is the STN
therefore more thoroughly described in terms of its stimulation-
based ethical consequences or is there evidence that the STN
intrinsically harbors to a greater extent problematic ethical
issues including the potential of inducing undesired effects? The
debate of which target is most appropriate (mostly including
STN and GP, Follett et al., 2010; Krack and Hariz, 2010;
Odekerken et al., 2013) is an old one. But since currently,
there is evidence for a statistical chance selection rather than
one based on (patho)-physiological evidence for either receiving
STN or GP stimulation (Christen et al., 2014; Gilbert, 2014)
[besides clinical considerations such as envisaging drug reduction
(STN) or preexistence of cognitive symptoms (GPi) (Da Cunha
et al., 2015)], this difference might be an important one.
As long as there is no proven display regarding superiority
in terms of therapeutic action, there might be a duty to
investigate ethical issues to a similar extent for all nuclei used
for stimulation.
Depression and Its Connection to Ethics
Another interesting finding is an observed imbalance reflected
in a strong connection between the issue which incorporates
the topic ethics on the one hand and MDD on the other
and a substantially weak connection of the former topic and
the one involving the most often used anatomical targets in
the context of depression. Whenever ethical issues are being
discussed, MDD is most often also discussed. However, the
factual co-occurrence dramatically decreases in the case of
neuropsychiatric anatomical targets: ethical issues co-occur only
in 6.5% of cases when discussing the Nacc, in 3.5% when
discussing the ALIC and in 1.75% when discussing the SG. This
apparent dissociation between indication and anatomical target
is questionable and more pronounced as in the case of PD and
STN. As DBS has not faced a comparably long history regarding
randomized controlled clinical trials for psychiatric disorders,
studies have to be continued in order to identify which nucleus
(or nuclei) shows greatest potential for the treatment of MDD
and other neuropsychiatric disorders but also to identify which
nucleus might be especially vulnerable for (behavioral) side-
effects, psychosocial maladjustments and consequently ethical
issues (e.g., non-maleficence).
Hardware Related Issues
As evidenced in some publications (Kondziolka et al., 2001;
Okun et al., 2005; Fins, 2009) hardware related complications
do impose ethical challenges. This is also backed by our results
highlighting an apparent tension between hardware and ethical
issues. Concomitantly, our data set indicates a continuous
decrease of the discussion of hardware related topics (evidenced
in the trend analysis; data not shown) but also particularly
high BC. The strong link to ethical issues, apart from the mere
description of hardware-related side-effects, might be evaluated
as unintuitive. However, the data suggests that hardware related
issues in the context of social, ethical and moral questions
apparently have already been a topic of debate (e.g., Hilimire
et al., 2015; Fumagalli et al., 2015). Generally, the topic of ethical
and social implications of technological devices is certainly an
important one which, e.g., in the context of emerging closed-loop
devices, will nourish further discussions in the future. Therefore,
closely investigating ethical, social, and clinical aspects of
the follow up process longitudinally, including e.g., the often
challenging postoperative phase for precise DBS parameter
adjustments (Ineichen et al., 2014) as well as fiscal and legal
aspects of hardware replacement apart from ethical issues
specifically in the context of hardware is important. In parallel,
our result may emphasize not only a duty to investigate hardware
related ethical issues which transcend merely and well-known
technical problems (Christen et al., 2014) thoroughly, but also
that ethical duties already instantiated also apply to engineers
which represent key players and which are well-positioned to
support the deployment of innovative hardware in order to
diminish the burden of patients (Fins, 2009). In the general
DBS review literature, hardware-related issues such as the ones
attached to recording devices and the related implications for
patients’ autonomy and responsibility but also the potential use
and abuse of such recorded signals in connection with privacy
issues, the dependency on device manufacturers (Underwood,
2015) and conflicting interests (Clausen, 2011), the long-term
risk of living with implanted hardware (Farris et al., 2008)
apart from psychological issues have in comparison to surgical
complications probably received less attention. The fact that
hardware-related issues receive dramatically more weight in
the context of ethical challenges than impulsivity, concrete
side-effects and death/suicide is certainly surprising and needs
further analysis. Whether this means that hardware-related
issues are already sufficiently discussed in an ethical and social
context or need further exploration has to be identified by a
qualitative in-depth analysis.
Although DBS has alleviated patients suffering tremendously,
many obstacles still remain. Recently, the development of
innovative neuromodulation exemplified by current steering
(Martens et al., 2011; Hariz, 2014b), adaptive DBS (Little et al.,
2014) but also the potential deployment of closed-loop devices
(e.g., Rosin et al., 2011; Grahn et al., 2014; Williams, 2015) have
increasingly gained weight within the discussion of DBS. In the
meanwhile, magnetothermal neuromodulation in translational
models (Chen et al., 2015) shows potential to increase our
knowledge of neuronal microcircuitries (Temel and Jahanshahi,
2015). Apart from technological as well as biological hurdles (e.g.,
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identification of true biomarkers) also ethical issues might arise.
As our data highlights a tremendously weak co-occurrence of the
topics ethics and closed-loop, it might be time to think about
how emerging closed-loop devices may affect already instantiated
guidelines and what differences as well as implications might be
identified both from a theoretical (i.e., philosophical) but also
practical (i.e., what it would mean for patients) perspective.
Limitations
This study, of course, incorporates some limitations. First of
all, as in any quantitative text-network approach, we are unable
to make qualitative statements. This however, is within the
nature of a heuristics approach. Additionally, various topics
might in fact be used in a different context than used as a
basis for interpretation within this study. For example, the
neuroanatomical targets may in fact very well also be mentioned
without referring to a target for stimulation. For example, the
STN may be described within a DBS-publication not as a
target for stimulation but within the context of hyper-reactivity
in the case of hemiballism. Due to the fact that we have
limited our analysis to abstracts, we assume this scenario to
be quite infrequent and would hypothesize such a wording to
be included in a general introduction rather than within an
abstract. Moreover, the Web of Science database is associated
with a language bias. As papers emphasizing psychosocial and
philosophical issues are often published in other languages, they
are likely to be underrepresented in our sample. Finally, topics
which incorporated multiple terms, of course, inevitably have a
greater probability of co-occurrence.
Outlook
The proposed analysis is by no means complete and has no
prerogative of accuracy. It is one additional possibility to read any
text in order to gain new insights about its structure and hidden
messages, suitable to deal with a large number of texts. We are
of the opinion that applying network approaches, visualization
techniques and graph theory to a text corpus might be an
innovative and promising alternative which entails fruitful and
worth considering aspects. The final interpretation of the data,
once visualized as a graph, is certainly open for discussions and
by no means definitive.
Hariz recently wrote in his book chapter “The literature
revisited” that “serendipitous discoveries and advances in
functional imaging are providing ‘new’ brain targets for an
increasing number of pathologies, and the corollary is an
exponentially growing literature on DBS, such that it is simply
impossible to keep track of all papers and books appearing on
this subject.” He then goes on by stating “While most of the
literature constitutes an invaluable wealth of knowledge, a small
but important part gives rise to serious concern and needs to be
revisited and discussed” (Hariz, 2014a). By using a quantitative
network approach, we tackled this issue from another perspective
and tried to identify potentially hidden and underrepresented
issues which might be relevant for further discussions and future
research.
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Synopsis
In order to achieve insights into the global practice of DBS, we performed a survey among DBS 
centers (n = 135) and experts (n = 113). The following results frame the problem of conflicting out-
come interpretations (discussed in the introduction) and provide elements which might constitute 
tension-points in the context of psychosocial and behavioural management post-operatively.
In terms of decision making, we discovered some mismatch between fears patient mention fre-
quently and the actual risks. The results highlight that the frequency of patient fears and expert 
assessment of risk probability differ. Surgical complications are mentioned often by patients, al-
though their incidence is small; technical problems and personality changes are less often mentioned, 
although they are more frequent. The fact that patients rather seldom raise issues like technical 
problems with the device and postoperative personality changes due to stimulation might indicate 
an information-gap between patients and experts. This may partly be responsible for the relative high 
prevalence of satisfaction gaps reported.
We also found that complex changes in behaviour (“personality changes”) and the “satisfaction 
gap” seem to be more common problems than expected: 26.5% of the experts believed that “perso-
nality changes” may occur in more than 5% of the cases. 38.0% of the experts believed that “satisfac-
tion gaps” occur in more than 10% of the cases (30%,11-20% & 8% >20%). When asking for likely 
causes for the emergence of personality changes, 43.4% of the experts considered stimulation to be 
the more likely cause of personality changes compared to changes in medication. The experts descri-
bed personality changes both as an increase as well as decrease of a patient’s activity level.
With respect to the institutional dimension, we find a surprisingly fast dynamic with respect to 
the expansion of DBS indications: 12% of all centers already perform DBS for depression (research 
trials) and 40% of all centers plan to offer a therapeutic intervention for depression within the next 
5 years. Depression therefore is the indication which is most frequently planned to be offered by the 
centers.
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Deep brain stimulation (DBS) is a standard therapy for several movement disorders, and the list of further indications that are
investigated is growing rapidly. We performed two surveys among DBS experts (n1 D 113) and centers (n2 D 135) to identify
ethical focal points in the current global practice of DBS. The data indicate a mismatch between the patients’ fears and the
frequencies of the suspected side effects, a significant “satisfaction gap,” signs of improvements of outcome, habituation effects
in terms of involved disciplines, a growing spectrum of novel indications that partly conflicts with the experts’ success
probability ratings, and differences in the density of supply between countries that might affect the future development of DBS.
We formulate ethical recommendations with regard both to patient-related practices (e.g., recruitment, assurance of
alternatives) and to institutional development (e.g., measures for quality assurance and for the development of novel DBS
indications).
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Deep brain stimulation (DBS) reflects a fundamental shift
in the understanding of neurological and psychiatric dis-
eases: namely, as resulting from a dysfunctional activity
pattern in a defined neuronal network that can be normal-
ized by targeted stimulation. DBS has been developed
since the 1950s (Hariz et al. 2010); its “modern era” began
in the 1980s (Benabid et al. 1987; Siegfried 1986). In recent
years, the application of DBS has grown remarkably
(M€uller and Christen 2011) and is increasingly investigated
as a therapy option for various intractable neurological
and psychiatric disorders (Goodman and Alterman 2012;
Holzheimer and Mayberg 2011), primarily for obsessive-
compulsive disorder (OCD) (De Koning et al. 2011) and
major depressive disorder (Anderson et al. 2012; Schl€apfer
et al. 2013). The spectrum of indications for which DBS is
used in pilot studies is rapidly expanding; it comprises
drug addiction (Luigjes et al. 2012), Tourette’s syndrome
(M€uller-Vahl 2013), aggressive and disruptive behavior
(Franzini et al. 2012), severe obesity (Halpern et al. 2011;
Whiting et al. 2013), anorexia nervosa (Lipsman et al.
2013a), and Alzheimer’s disease (Hardenacke et al. 2013;
Laxton and Lozano 2013; Laxton et al. 2010). To date, DBS
has been approved (European CE mark) in Parkinson’s
disease (PD), essential tremor (ET), dystonia, epilepsy, and
obsessive-compulsive disorder (OCD).
The beneficial effects of DBS on motor functions are
well established (Deuschl et al. 2006; Kleiner-Fisman et al.
2006; Wider et al. 2008). The evaluation of cognitive, affec-
tive, and behavioral sequelae of the intervention (Vide-
novic and Metman 2008; Volkmann, Daniels, and Witt
2010; Witt, Daniels, and Volkmann 2008) is nontrivial, as
they may result from surgery, stimulation, or drug reduc-
tion, and—in particular in PD—similar effects can result
both from disease progression and from medication. Tak-
ing these issues into account, the focus of research is shift-
ing to practical issues like decision-making of patients,
psychosocial effects of the interventions, and optimal long-
term care. Thus, DBS has become an established therapeu-
tic option with new indications on the horizon.
We propose to investigate the practice of DBS along
two dimensions: The first dimension relates to all processes
that influence the individual intervention (patient-related
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dimension), and the second relates to the development of
the infrastructure (infrastructure-related dimension). The
first dimension involves information of patients, the refer-
ral practice, exclusion criteria, decision-making, the inter-
vention, and the follow-up (Clausen 2010; Kubu and Ford
2012; Lipsman et al. 2012). The infrastructure-related
dimension captures aspects of the development of the DBS
infrastructure that are decisive for high-quality interven-
tions. This includes issues like the emergence of new DBS
indications, involvement of different disciplines, differen-
ces in the DBS procedures between centers (e.g., target
preferences), center capacities, the financing of DBS
research, and the long-term planning of center develop-
ment given the growing spectrum of DBS indications
(Abosch et al. 2013; Bell, Mathieu, and Racine 2009; Fins
et al. 2012).
In order to obtain an overview of the global practice of
DBS we performed two surveys: a survey of researchers/
clinicians and a survey of DBS centers. The surveys
addressed the decision-making process of patients, disci-
plines involved in the DBS procedure, target preferences
of centers, exclusion criteria, risk evaluation, outcome
analysis, expert opinions about characterization, incidence
and causes of “personality changes” following DBS, and a
possible “satisfaction gap” (Agid et al. 2006; Kluger et al.
2011). Furthermore, the surveys collected data that allows
for assessing the referral practice, trends for novel indica-
tions, and the experts’ opinions with respect to controver-
sial DBS issues. Cross-comparison of both surveys allowed
for validating the results.
MATERIALS ANDMETHODS
Survey of Experts
The anonymous survey of DBS researchers and clinicians
was performed in two waves between mid 2011 and mid
2012, each of them including two follow-ups (by e-mail).
The first wave addressed researchers identified by us
(Christen et al. 2012) who published about DBS in
Parkinson’s disease since the early 1990s. The second wave
addressed clinicians whom we identified in a global search
of DBS centers. Both search strategies were complemented
by bibliometric research to ensure that those 100 authors
who published most on DBS are included in the data set.
For all persons identified we searched for valid e-mail
addresses. In total, 656 persons with valid e-mail addresses
have been approached. Since 22 of them did not publish
about DBS for more than 10 years, it is unlikely that they
are still active in the field, so that the universal set consists
of 634 researchers and clinicians.
The survey questionnaire was developed based on pre-
vious research (Christen et al. 2012; Christen and M€uller
2011; M€uller and Christen 2011) and has been cross-
checked by a board of researchers (see acknowledgments).
It included 31 questions; the mean responding time was
20.5 minutes.
Survey of Centers
The non-anonymized survey of centers that offer DBS
interventions was restricted to 12 countries that ranked
highest in the number of DBS research papers published:
Australia, Canada, England, France, Germany, Italy, Japan,
the Netherlands, Spain, Sweden, Switzerland, and the
United States. For these countries we have performed an
Internet-based search to find clinics (public and private)
that offered DBS according to their website at least sporad-
ically in 2010 or 2011. This was complemented by biblio-
metric research to identify home institutions of persons
that published on DBS. Five hundred and thirteen institu-
tions that claim to offer DBS have been identified. The
questionnaire was sent to these institutions by postal mail
in June 2012; two follow-ups were performed (via e-mail,
until October 2012). In the postal mail, we included the list
of all centers of the respective country and asked the
responsible person to check the list for completeness and
for false entries. We also approached all 12 national neuro-
surgical associations and the leading DBS supplier Med-
tronic to check our lists. Based on the feedback, we
identified 408 sites in the 12 countries that were confirmed
to offer DBS or that are likely to do so at least sporadically.
The questionnaire for the survey of centers included only
eight questions, to promote a high response rate. It had
been pretested in a Delphi study among all Swiss DBS cen-
ters (Christen and M€uller 2012).
Both the surveys of experts and the survey of centers
did not need approval from the responsible ethical review
committee (Kantonale Ethikkommission Z€urich) given our
institutional guidelines, as patients were not addressed by
the surveys and no information was collected that could
be related to individual patients. Furthermore, we fol-
lowed the CHERRIES guidelines (The Checklist for
Reporting Results of Internet E-Surveys; see http://www.
jmir.org/2004/3/e34) as far as they were applicable.
Bibliometric Study and Literature Search
Using the Thomson Reuters Web of Science database, we
performed a bibliometric study on January 26, 2012, to
check the completeness of our expert database. On Decem-
ber 6, 2012, we identified the funding sources mentioned
in DBS papers. The study was accompanied by a study of
the DBS literature for identifying controversial issues, and
we consulted our review board to make a selection. In
addition, we searched for papers for estimating the inci-
dence and prevalence of the major DBS indications. Since
we found that the data is rather controversial, we restricted
the research to PD, where the data is most reliable. We
used Mathematica 9.1 for statistical calculations.
RESULTS
Survey of Experts
One hundred and twenty-three persons provided answers
in the survey of experts. Ten persons were excluded due to
AJOB Neuroscience
66 ajob Neuroscience October–December, Volume 5, Number 4, 2014
D
ow
nl
oa
de
d 
by
 [U
ZH
 H
au
pt
bi
bl
io
th
ek
 / 
Ze
nt
ra
lb
ib
lio
th
ek
 Z
ür
ic
h]
 a
t 0
1:
10
 2
3 
D
ec
em
be
r 2
01
5 
the low number of answers provided (less than 50%), leav-
ing usable data of 113 persons (response rate: 17.8%; see
also Table 1). Ninety-nine experts answered all questions.
We note that the search of experts included all (co)authors
of DBS papers published since 1991; therefore, most of
them were not principal investigators and probably many
do not work in the field of DBS anymore. Hence, many of
the approached persons may have been reluctant to pro-
vide answers, since they are not “true” DBS experts. Thus,
the reported response rate is the lower limit of the “true”
response rate of experts who are still active in the field of
DBS. The DBS core disciplines neurosurgery (46.9%) and
neurology (39.8%) are most represented in the expert sam-
ple. The median age of the responders was 48 years, and
their majority is male (72%). The five most represented
countries of origin (17 in total) were the United States
(23.9%), Germany (13.3%), France (12.4%), Italy (12.4%),
and the United Kingdom (4.4%).
Survey of Centers
One hundred and thirty-five institutions provided answers
to the survey of centers. The overall response rate was
32.8% (see also Table 1); the response rates of the countries
varied between 54.5% (Canada) and 23.6% (the United
States); the response rate of 100% in Switzerland results
from the fact that the pretest of the survey included all
Swiss centers. The total number of patients that received a
DBS intervention in the responding centers is at least
29,350, that is about one-third of an estimate of 85,000
patients that have received a DBS intervention globally
(data as of January 2011; Christen and M€uller 2012).
Validating Expert Experience
On average, the centers in which the experts work (in the
following, “expert centers”) had started DBS treatments
earlier and had implanted more patients than reported in
the survey of centers (data not shown). This indicates that
the expert centers tend to be experienced above average.
Of the responding experts, 69.9% had treated at least 100
patients; 68.1% are regularly or often involved in research
(clinical, basic, validation, technology); 77.0% have expert
knowledge in patient selection, 77.9% in patient follow-up,
65.5% in surgery, 64.6% in patient information, 58.4% in
device programming; and 36.3% in novel DBS applica-
tions. Based on these findings, we conclude that the
sample of the survey of experts consists mainly of experi-
enced DBS researchers and clinicians.
Patient-Related Dimension of DBS Practice
The first dimension of DBS practice concerns the interven-
tion process in individual patients: that is, the information
of patients, the referral practice, exclusion criteria, decision
making, the intervention, and the follow-up. The complete
results are contained in Figure 1, Table 2, and Table 3.
Information of patients and referral practice. With
respect to information sources used by the patients and to
the referral of patients to DBS centers, the neurologists (in
private practice) seem to be the decisive “entry point” to
DBS (Table 2).
Exclusion criteria. Dementia is the most important rea-
son for excluding a patient from a DBS intervention, fol-
lowed by general medical risk factors, the psychiatric
history, and the age of the patient (Table 3).
Decision making. According to the experts, most
patients uttered the hope for symptom relief, followed by
more independence, enjoying life again, and going back to
work. The patients’ greatest concerns are surgery-caused
problems, followed by technical problems, death, person-
ality changes, and being remote-controlled. The frequency
of fears uttered by the patients does not always match
with the experts’ assessment of risk probability. Particu-
larly, surgical complications are mentioned often by the
patients, although they have the lowest probability accord-
ing to the DBS experts, whereas fears of technical problems
and of personality changes are less often mentioned by the
patients, although the experts consider these sequelae to
be more frequent (Figure 1a).
Intervention. In the course of the DBS intervention for
movement disorders, a broad spectrum of tests is used:
Motor functions, medication dose, cognitive functioning,
and mood are always checked before and after the inter-
vention. Emotional functioning, language, quality of life,
and social functioning are not always, but still routinely
part of the assessment procedure. Other aspects like sleep,
autonomous functions, weight change, and sensory sys-
tems are often, but not routinely, part of the assessment.
The before–after comparison is insufficiently monitored
Table 1. Response rates of the center and expert surveys
Experts Centers
Initial set of experts/centers that have been approached 656 513
Confirmed or likely set of experts/centers active in DBS 634 408
Valid responses 113 (18%) 135 (33%)
Experts/centers that operated at least 100 patients 79 (70%) 77 (57%)
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the low number of answers provided (less than 50%), leav-
ing usable data of 113 persons (response rate: 17.8%; see
also Table 1). Ninety-nine experts answered all questions.
We note that the search of experts included all (co)authors
of DBS papers published since 1991; therefore, most of
them were not principal investigators and probably many
do not work in the field of DBS anymore. Hence, many of
the approached persons may have been reluctant to pro-
vide answers, since they are not “true” DBS experts. Thus,
the reported response rate is the lower limit of the “true”
response rate of experts who are still active in the field of
DBS. The DBS core disciplines neurosurgery (46.9%) and
neurology (39.8%) are most represented in the expert sam-
ple. The median age of the responders was 48 years, and
their majority is male (72%). The five most represented
countries of origin (17 in total) were the United States
(23.9%), Germany (13.3%), France (12.4%), Italy (12.4%),
and the United Kingdom (4.4%).
Survey of Centers
One hundred and thirty-five institutions provided answers
to the survey of centers. The overall response rate was
32.8% (see also Table 1); the response rates of the countries
varied between 54.5% (Canada) and 23.6% (the United
States); the response rate of 100% in Switzerland results
from the fact that the pretest of the survey included all
Swiss centers. The total number of patients that received a
DBS intervention in the responding centers is at least
29,350, that is about one-third of an estimate of 85,000
patients that have received a DBS intervention globally
(data as of January 2011; Christen and M€uller 2012).
Validating Expert Experience
On average, the centers in which the experts work (in the
following, “expert centers”) had started DBS treatments
earlier and had implanted more patients than reported in
the survey of centers (data not shown). This indicates that
the expert centers tend to be experienced above average.
Of the responding experts, 69.9% had treated at least 100
patients; 68.1% are regularly or often involved in research
(clinical, basic, validation, technology); 77.0% have expert
knowledge in patient selection, 77.9% in patient follow-up,
65.5% in surgery, 64.6% in patient information, 58.4% in
device programming; and 36.3% in novel DBS applica-
tions. Based on these findings, we conclude that the
sample of the survey of experts consists mainly of experi-
enced DBS researchers and clinicians.
Patient-Related Dimension of DBS Practice
The first dimension of DBS practice concerns the interven-
tion process in individual patients: that is, the information
of patients, the referral practice, exclusion criteria, decision
making, the intervention, and the follow-up. The complete
results are contained in Figure 1, Table 2, and Table 3.
Information of patients and referral practice. With
respect to information sources used by the patients and to
the referral of patients to DBS centers, the neurologists (in
private practice) seem to be the decisive “entry point” to
DBS (Table 2).
Exclusion criteria. Dementia is the most important rea-
son for excluding a patient from a DBS intervention, fol-
lowed by general medical risk factors, the psychiatric
history, and the age of the patient (Table 3).
Decision making. According to the experts, most
patients uttered the hope for symptom relief, followed by
more independence, enjoying life again, and going back to
work. The patients’ greatest concerns are surgery-caused
problems, followed by technical problems, death, person-
ality changes, and being remote-controlled. The frequency
of fears uttered by the patients does not always match
with the experts’ assessment of risk probability. Particu-
larly, surgical complications are mentioned often by the
patients, although they have the lowest probability accord-
ing to the DBS experts, whereas fears of technical problems
and of personality changes are less often mentioned by the
patients, although the experts consider these sequelae to
be more frequent (Figure 1a).
Intervention. In the course of the DBS intervention for
movement disorders, a broad spectrum of tests is used:
Motor functions, medication dose, cognitive functioning,
and mood are always checked before and after the inter-
vention. Emotional functioning, language, quality of life,
and social functioning are not always, but still routinely
part of the assessment procedure. Other aspects like sleep,
autonomous functions, weight change, and sensory sys-
tems are often, but not routinely, part of the assessment.
The before–after comparison is insufficiently monitored
Table 1. Response rates of the center and expert surveys
Experts Centers
Initial set of experts/centers that have been approached 656 513
Confirmed or likely set of experts/centers active in DBS 634 408
Valid responses 113 (18%) 135 (33%)
Experts/centers that operated at least 100 patients 79 (70%) 77 (57%)
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Figure 1. Patient-related dimension: (a) Frequency that the patients express specific hopes and fears in the DBS deci-
sion-making process. (b) Assessment of personality change by the experts. (c) Assessment of the satisfaction gap by
the experts.
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only for weight changes, as eight participants in the survey
of experts reported that weight is an issue only before the
intervention, but not after.
Follow-up. In the bioethical literature on (subthalamic
nucleus [STN]) DBS, two issues of follow-up received par-
ticular attention, namely, the possibility of “personality
changes” and the “satisfaction gap,” i.e., physicians
express satisfaction with the result whereas patients are
less satisfied. Personality changes as understood in psy-
chology refer to alterations in the “Big Five” personality
traits (i.e., extraversion, neuroticism, agreeableness, consci-
entiousness, openness to experience; see Costa and
McCrae 1992), and it is known from the literature that
(STN) DBS can influence each of these in some patients
(M€uller and Christen 2011). We have exemplified the term
with examples like hypomania, hypersexuality, aggressiv-
ity, and risk-taking behavior. We found that 26.5% of the
experts believed that “personality changes” occur in more
than 5% of the cases, 38.1% estimate their incidence at 2–
5% of all cases, and 23.9% believe that they happen in less
than 1% of the cases (11.5%: don’t know). Of the experts,
43.4% considered stimulation to be the likely cause of per-
sonality changes compared to changes in medication
(Figure 1b). The experts described personality changes
after DBS mostly as alterations of mood: The patients
became either more depressive and apathetic or more
hypomanic.
The issue of a satisfaction gap is not uncommon: 38.0%
of the experts believed that it occurs in more than 10% of
the cases, 23.0% estimate its prevalence at 6–10%, and
23.9% think that it happens in 5% of the cases or less
(15.0%: don’t know). The experts mention a multitude of
reasons, particularly an expectation mismatch, but also
motor function problems and increased apathy (Figure 1c).
The experts reported lower incidences of adverse
effects for the case of apathy, depression, and language
problems than reported in the literature about STN DBS in
PD (Table 3). Of the experts, 67.3% document adverse
effects (publications, database, or standardized reporting
form), although only 12.4% indicated a reporting
obligation.
The time span for device programming varied over a
remarkably broad spectrum: 10 experts claim to use less
than 4 weeks for device programming, 29 use 4–8 weeks,
Table 2. Factors characterizing the DBS intervention process: information sources of the patient, referral of the
patient, and the frequency of exclusion criteria used in patient selection based on the survey of experts
Usually/often Sometimes Never Don’t know/no answer
Information sources of the patient
Neurologist in private practice 76.1% 19.5% 0.9% 3.5%
Physician of the DBS institution 53.1% 30.1% 8.8% 8.0%
Internet 53.1% 42.5% 0.0% 4.4%
Support groups 47.8% 40.7% 5.3% 6.2%
Brochure of the DBS institution 42.5% 31.0% 17.7% 8.8%
General media 31.0% 50.4% 8.0% 10.6%
Family and friends 24.8% 67.3% 1.8% 6.2%
Brochure of the device producer 23.9% 46.9% 21.2% 8.0%
General practitioner 11.5% 53.1% 22.1% 13.3%
Scientific literature 12.4% 58.4% 17.7% 11.5%
Referral of the patient by. . .
. . . neurologist in private practice 91.2% 8.0% 0.0% 0.9%
. . . other medical institutions 47.8% 41.6% 6.2% 4.4%
. . . departments of the same institution 37.2% 38.9% 12.4% 11.5%
. . . himself/herself (self-referral) 20.4% 48.7% 20.4% 10.6%
. . . the general practitioner 15.9% 59.3% 19.5% 5.3%
Frequency of exclusion criteria
Dementia 71.7% 21.2% 0.9% 6.2%
General medical risk factors 40.7% 50.4% 1.8% 7.1%
Psychiatric history of the patient 38.9% 53.1% 0.9% 7.1%
Age of the patient 37.2% 50.4% 6.2% 6.2%
Insufficient compliance suspected 21.2% 57.5% 12.4% 8.8%
Unrealistic expectations by the patient 22.1% 53.1% 15.9% 8.8%
Alcohol addiction 19.5% 38.9% 32.7% 8.8%
Drug addiction 23.0% 28.3% 39.8% 8.8%
Anxiety of the patient 8.0% 46.9% 37.2% 8.0%
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only for weight changes, as eight participants in the survey
of experts reported that weight is an issue only before the
intervention, but not after.
Follow-up. In the bioethical literature on (subthalamic
nucleus [STN]) DBS, two issues of follow-up received par-
ticular attention, namely, the possibility of “personality
changes” and the “satisfaction gap,” i.e., physicians
express satisfaction with the result whereas patients are
less satisfied. Personality changes as understood in psy-
chology refer to alterations in the “Big Five” personality
traits (i.e., extraversion, neuroticism, agreeableness, consci-
entiousness, openness to experience; see Costa and
McCrae 1992), and it is known from the literature that
(STN) DBS can influence each of these in some patients
(M€uller and Christen 2011). We have exemplified the term
with examples like hypomania, hypersexuality, aggressiv-
ity, and risk-taking behavior. We found that 26.5% of the
experts believed that “personality changes” occur in more
than 5% of the cases, 38.1% estimate their incidence at 2–
5% of all cases, and 23.9% believe that they happen in less
than 1% of the cases (11.5%: don’t know). Of the experts,
43.4% considered stimulation to be the likely cause of per-
sonality changes compared to changes in medication
(Figure 1b). The experts described personality changes
after DBS mostly as alterations of mood: The patients
became either more depressive and apathetic or more
hypomanic.
The issue of a satisfaction gap is not uncommon: 38.0%
of the experts believed that it occurs in more than 10% of
the cases, 23.0% estimate its prevalence at 6–10%, and
23.9% think that it happens in 5% of the cases or less
(15.0%: don’t know). The experts mention a multitude of
reasons, particularly an expectation mismatch, but also
motor function problems and increased apathy (Figure 1c).
The experts reported lower incidences of adverse
effects for the case of apathy, depression, and language
problems than reported in the literature about STN DBS in
PD (Table 3). Of the experts, 67.3% document adverse
effects (publications, database, or standardized reporting
form), although only 12.4% indicated a reporting
obligation.
The time span for device programming varied over a
remarkably broad spectrum: 10 experts claim to use less
than 4 weeks for device programming, 29 use 4–8 weeks,
Table 2. Factors characterizing the DBS intervention process: information sources of the patient, referral of the
patient, and the frequency of exclusion criteria used in patient selection based on the survey of experts
Usually/often Sometimes Never Don’t know/no answer
Information sources of the patient
Neurologist in private practice 76.1% 19.5% 0.9% 3.5%
Physician of the DBS institution 53.1% 30.1% 8.8% 8.0%
Internet 53.1% 42.5% 0.0% 4.4%
Support groups 47.8% 40.7% 5.3% 6.2%
Brochure of the DBS institution 42.5% 31.0% 17.7% 8.8%
General media 31.0% 50.4% 8.0% 10.6%
Family and friends 24.8% 67.3% 1.8% 6.2%
Brochure of the device producer 23.9% 46.9% 21.2% 8.0%
General practitioner 11.5% 53.1% 22.1% 13.3%
Scientific literature 12.4% 58.4% 17.7% 11.5%
Referral of the patient by. . .
. . . neurologist in private practice 91.2% 8.0% 0.0% 0.9%
. . . other medical institutions 47.8% 41.6% 6.2% 4.4%
. . . departments of the same institution 37.2% 38.9% 12.4% 11.5%
. . . himself/herself (self-referral) 20.4% 48.7% 20.4% 10.6%
. . . the general practitioner 15.9% 59.3% 19.5% 5.3%
Frequency of exclusion criteria
Dementia 71.7% 21.2% 0.9% 6.2%
General medical risk factors 40.7% 50.4% 1.8% 7.1%
Psychiatric history of the patient 38.9% 53.1% 0.9% 7.1%
Age of the patient 37.2% 50.4% 6.2% 6.2%
Insufficient compliance suspected 21.2% 57.5% 12.4% 8.8%
Unrealistic expectations by the patient 22.1% 53.1% 15.9% 8.8%
Alcohol addiction 19.5% 38.9% 32.7% 8.8%
Drug addiction 23.0% 28.3% 39.8% 8.8%
Anxiety of the patient 8.0% 46.9% 37.2% 8.0%
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28 use 9–12 weeks, 16 use 13–24 weeks, and 2 experts use
more than 24 weeks (not involved in programming or
“don’t know”: 28).
Infrastructure-Related Dimension of DBS Practice
The second dimension concerns the institutional develop-
ment of DBS, particularly the offer of new DBS indications,
multidisciplinary teams, differences of the DBS procedures
(e.g., different target preferences), center capacities, the
financing of DBS research, and the long-term planning of
center development given the growing spectrum of DBS
indications. The detailed results are contained in Figure 2
and Tables 4, 5, and 6.
New DBS indication. Almost all centers offer DBS for
PD, ET, and dystonia, but also Tourette’s syndrome, OCD,
and depression are quite common indications (Figure 2a).
DBS for Tourette’s syndrome is performed by 25.9% of the
centers (and by 50.4% of the expert centers); for OCD by
27.4% (46.0% of the expert centers); and for depression by
Figure 2. Infrastructure-related dimension: (a) Overview of current main DBS indications offered by centers. (b)
Comparison of the frequency of (planned) application of DBS for novel indications with the success evaluation of
the experts.
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28 use 9–12 weeks, 16 use 13–24 weeks, and 2 experts use
more than 24 weeks (not involved in programming or
“don’t know”: 28).
Infrastructure-Related Dimension of DBS Practice
The second dimension concerns the institutional develop-
ment of DBS, particularly the offer of new DBS indications,
multidisciplinary teams, differences of the DBS procedures
(e.g., different target preferences), center capacities, the
financing of DBS research, and the long-term planning of
center development given the growing spectrum of DBS
indications. The detailed results are contained in Figure 2
and Tables 4, 5, and 6.
New DBS indication. Almost all centers offer DBS for
PD, ET, and dystonia, but also Tourette’s syndrome, OCD,
and depression are quite common indications (Figure 2a).
DBS for Tourette’s syndrome is performed by 25.9% of the
centers (and by 50.4% of the expert centers); for OCD by
27.4% (46.0% of the expert centers); and for depression by
Figure 2. Infrastructure-related dimension: (a) Overview of current main DBS indications offered by centers. (b)
Comparison of the frequency of (planned) application of DBS for novel indications with the success evaluation of
the experts.
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11.9% (32.7% of the expert centers). For epilepsy, depres-
sion, OCD, and Tourette’s syndrome, about half of the cen-
ters either offer DBS currently or plan to implement it in
their programs within the next 5 years (Figure 2b). Further
indications that are planned to be offered in the next
5 years by some centers are Alzheimer’s disease (17.0% of
the centers; one center already does research in this field),
addiction (16.3%), obesity (12.6%), and aggression (5.2%).
When these numbers are compared to the fraction of
experts who expect a high success probability for these
indications, two discrepancies have to attract attention:
First, 17% of the centers plan to treat Alzheimer’s disease
with DBS, although only 3.0% of the experts consider the
success probability to be high, whereas 68.0% consider it
to be low. Second, only 5.2% of the centers plan to treat
aggression with DBS, although 19.0% of the experts con-
sider its success probability to be high.
Multidisciplinary teams. In routine DBS interven-
tions, 60.7% of the centers involve at least two additional
disciplines besides the core disciplines neurology and
neurosurgery, for example, (neuro)psychology, care,
rehabilitation, or social work. Centers that offer DBS not
only for movement disorders but also for further neuro-
logical and psychiatric disorders involve significantly
more disciplines (3.61 disciplines in the mean) than
those centers that restrict DBS to movement disorders
(2.89 disciplines) (Mann–Whitney; p < .002).
Differences of the DBS procedures (e.g., different target
preferences). Because of the discussion about the opti-
mal target of DBS in Parkinson’s disease, particularly
about the STN (stimulation of which can address more
symptoms than the other targets, but it has higher risks of
psychiatric side effects; Hariz et al. 2008), we investigated
the preferences for different stimulation targets for
Parkinson’s disease. We found a considerable difference
with regard to the preferred stimulation target between
U.S. and European centers: By weighting the survey
entries of target frequencies (usually D 4, often D 3, some-
times D 2, rarely D 1) we found a relative distribution of
STN, globus pallidus pars interna (GPi), and nucleus ven-
tralis intermedius (VIM) target preferences of 74.4%/
19.9%/5.6% for European and 60.4%/31.9%/7.7% for U.S.
centers. When additionally weighting this data by the
number of patients the centers operated, the distribution is
72.7%/20.7%/6.6% for Europe and 54.5%/33.6%/11.9%
for the United States. These results show that European
PD patients are more likely to be stimulated in the STN
than were U.S. patients.
Center capacity. Of all DBS centers (survey of centers),
58.8% operated on 20 or fewer patients per year (Table 4).
Given the current infrastructure, 64.9% of the centers
would have the capacity to operate on more than 20
patients per year. We estimated whether the number of
centers available and their capacity match with the
expected number of patients that qualify for DBS in PD.
The prevalence of PD in industrialized countries is around
0.3% of the entire population; reported standardized inci-
dence rates are 8–18 per 100,000 person-years (De Lau and
Breteler 2006). Table 5 gives a rough prediction of the eligi-
bility rate of PD patients, that is, the number of PD patients
per year that could qualify for DBS given an estimate of the
available capacity and the annual incidence of PD (the
number of patients that all centers could operate per year
divided by the number of new PD patients per year). The
data reveal a large variance of the estimated eligibility rate
between the different countries.
Funding. The bibliometric study revealed indications of
a difference in public funding for DBS between the United
Table 4. Annual numbers of patients that have received a DBS intervention
Annual number of patients that received a DBS intervention
<10 10–20 21–50 51–100 >100
Survey of experts (excluding 5
that currently do not work in a
DBS site)—data of 2010
15.9% 29.0% 33.6% 13.1% 8.4%
Survey of centers: mean numbers
for 2009 to 2011 (excluding 4 that
did not provide data)
21.4% 37.4% 32.8% 8.4% 0.0%
Survey of centers: current capacity
(excluding 1 that did not provide data)
7.5% 27.6% 40.3% 20.9% 3.7%
Note. First row: annual numbers reported in the survey of experts (expert centers); second row: annual numbers reported in the survey of centers. The
experts reported higher numbers than the centers, reflecting the fact that the experts tend to work at sites that perform more interventions. However, 9
experts reported working at a site that operates on more than 100 patients—a number that is not met by the reporting of the centers. Potential reasons for
this mismatch are that some expert centers may not be present in the data of the survey of centers (the survey of experts was anonymous), slight differences
in the questions (the experts reported the number of surgeries in 2010, the centers a mean estimate of the last 2–3 years, i.e., 2009 to 2011), or over-/underre-
porting of the experts or centers.
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States and Europe: Of all U.S. papers, 19.8% mention pub-
lic funding by governmental institutions, whereas only
5.3% of the European DBS papers do so. In the DBS papers
that mentioned a funding source, 53.9% of funding came
from companies or private foundations. However, only
1,753 out of 8,016 DBS papers identified (21.9%) contained
explicit information on funding that was accessible in Web
of Science. This means that this data do not by far reflect
all funding sources for DBS. It is likely that many papers
do not reveal this information, if the funding source is pub-
lic. Thus, the result may only indicate differences in fund-
ing disclosure between the United States and Europe in
the sense that authors from the United States are more
likely also to mention public funding.
Finally, we collected the opinions of the experts on var-
ious controversial issues raised in the DBS literature.
Table 6 provides a summary of the results. In the follow-
ing, we outline the most important findings.
Lesion surgery versus DBS in movement disorders.
The majority of the responding DBS experts (51.9%) do not
consider lesion procedures as part of the past that should
not be performed anymore. A great majority (77.4%) thinks
that lesion procedures are a valid alternative to DBS for
some patients. Particularly, the majority agrees with offer-
ing lesion procedures in poorer countries (61.5%) or to
patients who probably will not comply with postoperative
care (51.5%). Almost half of the experts expect that soon
there won’t be experts who master lesion procedures
(27.6% are indifferent; 25.8% disagree).
DBS for movement disorders. Although a majority
thinks that bilateral procedures should be the standard
(60.6%), most experts think that the question of uni-/bilat-
erality depends on the symptoms or other prerequisites of
the patient (82.8%). Only a minority (17.9) thinks that DBS
surgery has a high risk of complications. Interestingly, the
majority considers DBS not to be a last-resort treatment
(67.0%) and that it should be offered even when the dis-
ease is still manageable by drugs (60.4%). The majority
supports the claim that DBS should be offered only in large
centers (76.1%).
DBS for novel indications. The great majority of the
experts (76.5%) endorse the expansion of indications for
DBS in favor of the enrichment of the therapeutic spectrum
for various diseases, and only a minority (9.8%) utters a
bad feeling when they learn about the increasing number
of DBS indications. Nevertheless, the majority (65.3%) also
thinks that there is an economic interest to offer DBS as a
novel therapeutic approach for diseases other than move-
ment disorders. Great agreement occurs also in the opinion
that DBS will allow us to understand the neurological basis
of psychiatric diseases (67.6%).
DISCUSSION OF ETHICAL FOCAL POINTS
We have investigated the current practice of DBS along
two dimensions: (1) the patient-related and (2) the infra-
structure-related dimension. We now carve out the ethical
focal points in the current practice of DBS.
Patient-Related Dimension
For the patient-related dimension, we found that neurolo-
gists are key players both for information and for referral
of patients. This finding highlights the importance of an
adequate and up-to-date training of neurologists in private
practice about DBS. Correct information is necessary, as a
timely elucidation about DBS, as well as responding to the
individual concerns by the consulting physician, is essen-
tial for the acceptance of the treatment (S€udmeyer et al.
2012). Adequate expertise is necessary, as movement dis-
order specialists are more likely to identify good candi-
dates for DBS (Katz et al. 2011). The development of DBS
requires that neurologists are regularly informed about
new indications, technological improvements, and newly
investigated risks.
Data from the survey of experts show that only a
minority of patients utter concerns about technical device
problems or stimulation-induced personality changes,
whereas the experts consider these risks as relevant. This
indicates an information gap between patients and experts.
We propose that this information gap may be partly
responsible for the relatively high prevalence of the satis-
faction gap reported by a considerable number of experts.
However, other aspects may contribute to this gap as well:
The finding that the experts´ ratings of the frequency of the
DBS sequelae apathy, depression, and language problems
tend to be lower than reported in the literature may indi-
cate a decreased sensibility for the patient’s own experi-
ence of side effects, although we consider this as less likely
(see further discussion). Another potential reason is that
even in case of sufficient information the fact that the
patient him- or herself experiences side effects may con-
tribute to the satisfaction gap. These hypotheses require
further empirical investigation on patients’ expectations
and how these expectations or other factors determine the
evaluation of outcome by patients (e.g., retrospection of
the preimplantation health status).
Another relevant finding concerns the mismatch
between the experts’ ratings of the frequency of the DBS
sequelae apathy, depression, and language problems com-
pared to the literature. However, we do not interpret this
in the sense that the experts underestimate risks. Rather,
the result more likely reflects an improvement in practice
not captured by reviews that usually refer to studies some
time ago; this, however, needs additional support. More
problematic may be that in DBS for movement disorders
the number of involved disciplines tends to decrease and
that the majority of experts use less device programming
time than a recent review on this matter suggests (3–6
months during 4–5 programming sessions; Bronstein et al.
2011). This indicates a habituation effect for established
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States and Europe: Of all U.S. papers, 19.8% mention pub-
lic funding by governmental institutions, whereas only
5.3% of the European DBS papers do so. In the DBS papers
that mentioned a funding source, 53.9% of funding came
from companies or private foundations. However, only
1,753 out of 8,016 DBS papers identified (21.9%) contained
explicit information on funding that was accessible in Web
of Science. This means that this data do not by far reflect
all funding sources for DBS. It is likely that many papers
do not reveal this information, if the funding source is pub-
lic. Thus, the result may only indicate differences in fund-
ing disclosure between the United States and Europe in
the sense that authors from the United States are more
likely also to mention public funding.
Finally, we collected the opinions of the experts on var-
ious controversial issues raised in the DBS literature.
Table 6 provides a summary of the results. In the follow-
ing, we outline the most important findings.
Lesion surgery versus DBS in movement disorders.
The majority of the responding DBS experts (51.9%) do not
consider lesion procedures as part of the past that should
not be performed anymore. A great majority (77.4%) thinks
that lesion procedures are a valid alternative to DBS for
some patients. Particularly, the majority agrees with offer-
ing lesion procedures in poorer countries (61.5%) or to
patients who probably will not comply with postoperative
care (51.5%). Almost half of the experts expect that soon
there won’t be experts who master lesion procedures
(27.6% are indifferent; 25.8% disagree).
DBS for movement disorders. Although a majority
thinks that bilateral procedures should be the standard
(60.6%), most experts think that the question of uni-/bilat-
erality depends on the symptoms or other prerequisites of
the patient (82.8%). Only a minority (17.9) thinks that DBS
surgery has a high risk of complications. Interestingly, the
majority considers DBS not to be a last-resort treatment
(67.0%) and that it should be offered even when the dis-
ease is still manageable by drugs (60.4%). The majority
supports the claim that DBS should be offered only in large
centers (76.1%).
DBS for novel indications. The great majority of the
experts (76.5%) endorse the expansion of indications for
DBS in favor of the enrichment of the therapeutic spectrum
for various diseases, and only a minority (9.8%) utters a
bad feeling when they learn about the increasing number
of DBS indications. Nevertheless, the majority (65.3%) also
thinks that there is an economic interest to offer DBS as a
novel therapeutic approach for diseases other than move-
ment disorders. Great agreement occurs also in the opinion
that DBS will allow us to understand the neurological basis
of psychiatric diseases (67.6%).
DISCUSSION OF ETHICAL FOCAL POINTS
We have investigated the current practice of DBS along
two dimensions: (1) the patient-related and (2) the infra-
structure-related dimension. We now carve out the ethical
focal points in the current practice of DBS.
Patient-Related Dimension
For the patient-related dimension, we found that neurolo-
gists are key players both for information and for referral
of patients. This finding highlights the importance of an
adequate and up-to-date training of neurologists in private
practice about DBS. Correct information is necessary, as a
timely elucidation about DBS, as well as responding to the
individual concerns by the consulting physician, is essen-
tial for the acceptance of the treatment (S€udmeyer et al.
2012). Adequate expertise is necessary, as movement dis-
order specialists are more likely to identify good candi-
dates for DBS (Katz et al. 2011). The development of DBS
requires that neurologists are regularly informed about
new indications, technological improvements, and newly
investigated risks.
Data from the survey of experts show that only a
minority of patients utter concerns about technical device
problems or stimulation-induced personality changes,
whereas the experts consider these risks as relevant. This
indicates an information gap between patients and experts.
We propose that this information gap may be partly
responsible for the relatively high prevalence of the satis-
faction gap reported by a considerable number of experts.
However, other aspects may contribute to this gap as well:
The finding that the experts´ ratings of the frequency of the
DBS sequelae apathy, depression, and language problems
tend to be lower than reported in the literature may indi-
cate a decreased sensibility for the patient’s own experi-
ence of side effects, although we consider this as less likely
(see further discussion). Another potential reason is that
even in case of sufficient information the fact that the
patient him- or herself experiences side effects may con-
tribute to the satisfaction gap. These hypotheses require
further empirical investigation on patients’ expectations
and how these expectations or other factors determine the
evaluation of outcome by patients (e.g., retrospection of
the preimplantation health status).
Another relevant finding concerns the mismatch
between the experts’ ratings of the frequency of the DBS
sequelae apathy, depression, and language problems com-
pared to the literature. However, we do not interpret this
in the sense that the experts underestimate risks. Rather,
the result more likely reflects an improvement in practice
not captured by reviews that usually refer to studies some
time ago; this, however, needs additional support. More
problematic may be that in DBS for movement disorders
the number of involved disciplines tends to decrease and
that the majority of experts use less device programming
time than a recent review on this matter suggests (3–6
months during 4–5 programming sessions; Bronstein et al.
2011). This indicates a habituation effect for established
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indications that may be positive with respect to cost-effec-
tiveness, but not adequate to the complexity of DBS in PD.
An interesting finding is that the majority of experts of
our survey has a relatively positive attitude regarding
lesion procedures in movement disorders. More than two
thirds believe that they are a valid alternative to DBS for
some patients, but also almost half of the experts expect
that soon there won’t be experts who master lesion proce-
dures. Also in the literature there is support to keep lesion
procedures as an important alternative for appropriately
selected patients both for movement disorders (e.g.,
Parkinson’s disease; Bronstein et al. 2011) and psychiatric
disorders (Leiphart and Valone 2010) like OCD or anorexia
nervosa (Barbier et al. 2011; D’Astous et al. 2013; Green-
berg, Rauch, and Haber 2010; Kondziolka, Flickinger, and
Hudak 2011). In particular, an international expert panel
has recently stated in a consensus paper that “until scien-
tifically proven otherwise, DBS is not superior to ablative
surgery for psychiatric disorders” (Nuttin et al. 2014).
However, the main disadvantage of lesion surgery is that
possible negative effects are not reversible. Adverse effects
that have been reported are the development of undesir-
able personality traits (after subcaudatetractotomy) and
transient mania and memory deficits (after cingulotomy)
(Feldman, Alterman, and Goodrich 2001). We also remark
that there are research initiatives for additional noninva-
sive lesion procedures like focused ultrasound (Jolesz and
McDannold 2014; Lipsman et al. 2013b) such that novel
expertise in ablative surgery may emerge.
Infrastructure Dimension
With respect to the infrastructure-related dimension sev-
eral aspects require advertence. First, 60% of the centers
operate 20 or less patients per year, although 20 patients
per year are considered to be the minimum quantity for
DBS training centers (Krauss et al. 2009) and although the
large majority of experts think that only large centers
should offer DBS. This finding indicates that measures
might be necessary to ensure quality also in centers with
low case numbers.
Second, we found a rapid expansion of new indications
for DBS. About half of the centers presently perform or
plan to perform DBS for epilepsy, depression, OCD, and
Tourette’s syndrome. However, research on DBS in partic-
ular for psychiatric indications is in an early state, and suc-
cess rates cannot be estimated correctly, particularly
because of the presumed publication bias (Schl€apfer and
Fins 2010). DBS is also planned for indications with consid-
erable prevalence, in particular obesity (the prevalence of
obesity varies nearly 10-fold among Organization for Eco-
nomic Cooperation and Development [OECD] countries,
from as low as 4% in Japan and Korea, to 30% or more in
the United States and Mexico; OECD 2012) and
Alzheimer’s disease (according to the World Health Orga-
nization [WHO 2012], the number of people globally who
are living with dementia in 2011 is estimated to be 35.6 mil-
lion, and studies indicate that this number is expected to
grow at an alarming rate). However, only a small minority
of experts considers the success probabilities for these dis-
eases to be high. This indicates that societal need partly
triggers the expansion of DBS indications. In the case of
Alzheimer’s disease, it’s worthwhile to mention that
dementia is considered to be the most common exclusion
criteria for DBS in case of PD. This tension that may have
an influence on DBS exclusion criteria is discussed neither
in recent reviews (Hardenacke et al. 2013; Hescham et al.
2013; Laxton and Lozano 2013) nor in case studies (Fon-
taine et al. 2013; Laxton et al. 2010) on DBS in Alzheimer’s
disease. We identified only one comment that points to
potential problems when selecting patients suffering from
dementia in clinical DBS trials (Salma, Vasilakis, and
Tracy, 2014).
Although more than three-fourths of the experts
endorse the expansion of indications for DBS in favor of
the enrichment of the therapeutic spectrum for various dis-
eases, two-thirds also think that there is an economic inter-
est to offer DBS as a novel therapeutic approach for
diseases other than movement disorders. Evidence on
cost-effectiveness of DBS is still limited. A recent study for
DBS in the case of PD in the United Kingdom calculated a
total of discounted costs in the DBS and best medical treat-
ment groups over 5 years of £68,970 and £48,243, respec-
tively. The quality-adjusted life years (QALYs) were 2.21
and 1.21, giving an incremental cost-effectiveness ratio of
£20,678 per QALY gained. Thus the results suggest that
DBS may be a cost-effective intervention in patients with
advanced PD who are eligible for surgery.
Finally, given these dynamics, the capacity of DBS cen-
ters may become an issue in some countries. Unfortu-
nately, there is very little research that estimates the
fraction of patients eligible for DBS even for the most
important indication, PD. Early estimations range from
1.6% to 4.5% (Morgante, Morgante, and Moro 2007) but
have been criticized as underrating the ratio of eligible PD
patients (Cacciola 2008). Several factors contribute to this
underrating: Referring clinicians may underestimate the
number of suitable patients (Oyama et al. 2012), women
are underrepresented in those referred (Setiawan et al.
2006), and the amount of suitable candidates could
increase if patients were referred earlier to DBS (Charles
et al. 2012; Sch€upbach et al. 2013). Therefore, a more rea-
sonable guess is that 10–20% of PD patients may qualify
for DBS (Christen and M€uller 2012). Given our findings,
countries like Canada, England, Italy, and Japan may have
insufficient capacities for dealing with the expectable
patient load, which may also affect research regarding
novel indications.
CONCLUSIONS AND ETHICAL RECOMMENDATIONS
In summary, our findings indicate a dynamic development
of DBS with respect to various issues. To ensure the ethical
future of DBS, more emphasis than hitherto should be put
on issues that are not directly related to the intervention,
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but to issues like the referral practice, the expansion of DBS
indications, the financing of DBS research, and the devel-
opment and quality control of DBS centers. We suggest
that the following aspects should become focal points of
the ethical discussion about DBS.
Patient Dimension
 Entry points: In movement disorders, the neurologists in
private practice are the gatekeepers for patient informa-
tion and patient selection; that is, they frame signifi-
cantly whether and how patients will consider DBS as a
therapy option. In light of the rapid expansion of DBS
indications, we should start to think about who will be
the gatekeepers for DBS for patients suffering from
addiction, depression, OCD, anorexia nervosa, or severe
obesity and what we should expect from them (Christen
and M€uller 2013).
 Reducing the satisfaction gap: A significant number of
patients seem to be dissatisfied with the outcome of their
DBS treatments. Various reasons may account for this,
and it is likely that psychological and social factors play
an important role. This phenomenon needs further
empirical research, and results of this research should
be incorporated as soon as possible in the shared deci-
sion-making process with patients.
 Multidisciplinary teams: Our study found indications of
habituation effects, which regularly occur when a ther-
apy becomes more and more accepted. An important
point is the number of experts that are routinely
involved, which is lower in centers that treat only move-
ment-disorder patients, although it is known that PD as
well as its treatment (DBS and medication) may involve
psychiatric effects. Centers should ensure that suffi-
ciently qualified personnel of several disciplines (includ-
ing psychiatry) can be called in case they are needed.
 Documenting the outcome: Clinics should follow each of
their patients long enough to evaluate improvements in
practice and possible long-term sequelae. This should
also include case registries on a national level. Outcome
analyses help to prevent the repetition of former failures
and to establish a good practice (Lieberman et al. 2008).
 Ensuring alternatives: The growing confidence in DBS
as a treatment option should not suppress alternative
treatments. We support to further investigate lesion
procedures (performed by either microsurgery, ther-
mocoagulation, or particularly by Gamma Knife) as
an alternative to DBS for particular groups of patients,
and to compare their efficiency, risks, and side effects
with DBS. There are two important reasons for pro-
viding the option of lesion procedures: first, the rela-
tive low cost (which is particularly important in
poorer countries); and second, certain exclusion crite-
ria or practical limitations of DBS (e.g., patients who
could tolerate neither the stress of an operation awake
nor an operation under full anesthesia; patients for
whom a craniotomy is contraindicated; patients who
would not tolerate implanted devices; or patients who
live in remote areas such that compliance with the
long-term follow-up after DBS is hard to achieve).
Institution Dimension
 Quality standards in smaller DBS centers: Although in
some countries (e.g., Switzerland) there is a discussion
to ensure high case numbers per DBS center (Christen
and M€uller 2012), obviously many centers operate on
only a few patients. However, we argue against fixed
minimal case numbers for DBS centers, as determining
the cutoff is arbitrary and other stereotactic interven-
tions besides DBS (which have not been captured in our
surveys) also account for the experience of a center.
Nevertheless, it is important to find ways (e.g., binding
guidelines) to ensure high quality also in smaller DBS
centers, with regard not only to the surgical procedure,
but also to patient information, patient selection, device
programming, and pre- and postsurgical neurological
and psychiatric assessment.
 Novel DBS indications planning: It is likely that DBS
will become a bearer of hope for many psychiatric disor-
ders—in particular, for depression, OCD, and Tourette’s
syndrome—for which known therapies have failed (e.g.,
recent studies estimate that more than 50% of patients
suffering from depression may be treatment-resistant;
Thomas et al. 2013). However, it will be important that
the development of novel DBS indications is theory
driven (i.e., based on a good understanding of the net-
work in which one intervenes) and evidence based and
not merely demand driven. In particular, the planning
should involve the buildup of (optimally international)
case registries, which should contain all clinical studies
and individual treatment attempts for all novel DBS
indications. Case registries are indispensable for pre-
venting a publication-bias and its negative consequen-
ces, namely, faulty evaluations of therapies, flawed
therapy recommendations, unpromising treatment
attempts, and unneeded clinical studies (M€uller and
Christen 2011; Rabins et al. 2009; Schl€apfer and Fins
2010; Woopen, Timmerman, and Kuhn 2012).
 Evidence-based evaluation of DBS for novel indications:
For novel indications of DBS, an evidence-based evalua-
tion is essential. Whenever possible, each novel indica-
tion should be investigated in clinical trials of the
appropriate size and statistical power, requiring collabo-
ration of centers. We support the demand of Fins and
colleagues (2011) that the U.S. Congress and federal reg-
ulators should revisit the Food and Drug Administra-
tion (FDA) humanitarian device exemption that allows
manufacturers to market a device under certain condi-
tions without subjecting it to a clinical trial, for DBS for
treating OCD. They argue convincingly that the humani-
tarian device exemption is misused for bypassing the
rigors of clinical trials, since OCD is not an orphan but a
prevalent condition, and that the current market-driven
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but to issues like the referral practice, the expansion of DBS
indications, the financing of DBS research, and the devel-
opment and quality control of DBS centers. We suggest
that the following aspects should become focal points of
the ethical discussion about DBS.
Patient Dimension
 Entry points: In movement disorders, the neurologists in
private practice are the gatekeepers for patient informa-
tion and patient selection; that is, they frame signifi-
cantly whether and how patients will consider DBS as a
therapy option. In light of the rapid expansion of DBS
indications, we should start to think about who will be
the gatekeepers for DBS for patients suffering from
addiction, depression, OCD, anorexia nervosa, or severe
obesity and what we should expect from them (Christen
and M€uller 2013).
 Reducing the satisfaction gap: A significant number of
patients seem to be dissatisfied with the outcome of their
DBS treatments. Various reasons may account for this,
and it is likely that psychological and social factors play
an important role. This phenomenon needs further
empirical research, and results of this research should
be incorporated as soon as possible in the shared deci-
sion-making process with patients.
 Multidisciplinary teams: Our study found indications of
habituation effects, which regularly occur when a ther-
apy becomes more and more accepted. An important
point is the number of experts that are routinely
involved, which is lower in centers that treat only move-
ment-disorder patients, although it is known that PD as
well as its treatment (DBS and medication) may involve
psychiatric effects. Centers should ensure that suffi-
ciently qualified personnel of several disciplines (includ-
ing psychiatry) can be called in case they are needed.
 Documenting the outcome: Clinics should follow each of
their patients long enough to evaluate improvements in
practice and possible long-term sequelae. This should
also include case registries on a national level. Outcome
analyses help to prevent the repetition of former failures
and to establish a good practice (Lieberman et al. 2008).
 Ensuring alternatives: The growing confidence in DBS
as a treatment option should not suppress alternative
treatments. We support to further investigate lesion
procedures (performed by either microsurgery, ther-
mocoagulation, or particularly by Gamma Knife) as
an alternative to DBS for particular groups of patients,
and to compare their efficiency, risks, and side effects
with DBS. There are two important reasons for pro-
viding the option of lesion procedures: first, the rela-
tive low cost (which is particularly important in
poorer countries); and second, certain exclusion crite-
ria or practical limitations of DBS (e.g., patients who
could tolerate neither the stress of an operation awake
nor an operation under full anesthesia; patients for
whom a craniotomy is contraindicated; patients who
would not tolerate implanted devices; or patients who
live in remote areas such that compliance with the
long-term follow-up after DBS is hard to achieve).
Institution Dimension
 Quality standards in smaller DBS centers: Although in
some countries (e.g., Switzerland) there is a discussion
to ensure high case numbers per DBS center (Christen
and M€uller 2012), obviously many centers operate on
only a few patients. However, we argue against fixed
minimal case numbers for DBS centers, as determining
the cutoff is arbitrary and other stereotactic interven-
tions besides DBS (which have not been captured in our
surveys) also account for the experience of a center.
Nevertheless, it is important to find ways (e.g., binding
guidelines) to ensure high quality also in smaller DBS
centers, with regard not only to the surgical procedure,
but also to patient information, patient selection, device
programming, and pre- and postsurgical neurological
and psychiatric assessment.
 Novel DBS indications planning: It is likely that DBS
will become a bearer of hope for many psychiatric disor-
ders—in particular, for depression, OCD, and Tourette’s
syndrome—for which known therapies have failed (e.g.,
recent studies estimate that more than 50% of patients
suffering from depression may be treatment-resistant;
Thomas et al. 2013). However, it will be important that
the development of novel DBS indications is theory
driven (i.e., based on a good understanding of the net-
work in which one intervenes) and evidence based and
not merely demand driven. In particular, the planning
should involve the buildup of (optimally international)
case registries, which should contain all clinical studies
and individual treatment attempts for all novel DBS
indications. Case registries are indispensable for pre-
venting a publication-bias and its negative consequen-
ces, namely, faulty evaluations of therapies, flawed
therapy recommendations, unpromising treatment
attempts, and unneeded clinical studies (M€uller and
Christen 2011; Rabins et al. 2009; Schl€apfer and Fins
2010; Woopen, Timmerman, and Kuhn 2012).
 Evidence-based evaluation of DBS for novel indications:
For novel indications of DBS, an evidence-based evalua-
tion is essential. Whenever possible, each novel indica-
tion should be investigated in clinical trials of the
appropriate size and statistical power, requiring collabo-
ration of centers. We support the demand of Fins and
colleagues (2011) that the U.S. Congress and federal reg-
ulators should revisit the Food and Drug Administra-
tion (FDA) humanitarian device exemption that allows
manufacturers to market a device under certain condi-
tions without subjecting it to a clinical trial, for DBS for
treating OCD. They argue convincingly that the humani-
tarian device exemption is misused for bypassing the
rigors of clinical trials, since OCD is not an orphan but a
prevalent condition, and that the current market-driven
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regulatory strategy is detrimental to patient safety, sci-
entific discovery, and research integrity.
 Capacity planning: Due to the rapid expansion of DBS
indications, capacity planning in centers—at least for
some countries—should become an issue soon. In some
countries (e.g., Switzerland; Christen and M€uller 2012)
not all patients who are suitable for DBS may obtain this
therapy. Unfortunately, there are almost no data avail-
able even for a disease like PD that allows for such plan-
ning (in particular, data that estimate the percentage of
patients who suffer from a DBS indication and who are
actually good DBS candidates, and data on the optimal
case number per center to ensure both sufficient inter-
vention quality—which speaks for higher case numbers
per center—and optimal care and follow-up—which
sets an upper limit for the number of patients operated
per center). Therefore, health service research should
put more resources into gaining information needed for
DBS center capacity planning.
 Funding: A recent market study claims that the brain
stimulation market “is expected to grow at a rapid pace
and achieve a similar market size to the Global Cardiac
Devices market” (Research and Markets 2013). Also
according to our data, the experts see economic driving
forces in the development of novel indications for DBS.
Unfortunately, the current data do not allow assessing
reliably the impact of private funding on DBS research.
We recommend that papers on DBS (and other fields)
should always disclose their funding source, indepen-
dent of whether this source is private or public.
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Clinical & ethical aspects of modulating behaviour and affect through DBS  Ineichen 2016
Publication 3: Questioning the technology-development of DBS de-
vices
Synopsis
Given the important ethical discussion of technological issues evidenced by the robust connection 
between the topics “hardware” and “ethics” (see publication 1), it was timely to critically address still 
insufficiently discussed issues. It also takes up the consideration outlined in the introduction that 
often it might be valuable to critically reflect on how the field is developing. Consequently, we felt 
it was time to pause for a moment in order to give room for critically reflecting on mainly unmet 
technological issues which at the end have ethical relevance for patients treated with DBS. The idea 
arose from discussions in the hospital mostly before and after surgeries for which I was always very 
welcomed.  Consequently, we tried to make an argument for demanding technological improvement 
for the sake of patient safety and better future treatment.
By providing the reader with an exemplary case example which demonstrates the uncritical stance 
of many professionals in the field, we went on by outlining the often frustrating and time-consu-
ming steps health-care professionals have to perform when having to choose by trial and error from 
thousands of stimulation parameter combinations in order to minimize side-effects. Often enough, 
unquestioned expert recommendations are used for every patient in clinical practice. 
After discussing technological drawbacks and the missing of an automatic or remote report system 
of e.g. “red flags” for adequate patient oversight, we outline the difficulty of capturing clinical chan-
ges that are meaningful to patients and their families.
Next, we argue that by including an ethical framework, which is relevant for the neuroethical 
assessment of neuromodulatory interventions including beneficence and non-maleficence, one is able 
to structure the normative claim. Because device manufacturers can determine which experiments are 
worthwhile and which should be conducted and because it is unclear what happens when a device 
manufacturer goes out of business and equipment is no longer available, the industry would have to 
accept more responsibilities. Hence, we claim that the goals of technological innovation and patient 
welfare should be complementary and should involve device-makers and clinicians equally.
In summary, there is great need for sensitivity to the ethical duty to actively promote and demand 
technological advancements for the sake of minimizing undesirable complex side-effects.
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Since the translational research findings of Benabid and colleagues which partly led to
their seminal paper regarding the treatment of mainly tremor-dominant Parkinson patients
through thalamic high-frequency-stimulation (HFS) in 1987, we still struggle with identifying
a satisfactory mechanistic explanation of the underlying principles of deep brain stimulation
(DBS). Furthermore, the technological advance of DBS devices (electrodes and implantable
pulse generators, IPG’s) has shown a distinct lack of dynamic progression. In light of
this we argue that it is time to leave the paleolithic age and enter hellenistic times:
the device-manufacturing industry and the medical community together should put more
emphasis on advancing the technology rather than resting on their laurels.
Keywords: deep brain stimulation, technology, development, innovation, functional neurosurgery, stereotactic
operation, ethics
INTRODUCTION
Early lesion studies in humans and translational preclinical
research using laboratory models as well as concomitant early
stimulation experiments, pharmacological treatment approaches
with L-DOPA in 1968 and the identification of circuit physiology
in the early 1980’s have led to the development of neuromodula-
tion techniques such as deep brain stimulation (DBS). In contrast
to medication-based approaches, knowledge gained from DBS as
both a probe and modulator of the underlying neural circuitry
resulted in a new way of describing and understanding (neuro)-
pathologies (top-down approach). Early stimulation experiments
such as those using non-human primates (Kringelbach et al.,
2010) were a glowing example of such development. However,
we still struggle with explaining the mechanisms of action of
DBS as Montgomery stated in his paper on logical pitfalls on
DBS results andmechanisms of action (Montgomery, 2012). 2012
marked the 25th anniversary of modern DBS. Although DBS is
being performed increasingly in centers worldwide, not much has
changed regarding the integration of new technological know-
how. This poses the distressing question of whether there is a
duty to overcome this lack of progress. The general picture of an
apparent arrested development does not at all light up when ana-
lyzing the approximately 40 years of emerging neurostimulation
technologies which were adapted into therapies by neurosurgeons
for different conditions during the 1970s (Gardner, 2013), besides
early stimulation experiments on patients e.g., by Robert Heath
and Jose Delgado. Compared to other technological advances in
different domains ranging from consumer electronics to medical
applications, the technological advance of DBS devices seems to
be almost nonexistent.
Furthermore, DBS is at a critical turning point which is
characterized by a subsequent collapse of the “last-resort” con-
notation DBS once had as a treatment for refractory disor-
ders. Indeed, beyond broadening indications to younger patients
with well-studied diseases, even questionable indications arise
(Hariz, 2012). Is it legitimate to use the same electrodes
and stimulation techniques in every region of the brain for
movement or psychiatric disorders? And isn’t it plausible that
local anatomy may need different hardware/software combina-
tions? Will old concepts of lesioning with new technologies,
e.g., high-intensity focused ultrasound, replace DBS in some
domains (Lipsman et al., 2013)? Is it possible that genetic
and cell culture technologies could overrun the “gold stan-
dard” DBS for Parkinson’s disease in the future (Lindvall,
2013)?
TECHNOLOGICAL DEVELOPMENTS: DIFFERENT
CONTEXTS—SAME PATTERNS?
Figure 1 depicts some of the technological advances that have
had applications both inside and outside the medical domain. For
our purpose it is sufficient to state that the driving factors for
technological evolution and innovation are the following:
1. reduction of size dimensions
2. increase of complexity and variability of tasks which can be
executed
Lewis H. Morgan’s stage model of social evolution involves
the analysis of technological milestones and declares technological
progress to be the primary factor driving the development of
human civilization. On the basis of this model, there is the
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FIGURE 1 | Illustrative examples of technological developments in the
past 25 years which refer to miniaturization aspects and
ground-breaking change of technological complexity. Wheel chair bound
patients could in the meanwhile benefit from the possibility of full
mobilization due to an exoskeleton device (adapted from: http://www.
medicalspro.com/manual_wheelchair.php, http://www.designboom.
com/technology/elegs-exoskeleton-by-berkeley-bionics/). External devices
of cochlear implants have become remarkably smaller (adapted from:
http://www.enttoday.org/details/article/4550891/History_of_the_Cochlear_
Implant.html, http://www.audiology.org.nz/Userfiles/Image/implant6_lge.jpg).
Television, Walkman and Mobile Phone have become a single, extremely
sophisticated multifunctional tool with wireless connections to other
technical devices and integrating Internet (Smart-Phone). (adapted from:
http://www.radiomuseum.org/r/waltham2_tele_star_4004.html,
http://www.telegraph.co.uk/technology/5733286/Sony-Walkman-in-pictures.
html?image=4, http://www.webdesignerdepot.com/2009/05/the-evolution-of-
cell-phone-design-between-1983-2009/; IPG & mobile phone images used by
courtesy of owner).
question of how to interpret our current evolutionary stage by
focusing on DBS device advances (see Figure 1). Have we pro-
gressed beyond Morgan’s savagery stage?
Pragmatically we think it is fair to say that in the con-
text of DBS, neither (1) nor (2) have yet been satisfied (also
see Figure 1 for a direct, schematized visual comparison).
The possibility of spatial steering brain stimulation (Martens
et al., 2011; Hariz, 2014) or adaptive DBS (Little et al., 2014)
barely rises at the horizon. Furthermore, settings are pre-
determined per electrode site and can be changed only in a
very restricted way due to the missing feedback path (Eberle
et al., 2011). Also it appears as if technological trends from
neighboring disciplines (i.e., “technology-transfer” (Morlacchi
and Nelson, 2011)), such as the gravitation-field sensor sys-
tem in the context of spinal cord stimulation or nano-
technology have not in the least been adopted by the DBS
industry. Currently, greater emphasis is put on the issue of
MRI safety of DBS implants due to diagnostic highfield-MRI
(Paek et al., 2013), which is increasingly being used in clinical
work.
A THOUGHT-PROVOKING PIECE OF SURGICAL EVIDENCE
Results of randomized controlled trials have just recently been
published without major differences regarding outcome of STN-
DBS vs. GPi-DBS (Weaver et al., 2012; Odekerken et al., 2013).
Figure 2 depicts the desperate search and use of the newest
technology available for treating a patient with Parkinson’s
disease. Both physician and patient were willing to try the
best treatment possible for alleviating the symptoms of this
disabling disease. The X-ray images were acquired in 2009
before exchange of the implantable pulse generators (IPGs)
connected to the STN (subthalamic nucleus) electrodes. One
could speculate that a change to a more sophisticated tech-
nological system in GPi (globus pallidus internus) stimula-
tion could have served the purpose of inducing a therapeutic
effect without undergoing additive stereotactic surgery. Those
Frontiers in Human Neuroscience www.frontiersin.org September 2014 | Volume 8 | Article 730 | 2
Ineichen et al. A critical reflection of DBS-development
FIGURE 1 | Illustrative examples of technological developments in the
past 25 years which refer to miniaturization aspects and
ground-breaking change of technological complexity. Wheel chair bound
patients could in the meanwhile benefit from the possibility of full
mobilization due to an exoskeleton device (adapted from: http://www.
medicalspro.com/manual_wheelchair.php, http://www.designboom.
com/technology/elegs-exoskeleton-by-berkeley-bionics/). External devices
of cochlear implants have become remarkably smaller (adapted from:
http://www.enttoday.org/details/article/4550891/History_of_the_Cochlear_
Implant.html, http://www.audiology.org.nz/Userfiles/Image/implant6_lge.jpg).
Television, Walkman and Mobile Phone have become a single, extremely
sophisticated multifunctional tool with wireless connections to other
technical devices and integrating Internet (Smart-Phone). (adapted from:
http://www.radiomuseum.org/r/waltham2_tele_star_4004.html,
http://www.telegraph.co.uk/technology/5733286/Sony-Walkman-in-pictures.
html?image=4, http://www.webdesignerdepot.com/2009/05/the-evolution-of-
cell-phone-design-between-1983-2009/; IPG & mobile phone images used by
courtesy of owner).
question of how to interpret our current evolutionary stage by
focusing on DBS device advances (see Figure 1). Have we pro-
gressed beyond Morgan’s savagery stage?
Pragmatically we think it is fair to say that in the con-
text of DBS, neither (1) nor (2) have yet been satisfied (also
see Figure 1 for a direct, schematized visual comparison).
The possibility of spatial steering brain stimulation (Martens
et al., 2011; Hariz, 2014) or adaptive DBS (Little et al., 2014)
barely rises at the horizon. Furthermore, settings are pre-
determined per electrode site and can be changed only in a
very restricted way due to the missing feedback path (Eberle
et al., 2011). Also it appears as if technological trends from
neighboring disciplines (i.e., “technology-transfer” (Morlacchi
and Nelson, 2011)), such as the gravitation-field sensor sys-
tem in the context of spinal cord stimulation or nano-
technology have not in the least been adopted by the DBS
industry. Currently, greater emphasis is put on the issue of
MRI safety of DBS implants due to diagnostic highfield-MRI
(Paek et al., 2013), which is increasingly being used in clinical
work.
A THOUGHT-PROVOKING PIECE OF SURGICAL EVIDENCE
Results of randomized controlled trials have just recently been
published without major differences regarding outcome of STN-
DBS vs. GPi-DBS (Weaver et al., 2012; Odekerken et al., 2013).
Figure 2 depicts the desperate search and use of the newest
technology available for treating a patient with Parkinson’s
disease. Both physician and patient were willing to try the
best treatment possible for alleviating the symptoms of this
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FIGURE 2 | A unique witness of DBS history. Bilateral monopolar
electrodes were implanted within the internal globus pallidus (GPi) in
1998 in a patient having suffered from typical Parkinson’s disease since
1984. Predominant disabling dyskinesia improved significantly afterwards
(black arrows: more lateral in (A) and more anterior in (B)). Because of
re-emerging motor fluctuations without further optimization possibilities
of the monopolar GPi electrodes (probably side effects), bilateral
quadripolar electrodes (white arrows) were then implanted within the
STN in 2001 accounting finally for four intracerebral electrodes and four
pulse generators (C,D). The patient profited for around 3 years before
developing late stage symptoms, like frequent falls, voice alteration,
On-dystonia in her lower extremities and cognitive decline. The two GPi
generators were explanted in 2009 as additional beneficial effects were
not seen.
images unmask the hopeful will to change treatment in regard
to hardware and target without having understood the fail-
ure of the monopolar GPi stimulation in this patient. The
transition from mono- to quadripolar electrodes still remains
the maximum of technological progress today. In daily clin-
ical work, there is a subliminal frustration on the imbal-
ance of having more than 10,000 programming possibilities,
e.g., frequency, pulse width and amplitude, without being able
to optimize stimulation for the individual patient (Volkmann
et al., 2006; Ricchi et al., 2012). Instead, expert recom-
mendations remain the evidential basis of setting param-
eters. Regarding multiple joint prostheses and four IPG’s,
this patient has reached nearly the limit of medical implant
costs.
TECHNOLOGICAL CONSIDERATIONS
The recent advances of increased magnetic field strength observed
in MRI-system technology should ultimately lead to an improve-
ment in the accuracy of electrode positioning. This is particularly
important given the high interindividual anatomical variability of
structures such as the STN, because personalized, image-based
targeting provides higher accuracy than atlas-oriented targeting
(Ashkan et al., 2007). Moreover, Zaidel et al. (2010) showed
optimal clinical efficacy by determining local electrophysiolog-
ical parameters characterized by increased β-oscillatory activ-
ity on multi-unit recordings rather than by pure anatomical
analysis.
Today, the impossibility of detecting specific alterations in
underlying brain activity depending on the condition being
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treated is a major limitation. Do we pay tribute to extremely
complicated homeostasis patterns of a billion years of evolution,
e.g., circadian neuroendocrine interaction and electrochemical
networks? Currently, IPGs can be programmed through
modifying frequency, pulse width, current output (amplitude),
interleaved mode (Baumann et al., 2012) between contacts and
limited possibilities of groups/cycling modes. In routine clinical
practice, the physician usually takes “standard” programs known
from the literature. In case of side effects of medication and
stimulation interaction in the variable disease patterns, “trial
and error” within thousands of programming possibilities can be
frustrating, extremely time-consuming and may require hospital-
ization of “difficult” patients (Volkmann et al., 2006; Hariz, 2012).
Steering the electrical current and granting MRI compatibility
are recent and important developments to solve the problem of
side effects, energy consumption and harmless hardware-tissue
interaction (Hariz, 2014). Given that the brain uses dual-mode
communication and feedback strategies, an effective treatment
needs to detect and return both real-time monitoring of chemical
neurotransmitter release levels as well as electrical firing patterns
(Rosin et al., 2011)—in other words, closed loop self-regulatory
systems (Grahn et al., 2014). One of these systems is currently
under investigation at multiple centers worldwide without any
information, yet on future efficacy or availability. The advances of
real-time, instantaneous neurochemical and electrophysiological
sensing combined with feedback-guided anticipatory adjustment
and sophisticated electrode (lead) design (Arcot Desai et al., 2014;
Hariz, 2014; Kent and Grill, 2014) could lead to a fully integrated,
small and high precision, low-power circuit supporting a wireless
neuromonitoring and neuromodulation system (Shah et al.,
2010). Hence, avoiding thick, unlabeled cables and clumpy
IPGs would reduce acute and long-term morbidity as hardware
complications still remain frequent adverse events in DBS surgery
in many centers (Hamani and Lozano, 2006).
Additionally, there is a lack of monitoring and integrating
disease symptoms together with general health and activity status
of the patients. There is no automatic or remote report system,
e.g., of “red flags” of symptoms or hardware-related problems, not
even for precise battery life duration.
We argue therefore that the time has come to focus on advanc-
ing the DBS system in terms of technological properties to better
meet individual patient needs, leading to more effective symptom
control, improved patient quality of life and reduced healthcare
costs.
Given the importance of DBS, the lack of biomarkers for many
complex conditions and the associated need for a critical and
objective pre- and post-DBS therapy evaluation, we argue that
we should emphasize improving means for a holistic evaluation
of patient’s clinical status. As Gardner (2013) brought to the
fore the decisive role of the invention of a (synthetic) UPDRS
rating scale for the emergence of DBS, we also have a duty to
critically question whether the creation of such an objective
numerical variable in order to have a basis for comparing pre-and
post-stimulation effects fully embraces the patient and results in
improvement of symptoms. Gardner further states: “Thus while
such a tool may generate the necessary “objective evidence” to
legitimate the intervention and enable device manufacturers to
market their device, it may not be capturing clinical changes that
are meaningful to patients and their families” (Gardner, 2013).
Thus, quantified rating scale scores have to be complemented by
qualitative measures (Bagby et al., 2004).
ECONOMIC CONSIDERATIONS
Of course, medical products are under stricter regulatory pro-
cesses than consumer goods, and doctors or patients are not
simple consumers. To the best of our knowledge, one sin-
gle company held the monopoly for DBS application systems
for almost 20 years. Even after the introduction of two other
key companies, besides newly emerging vendors highlighted in
a recent market study (Global Deep Brain Stimulator Market
2012–2016),1 there was no ground-breaking new technological
development. Not more than minor changes in programming
possibilities, lead and fixation design, and battery properties
have occurred. This is problematic since we find ourselves in
a context of severe diseases which depend on innovative treat-
ment options. The lack of favorable (see Hashmi, 2013) com-
petition for product-innovation for developing safer and more
effective neuromodulation techniques stands in marked contrast
to the situation of other technological domains outside the
medical field, such as the mobile phone or automobile indus-
try. Here we face a highly dynamic progression of consumer-
oriented new developments. In other, more competitive domains
within medicine, such as orthopaedic surgery/applications, a
more innovative landscape can be observed. A lack of com-
petition may be one reason why we are confronted with a
shortage of technological progression in the DBS field. By
looking at the economic literature, and by keeping in mind
that the health-economic sector is different, one could argue
that more product market competition can under certain cir-
cumstances increase product-innovation (Aghion et al., 1999,
2009; Aghion and Griffith, 2005; Hashmi, 2013; Roper et al.,
2013).
In the DBS context, it is unclear why we do not face a
pronounced conflict between attending physicians and industry
regarding differing claims. Possibly there is not enough demand
(supply-and-demand situation) verbalized by the medical estab-
lishment which could explain a lack of innovation potentially
due to daily work-intensity and time pressure, regulatory hurdles,
investment return considerations, installed base effects, a lack of
knowledge-transfer from basic science to users in clinic or a low
level of sensibility to grasp the responsibility to strive for more
benefit to the patient.
One could potentially identify a subliminal tendency towards
investing in other indications, thereby increasing the number of
implants instead of improving quality.
ETHICAL CONSIDERATIONS
We argue that there is a multidimensional obligation to pro-
mote innovation which should include all agents involved in
the process of helping patients in need. We restrict ourselves to
the two domains already highlighted above, namely the medical
community and the medical device industry. Those domains
1http://www.researchandmarkets.com/reports/2538063/
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should both promote innovation since they have complementary
rather than competing goals. In the following, we focus briefly on
the medical community on the one hand and more extensively
by the use of a framework-based argumentation on the medical
device industry on the other.
It appears that the medical establishment has failed to build
on the dynamic treatment breakthroughs of the past due to
overconfidence and a lack of vision. The initial clinical efficacy
in resolving some symptoms obscured the once broadly heralded,
noble aspirations of gaining deeper understanding of DBS. Even
though the subsequent unraveling of side effects could have driven
clinicians to obtain deeper scientific knowledge as well as to
optimize treatment, this unfortunately was not pursued with the
required vigor.
We believe that it is therefore time to include some ethical
reflection in the debate. One could argue that industry and the
medical community both have a duty to invest more in technolog-
ical advances by concomitantly ensuring that treatments are safe
and effective (Hofbauer et al., 2013). Generally more emphasis
should be put on basic scientific advances (Hamani and Temel,
2012), thereby reaching a level of development which in the end
will, as a manifestation of a sensitive pleading for the centrality of
patients, help those most in need. Also the question of an ethical
responsibility to strive for the best and latest technology for the
treatment of one of our most sheltered organs, our brain, should
be discussed.
An ethical framework is needed to make this normative
claim more transparent and more systematically structured. We
believe that interposing some normative considerations may
have beneficial effects in terms of sensitizing the community.
This could be a starting point for an eclectic and multifaceted
normative discussion. Moreover, such a framework is neces-
sary to guide innovation within the field of DBS. In order to
make a normative claim such as the duty or responsibility to
promote technological advance, one may pursue this idea by
making use of an already established ethical framework such as
the one provided by Beauchamp and Childress (2013), thereby
analyzing the effects of technological development on primary
ethically relevant parameters. We have chosen this particular
framework as a starting point for normative reflection because
of its established and wide use within the clinical context. It
incorporates two core bioethical principles, namely “primum
non nocere” (“First, Do No Harm”), reflected in the duty of
nonmaleficence and beneficence, which could be described as
the duty to promote the good of others. Regarding the need
for and further development of neuromodulating devices, the
principle of beneficence is especially ethically relevant. We believe
that it is important to incorporate the values reflected in these
principles into the context of industry. For one could argue
that patients’ well-being may be positively affected by the imple-
mentation of technological innovation. Beneficence and non-
maleficence apply not only to the medical domain but also to
that of industry and need to be balanced with the economics
of the medical device industry and the need for companies to
survive.
The application of these principles means that the ethical
justification of any technological advance in neuromodulation
depends on whether it is beneficial for patients and improves their
well-being. As stated above, we argue that ethical considerations
require that all stakeholders should be involved in the discussion.
Accordingly, a duty to promote technological advance should
not be restricted to the medical domain but also should be
radially projected in order to positively affect all agents involved.
If we genuinely care for the patient’s wellbeing, then the prin-
ciple of beneficence should not only apply to the medical con-
text but should have the power to transcend contextual barri-
ers.
The goals of technological innovation and patient welfare
should be complementary. Device-makers funding DBS clinical
trials have an obvious interest in proving that their product can
modulate neural circuits. Yet this has the potential to create a
conflict of interest for researchers wanting to know how DBS
affects the brain and mind of subjects if the manufacturer influ-
ences the design of the trial and the interpretation of the results.
The potential for conflict is greater when the researcher has
invested in such a company. Policies must be in place to prevent
or at least reduce the probability of this conflict by ensuring
the scientific integrity of clinical trials and that testing DBS is
consistent with the interests of patients in experiencing symptom
relief and improved quality of life. Ultimately, patient welfare
should be the main impetus of any duty of innovation to produce
more advanced neuromodulating devices (Fins and Schiff, 2010;
Fins et al., 2011).
In our discussion of beneficence, we identified one pertinent
principle which we thought to be easily accessible as well as used
in practice. But because it is beyond the scope of this paper,
we refrain from elaborating on the critical steps of balancing
and weighing different values against each other. There might
of course be other issues that potentially outweigh a duty of
innovation under certain circumstances.
Moreover, there is a need for interdisciplinary exchange
between and among representatives of patient organizations,
industry, basic science, medicine and ethics in order to shape
the future of DBS. A recent interdisciplinary, international forum
(“brains in dialogue”, BID project)2 trying to foster this dialogue
was unfortunately closed.
CONCLUSION
DBS is an established therapeutic intervention and has recently
provided hope for many patient groups including but not limited
to movement disorders. Significant innovation in the field of
DBS has mainly been reflected by introducing novel indications,
rather than advanced technologies. We still lack a mechanistic
explanation of the underlying processes involved. In turn, one
has to acknowledge that the limited understanding of brain func-
tions (bottom-up approach) poses a critical barrier to innova-
tion. Deeper insight is crucial to further advance DBS systems
towards intelligent, self-regulating closed-loop devices in combi-
nation with miniaturization and MRI-compatibility of hardware,
sophisticated electrodes and programming possibilities. Further-
more, especially in the case of new indications, international joint
2http://www.neuromedia.eu/NewsData.aspx?IdNews=1325&IdType=296&
type=Actual
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meetings should include preclinical translational researchers as
well as ethicists, recognized patient organizations, engineers and
healthcare providers in neurology, neurosurgery and psychiatry
for the translation of technological advances in order to create
consensus of future directions of development and to improve
outcomes of established indications. This consensus could be
addressed to regulatory bodies for a representative impact. Finally,
there is a greater need for sensitivity to the ethical duty to
actively promote and demand technological advancement in
neuromodulation.
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Publication 4: Developing an instrument for measuring complex chan-
ges
Synopsis
As outlined in the introduction, mental capacities and moral competencies (among others) of 
the patient have high ethical relevance in the context of autonomy. Hence, by incorporating the 
previously described moral-psychological framework of Moral Intelligence (see introduction), we 
emphasize the role of psychological skills required for moral behaviour. In this paper, we describe the 
construction of an instrument for measuring moral sensitivity. As outlined in the introduction, the 
idea of the instrument construction was the development of a not too fine-grained but also not too 
general tool which can be adapted in order to allow researchers to e.g. investigate moral-behavioural 
and personality-related changes post-lead implantation and stimulation.
More precisely, the instrument is based on the construct “value sensitivity” which denotes to the 
ability to recognize (moral) issues when they arise in practice. If interested in assessing complex 
behavioural and personality-related changes post-operatively, the need of psychologically informed 
instruments which include explicit and implicit measures and which are based on recent moral-psy-
chological insights of human behaviour is apparent. Hence, we developed an instrument for assessing 
value sensitivity and complemented this research with instrument validation by comparing nursing 
professionals with hospital managers. 
In accordance with our hypotheses, the group comparison demonstrates the expected differences 
in value-sensitivity regarding moral and non-moral related values of the two groups: We find that 
nursing professionals recognize and ascribe importance to principle-related issues more than profes-
sionals from hospital management. The latter are more likely to recognize and ascribed more import-
ance to strategy-related issues. Hence, the instrument displays adequate discriminatory power.
In a next step, the goal will be to adapt the instrument for assessing potential changes in patient 
sensitivities postoperatively related to relevant values for this domain. This will allow us to potential-
ly identify changes in patients’ perceptions which are meaningful for the patients and their relatives 
and which might explain some of the difficulties they face postoperatively when witnessing nuanced 
changes in personality and or in the expression of behavioural acts partly responsible for conflicting 
outcome interpretations and satisfaction gaps.
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Abstract (278 words) 
Background: Moral sensitivity – the ability to recognize moral issues when they arise in practice – is 
an indispensable competence for medical practitioners to enter decision-making processes related to 
ethical questions. However, the psychological competence of moral sensitivity is seldom an explicit 
subject in the training of medical professionals. In this contribution, we outline the concept of moral 
sensitivity in medicine, we propose an instrument that measures moral sensitivity, and we investigate 
risks and benefits of improving moral sensitivity in medicine. 
Methods: We developed an instrument for assessing the sensitivity for three value groups (moral-
related values, values related to the principles of biomedical ethics, strategy-related values) in a four 
step procedure: 1) value identification (n = 317); 2) value representation (n=317); 3) vignette 
construction and quality evaluation (n=37); and 4) instrument validation by comparing nursing 
professionals with hospital managers (n=48). This empirical analysis was complemented by literature 
research on moral sensitivity in medicine and related fields and with normative considerations. 
Results: We find that nursing professionals recognize and ascribe importance to principle-related 
issues more than professionals from hospital management. The latter are more likely to recognize 
and ascribed more importance to strategy-related issues.  
Conclusions: These hypothesis-driven results demonstrate the discriminatory power of our newly 
developed instrument, which makes it useful not only for health care professionals in practice but for 
students and people working in the clinical context as well. Finally, we provide a broad overview of 
normative questions associated with the performed research. We discuss the practical significance of 
moral sensitivity in medicine and the value of improving it. We also delve deeper into potential risks 
that may be associated with a moral-sensitivity-assessment instrument and attempts to improve it. 
Keywords: Moral Sensitivity; Ethical Sensitivity; Moral Values; Moral Competences; Medical Ethics 
Training  
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1. Introduction 
In medicine, there is a need to emphasize the psychological prerequisites for clinical acting [1]. 
Generally, psychological moral competencies of medical professionals are rarely assessed, and there 
are hardly any instruments that are appropriate to measure such competencies. One such relevant 
competence is moral sensitivity, a prerequisite for moral decision-making and behavior. In this 
contribution, we investigate means and justifications for developing competences that are required 
to implement virtuous behavior in clinical practice [2, 3]. Based on previous research (identification 
and characterization of context specific values [4]), we aimed at developing an instrument which 
measures moral sensitivity in medicine. The instrument is aimed at supporting medical professionals 
and their patients by empowering healthcare practitioners to recognize dilemmas when they arise in 
practice. As it is not clear whether enhancing moral sensitivity per se is positive under all 
circumstances, we address the need to explore the normative implications resulting from the 
proposed research. With this work, we outline the procedural steps necessary for the development 
of the instrument. Next, we describe the validation of the instrument by means of a group 
comparison. Finally, we complement the work by a broad normative reflection with an emphasis on 
potential risks and benefits of improving moral sensibility. 
 
1.1. The concept of moral sensitivity 
Moral sensitivity (also referred to as moral awareness or ethical sensitivity/sensibility) is commonly 
defined as the ability to recognize moral issues when they arise in practice [3, 5 - 8, see also 9 or 10 
for reviews on varying definitions of the construct]. More precisely, moral sensitivity incorporates 
both the ability to recognize moral issues in a morally ambiguous situation and the ascription of 
importance to these same issues [11]. It includes being responsive to the needs of others in addition 
to anticipating whether a course of action can harm or help others or whether it violates internalized 
moral standards or codes of conduct. In line with this conceptualization, we adopt a definition of 
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moral sensitivity that includes both the recognition and the ascription of importance to moral issues. 
Accordingly, moral sensitivity is proposed to cover both, an intuitive- (quick, reflexive recognition of a 
morally relevant aspect in a situation) and a deliberative process (vectored attentiveness to morally 
relevant aspects). 
 
Lack of moral sensitivity – also called moral blindness – is likely to have far-reaching consequences. 
Researchers found that “morally blind” people can act with the best of intentions but behave in 
contradiction to their own values and principles, without being aware of it [12]. If the moral issues at 
stake are not identified, no moral problem will exist for the individual and therefore there will be no 
need to enter into a moral problem-solving phase [13]. Thus, it is obvious that without a certain 
moral awareness, there is no reason to question one’s or other’s behaviors from a moral point of 
view. Consequently, without moral sensitivity, professionals may not be able to appropriately 
recognize, interpret and respond to the concerns of patients and their relatives.  
 
Although many researchers agree on categorizing moral sensitivity as a prerequisite for the initiation 
of moral decision making (e.g. [6, 13]), past research has focused more on the development of 
instruments for measuring the latter while largely neglecting the former [14]. The Dental Ethical 
Sensitivity Test (DEST) by Bebeau and Rest (1982) [15] is the oldest measure of moral sensitivity and 
was created to measure individuals’ ability to identify ethical issues and deviations from professional 
codes of ethics in dental practice. More recent attempts focus on the measurement of moral 
sensitivity in the business domain (e.g., in accounting or business situations). In 2007, Jordan [9] 
provided a comprehensive review and critical evaluation of the available measurements, pointing out 
that there is still a great need for validated measures of moral sensitivity (see also [16] for an 
emphasis of the medical context). A concise evaluation of those tests indicates that current 
instruments fall short regarding several aspects (see also [9]). For example, they often lack an 
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evaluation based on criteria of diagnostic test theory. Our research project aims at developing an 
instrument for the measure of moral sensitivity which overcomes such pitfalls and is part of a 
comprehensive theory of moral intelligence [3]. 
 
We will expand the concept of moral sensitivity by considering a broader spectrum of values. The 
reason for this is that the current research on moral sensitivity focuses on values whose relation to 
morality is undisputed both from a theoretical perspective (i.e., they are discussed as prototypical 
moral values in the ethics literature) and based on empirical findings (i.e., people consider those 
values to be moral values). Examples include benevolence, honesty, or fairness. However, in 
professional contexts, other values may be relevant as well, although they may not be perceived as 
moral values (e.g. cost-effectiveness or reputation). By the term ‘value’ we refer to stable beliefs 
about desirable states or conducts of behavior, which serve as general normative standards to judge 
and justify actions not necessarily related to ethics [17]. Therefore, we suggest that an assessment of 
moral sensitivity should include values that are not intuitively perceived as moral but that refer to 
legitimate claims within the specified domain.  By “domain”, we refer to any social sector, for 
example, professional fields such as medicine or business, associated with a specific set of values that 
are considered to be important in that sector. In the following, we therefore refer to the notion of 
“value sensitivity”. Based on previous research [4], value sensitivity in the research context of 
medicine is composed of three subcomponents: sensitivity for moral-related, principle-related and 
strategy-related values.  
 
1.2. The relevance of moral sensitivity in medicine 
The medical domain exceptionally challenges ones’ moral competencies because of numerous 
problems in that domain. These include actions under time pressure, inclusion of high-level moral 
values (e.g. non-maleficence) and dilemmas involving numerous stakeholders apart from structural 
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barriers. Much of the controversial discussion focuses on codes of conduct. Some authors certify that 
these codes have only minor impacts on daily practice [18] and found that nurses evaluate them as 
being of little use [19]. Some studies investigating the success of teaching medical ethics even 
observed that the student’s moral sensitivity diminished over the course [20]. This result may 
indicate that traditional teaching strategies tend to overlook the key competence of recognizing 
dilemmatic moral aspects in ambiguous clinical situations. In the past, authors such as Kleinmann 
complained about the neglect to promote psychological competences in teaching programs [1]. 
Consequently, the question of which specific psychological abilities have to be trained to realize such 
competency has not been adequately emphasized. Accordingly, we point out that moral behavior is 
not solely reflected in knowledge about ethical theories but also by paying attention to the 
psychological conditions of ones’ own moral ability. Both aspects should be included in medical 
education.  
 
If moral behavior rests on moral competencies, the need for tools to measure the baseline status 
with the possibility of training such skills becomes an important undertaking [21]. We suggest that 
one way of supporting health care professionals’ training is to allow them to learn about their 
individual strengths and weaknesses with respect to their own moral sensitivity. In medicine, it is 
important to be able to obtain a swift recognition of which values are involved in a particular 
situation and which stakeholders could be affected by the ethical decision (e.g. patient, physician, or 
close relatives). Therefore, we consider it as an imperative to holistically integrate the insights of 
recent moral (psychological) research about the conditions of human moral ability into medicine in 
general and in the process of education of medical professionals in particular. Potential applications 
of our model are: (1) as a diagnostic tool for medical professionals in order to mirror possible 
strengths and weaknesses, (2) as an educational tool in the context of medical school and (3) as an 
instrument for advanced training of individuals, who work, for example, as clinical ethicists. 
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Interestingly, previous research on moral sensitivity indicates that there are differences between 
professions and the gender of those who work in these professions [11, 22 - 29]. Jordan [9], for 
example, demonstrated that business managers are less likely to detect moral-related dimensions 
than academics when providing them with morally ambiguous business situations. Furthermore, 
Harenski and collegues [29] have emphasized gender differences in the context of moral sensitivity. 
Specifically, females show increased care-based processing. 
 
Yet, the body of evidence that people differ quite substantially in terms of moral sensitivity and that 
this capacity is related to moral behavior makes moral sensitivity a subject of normative inquiry. In 
this paper, we wish to extend this work by providing a broad overview of key normative issues, such 
as the practical significance of moral sensitivity in medicine. We also discuss advantages and 
disadvantages in promoting and assessing this capacity. 
 
2. Developing an instrument for measuring value sensitivity. 
As outlined in the last paragraph of section 1.1., we embed moral sensitivity into the broader concept 
of value sensitivity. We performed steps towards developing an instrument designed to assess value 
sensitivity. First, based on previous research we gained empirical evidence for a domain-specific 
value selection as well as insights into what extent the values are perceived as moral values (step1: 
value identification). Notably, domain-specificity may include the possibility that the perceived 
morality of values differ between domains. Thus, in business compared to medicine, it is likely that 
other values are deemed important and shared values might cluster differently. This relates to the 
work of Bebeau and Thoma [30] who used the term “intermediate ethical constructs” to refer to 
profession-specific concepts within a given domain (e.g. in medicine: professional autonomy, 
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informed consent, privacy). Second, we obtained representative statements which were used as 
stimulus material instead of naming the values explicitly (step 2: value representation). Third, we 
developed and validated morally ambiguous vignettes characteristic of the clinical context (step 3: 
vignette construction and selection). These three steps are described below in Sections 2.1 to 2.3. In 
paragraph 3, we describe the validation of the instrument by means of a group comparison.  
The functioning of the instrument is summarized as follows (see infographic below): Using a vignette-
based approach, the instrument has been designed to present people with morally ambiguous 
situational descriptions and to investigate 1) which values they are more or less likely to identify and 
2) which values they consider important within the presented scenario. After vignette presentation, 
respondents were provided with a list of value-related statements (items, see step 2: value 
representation) among which they could choose. The extent to which respondents to several 
vignettes choose more moral-related values and rank them as more important relative to other 
categories of values is indicative for value sensitivity.  
All studies in this research were conducted in accordance with the ethical review processes of the 
University of Zurich and with the “Ethical Guidelines for Psychologists of the Swiss Society for 
Psychology” (http://www.ssp-sgp.ch/06_pdf/ersgp2003.pdf) and were analyzed using the software 
package SPSS Version 23. 
2.1. Step 1: value identification: 
A general challenge when assessing moral sensitivity is the identification of relevant values for the 
domain under consideration. There is also the challenge of investigating to what extent these values 
are perceived as moral- or non-moral in order to develop balanced vignettes that reflect the moral 
ambiguity of a particular situation (see step 3). Therefore, the first step of the construction phase 
involves the investigation of the “moral foundation” relevant for the medical context. 
2.1.1. Participants and Procedures 
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In order to examine which values are perceived as being examples of moral or other categories of 
values, a sample of medical students and professionals (n = 317; 54.3% females, mean age: 26.6) was 
asked to evaluate a number of values along four moral-related dimensions (for more details see [4]).  
2.1.2. Results: value identification 
The main outcome involved an empirically informed classification of distinct value-clusters along the 
moral vs. strategic (non-moral) continuum. Based on that, we were able to classify 11 values in three 
clusters: A first cluster (the “general morality-related cluster”) was composed of the values of 
responsibility, honesty, loyalty and respect. These values obtained higher ratings on all moral-related 
dimensions, suggesting that they were perceived as examples of moral values. A second cluster 
(“strategy-related cluster”) included the values performance, cost-efficiency and reputation. These 
values received consistently low ratings on all dimensions, suggesting that they were perceived as 
unrelated to moral aspects. Interestingly, we found that all values associated with the principles of 
biomedical ethics [31] – non-maleficence, justice, beneficence (in our context: care, for an 
explanation see [4]) and autonomy – formed a separate, third cluster (“principle-related cluster”). 
Based on the ratings, those values were between the other two clusters, yet closer to the moral than 
to the strategy-related value-cluster. Due to their importance in training medical personnel in 
biomedical ethics, this group was included in the instrument development as well. (For an in-depth 
description of the rationale for selecting values and their categorization into three groups, see [4]). 
Notably, some of the values (care, non-maleficence, loyalty, justice) relate to Haidt’s moral 
foundations [32], although not all of them received ratings such that they have been classified in the 
general morality-related cluster. 
2.2. Step 2: value representation: 
Since our assessment of individuals’ sensitivity to particular categories of values is based on the kind 
of value-related items that people consider relevant for the dilemma contained in the vignette, 
another challenge was to minimize the flaw of provoking socially desirable answers. Such a risk may 
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be likely when values (such as honesty, fairness, and the like) are explicitly named in an item. A 
central issue was therefore to avoid naming the value in the wording of the items, such that the 
presentation of stimulus material to subjects did not guide participants to attend to ethical (or 
related) issues. The method used here was designed to minimize this flaw. Furthermore, providing 
only a single value term involves the risk that the meaning of the term is under-determined for the 
participant. In step 2 of the construction phase, we therefore wanted to obtain adequate 
descriptions of such values, preferably by using short statements for each value describing typical 
behavioral manifestations of the corresponding value. The statements had to fulfill the criteria (1) of 
inherent and related normativity (i.e. they had to be similar to the values they describe), (2) they 
should incorporate the perspectives of different stakeholders (patients, doctors; hospitals and care-
centers), (3) they should incorporate different behavioral actions which match the values, and (4) 
finally they should be synonymous, as opposed to explicitly naming the value at stake. In order to 
present material for quality-assessment, we developed four statements for each value. 
2.2.1. Participants and Procedures 
The statements were presented in randomized order. Participants (same sample as in step 1, n = 317) 
quality-checked each statement using a bipolar 6-point Likert scale ranging from 1 (not 
representative at all) to 6 (very representative). In order to effectively avoid socially desirable answer 
tendencies, we included one distractor-statement in every set of statements. For example, one 
distractor-statement describing “performance” was included in a set of four statements describing 
“autonomy”. Accordingly, participants were presented with five statements per value. As distractors, 
we used preliminary developed but superfluous value statements.  
2.2.2. Results: value representation 
In order to obtain representative statements for each value, we calculated the mean of each 
statement based on the Likert scale evaluation of participants (due to the vast number of 
statements, the whole list of statements is presented in Table 1a/1b in Supplementary Materials 
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only). Statements resembled the following structure: For care we used “A physician or a caregiver 
should provide assistance to patients who cannot help themselves”. A high mean value indicated 
high representativeness. Statements were selected only if their mean value was above 4.5. Six out of 
44 statements did not meet this criterion and were excluded for step 3 and 4. After 
representativeness-testing, we retrieved two to three statements for each value which could be 
integrated as stimulus material into our instrument. 
 
Most distractors achieved the lowest mean-values for each value-group (9 of 11; see Supplementary 
Materials Table 2: Distractor analysis). In one case including the value “responsibility” where the 
distractor achieved a higher mean value, the distractor was inappropriately chosen due to excessive 
semantic overlap (distractor for responsibility was “care”). We also conducted t-tests for verifying 
statistical significant differences between distractors and the mean-wise lowest statement for every 
value. Results demonstrated a statistically significant effect on 8 of the 11 comparisons (see 
Supplementary Materials Table 2: Distractor analysis). 
2.3. Step 3: vignette construction and selection: 
Step 3 consisted of constructing vignettes that describe conflict situations that are relevant for the 
medical context. Based on a literature research and interviews with medical experts in Switzerland, 
we developed 12 vignettes of approximately equal length, morally ambiguous content and the 
integration of multiple stakeholders. Prior to study inclusion for quality assessment, these vignettes 
were reviewed by external experts from medical ethics. 
2.3.1. Participants and Procedures 
After assessing demographic information (gender, age, field of study, number of completed 
semesters) and information about participants’ work experience in medicine (whether they have 
work experience, and what kind of experience), participants (n = 37; 78.4% females, mean age M = 
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25.9 years, 62% medical students, 16% from nursing school, 45.9% reported to have work 
experience) were instructed to put themselves in the role of a clinical expert in charge who is partly 
involved as a committee member of a clinical expert-group. They were told that currently, there 
were six cases (2 cohorts, 6 cases/vignettes per cohort) to be discussed during the next committee 
meeting. In this way, the participants were primed in a similar way as in the main study (see step 4, 
below). Then, the participants were asked to evaluate the vignettes according to the following 
quality criteria: (1) comprehensibility, (2) required level of expert-knowledge, (3) relation to reality, 
(4) extent of achievement-oriented, reputation-related or economic-related content and (5) extent of 
moral-related or social-oriented content by the use of a bipolar 5-point-Likert scale. (4) and (5) were 
assessed as quality criteria for moral ambiguity (i.e. balanced involvement of moral and strategic 
aspects in the vignette, [6]). Moral ambiguity is a vital prerequisite of vignettes to prevent biased 
responses.  The vignettes were all between 137 and 202 words long, developed and preselected by 
two writers and one external reviewer and written based on the results of steps 1 and 2. 
2.3.2. Results: vignette construction and selection 
We calculated the means of the 5-point-Likert scale evaluations regarding quality and moral 
ambiguity of the vignettes (the results of the descriptive analysis are given in Table 1). Vignettes were 
selected for further review if (1) comprehensibility was achieved (i.e. mean values ≤ 2.5), if (2) the 
requirement of expert-knowledge was moderate (i.e. mean values between 1.5 and 3.5), if (3) 
relation to reality was high (i.e. mean values < 2.5) and if (4) the vignettes incorporated both 
strategic as well as moral aspects but not to a very obvious but rather ambiguous extent (i.e. mean 
values < 4.5).  
A pivotal criterion was the balance between strategic and moral elements in each vignette (i.e. moral 
ambiguity). To test moral ambiguity and based on the average rating (MMoral, MStrategic), we conducted 
single t-Tests to test for dissimilarity. If means differed significantly, the vignette was excluded. 
Moreover, a Shapiro-Wilk test was conducted and yielded a significant result highlighting non-
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normality of the data due to the low sample sizes of the preselected vignettes. Therefore, a non-
parametric Wilcoxon signed-rank test was executed. All results of the single t-Tests were confirmed. 
Five vignettes (number 1, 3, 5, 6 and 7, see Table 1) fulfilled the necessary criteria and were included 
as stimulus material in our instrument. The five chosen vignettes involved work-place problems 
within a clinic (V1 & V3), conflict within a nursing home (V5) and two vignettes including research 
issues in neurology (V6 & V7). The results are described for the selected vignettes only (the selected 
vignettes are displayed in Supplementary Materials). 
TABLE 1 ABOUT HERE PLEASE 
As mentioned earlier, the previously described three steps encompassed the first phase in the 
development of our value-sensitivity measure. In what follows, we advance this work by providing a 
first validity test of this measure.  
 
3. Testing the validity of the value-sensitivity measure 
3.1 Hypothesis generation for expected group differences 
In our final step, we aimed at demonstrating the validity of the measure by making use of a group 
comparison. 
Hypothesis generation for the group comparison included some theoretical concepts: Regarding the 
reasons for inter-individual differences in perceiving moral issues in ambiguous situations, 
contemporary research predominately refers to social cognition theory (e.g., [33]) positing that 
individuals hold cognitive schemas (i.e. cognitive representations) depending on socialization. These 
models also imply that priming (activating a concept by providing external stimuli such as a word, a 
picture or an object; [34]) of a representation would foster its future activation by increasing its 
accessibility. Consistent with this, a substantial body of research clearly demonstrated that 
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normality of the data due to the low sample sizes of the preselected vignettes. Therefore, a non-
parametric Wilcoxon signed-rank test was executed. All results of the single t-Tests were confirmed. 
Five vignettes (number 1, 3, 5, 6 and 7, see Table 1) fulfilled the necessary criteria and were included 
as stimulus material in our instrument. The five chosen vignettes involved work-place problems 
within a clinic (V1 & V3), conflict within a nursing home (V5) and two vignettes including research 
issues in neurology (V6 & V7). The results are described for the selected vignettes only (the selected 
vignettes are displayed in Supplementary Materials). 
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(consciously or subconsciously) primed information guide attention, encoding and the categorization 
of the situation by making concepts temporarily more accessible (for an overview see [35 – 37]). 
Some schemas are chronically accessible in that they become automatically and habitually activated 
[36, 38]. Examples of chronic accessible representations are strong attitudes and deeply held values, 
beliefs or traits that are central to one’s identity or culture. In line with this, moral standards or 
values are acknowledged as moral schemas that vary in their accessibility [2, 11, 39]. Hence, 
individuals whose moral schemas are more accessible or even chronically accessible are expected to 
be more likely to direct attention more or less automatically and swiftly to moral issues. For example, 
Jordan [11] has argued that business managers are less likely to detect moral-related dimensions 
than academics, because business managers have business rather than moral schemas guiding their 
attention and information processing more dominantly. Overall, researchers in moral psychology 
consistently conceive the activation and accessibility of moral schemas as crucial conditions of 
demonstrating moral sensitivity [9, 23, 40 – 42]. 
Based on the above delineation of the underlying theoretical concepts, our working hypothesis is 
that our instrument demonstrates ample discriminatory power between two groups of participants: 
care-professionals and professionals from hospital management. This hypothesis is built according to 
social cognition theory proposing that socialization in various working contexts shapes people’s 
cognitive schema (e.g. [11]). It is well-known from previous research that schemas strongly influence 
information processing, making people more likely to attend to, encode and recall information which 
match with the existing schemas (e.g., [36, 43]). In line with this, and because of being embedded in 
a working environment that expects from its members an orientation towards the principles of 
biomedical ethics which are also part of nurses’ training programs in ethics, we hypothesized nurses 
to be more likely to demonstrate greater sensitivity for principle-related issues. Of note is the fact 
that although the principles form a separate cluster, this cluster has a much stronger affinity to the 
moral as opposed to the strategic cluster. In contrast, we hypothesized that members of hospital 
management demonstrate greater sensitivity for strategy-related issues. This is because they are 
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more often faced with strategy- and business-related problems in their working life. We were 
indifferent about the expectations related to the other, more general moral values. Since both 
groups may be faced with problems tapping into issues of e.g. honesty or fairness, both may have 
evolved some sensitivity for such issues. Of main interest is, whether our measure is capable of 
revealing the expected group differences, supporting the validity of our instrument.  
In conducting the group comparison, we recruited professionals from nursing on the one hand and 
from hospital management, administration and human resources on the other. As outlined, we 
aimed at demonstrating the instrument’s capability to differentiate between these two cohorts 
(professionals from management: increased sensitivity for strategy-related issues, nursing 
professionals: increased sensitivity for values relevant in clinical practice, i.e. principle-related 
values).  
3.2. Participants and Procedures 
In this study, 57 participants from various clinics located in the German part of Switzerland filled out 
the questionnaire. After rigorous examination of the data, 48 datasets fulfilled our quality criteria: 
participants were required to self-categorize them to one of the two groups and were required to 
have patient contact either on a daily basis (nursing professionals) or fewer than once a month 
(hospital management). 37 (30 females) were nursing professionals whereas 11 (7 males) worked in 
the field of hospital management, human resources or administration. There was a statistically 
significant gender misbalance and mean age difference (mean age: nursing: 39 years, management: 
48 years). This gender misbalance, however, is not surprising given that nursing and management are 
among the most sharply sex-segregated of occupations. The two groups did not significantly differ in 
the time needed for completing the questionnaire (see Table 2).  
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In the questionnaire, we first assessed demographic information (gender, age, field of work) and 
information about participant’s work experience in medicine (duration and frequency of contact to 
patients). Participants then were briefly instructed how to fill out the questionnaire. Subsequently, 
they were asked to put themselves into the role of a clinical expert in charge who is partly involved as 
a committee member of a clinical expert-group. They were told that currently, there were five cases 
(i.e. vignettes) to be discussed during the upcoming committee meeting during which they were 
expected to bring in spontaneously the considerations they deem important for the case evaluation. 
We explicitly noted that decisions about which concrete actions to take would be elaborated at a 
later time. 
 
Next, the five vignettes were randomly presented on the computer screen: after having read one 
vignette which disappeared upon clicking the “next”-button, participants were provided with a list of 
11 value-related statements (see Section 2.2. Step 2: value representation). Thus, participants were 
provided with all 11 values from the three clusters (i.e. in form of 11 statements) for the value 
selection step following vignette inspection. For most values, there were multiple statements which 
satisfied quality criteria (see step 2: value representation). Hence, we presented participants with the 
most suitable statements to content. They were asked to select those statements which they 
consider to be associated with the situation. They could select as many statements as they liked. This 
task was designed to examine which values participants recognize in each vignette. The vignette 
reappeared together with all previously chosen statements, and participants were asked to distribute 
points (i.e. allocate importance) to these statements. In total, 10 points had to be distributed to the 
statements, including the possibility that some statements could receive 0 points. This task was 
designed to assess the perceived importance of the selected value (see infographic for instrument 
process illustration purposes).  
INFOGRAPHIC ABOUT HERE PLEASE 
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This procedure negates the possibility of “wrong” answers. Hence, we deliberately abstained from 
taking a normative stance of what is right and wrong. Morally sensitive individuals are generally more 
likely to associate moral values within ambiguous situations because they are expected to have more 
easily accessible moral schemas. As a result, they are also expected to be more likely to direct 
attention more or less automatically and swiftly to moral issues (see Section 3.1). This aligns with 
previous conceptualizations (e.g. see [42]) after which and as opposed to other ethics constructs (e.g. 
formalism) which hold a clear position on what is right and wrong, moral sensitivity has additional 
explanatory value in simply acknowledging that individuals are considering concepts associated with 
morality. Additionally, categorizing a perceived value as wrong in itself is a moral claim which would 
need justification in such a way that it would introduce the challenge of defining a deciding authority 
(i.e. who decides about the wrongness of a given value). In our view, the process of perception of 
values is a hermeneutical rather than absolutist process. Hence it would take a fairly strong and in 
fact paternalistic stance condemning certain perceptions as being plain wrong. Typically, the problem 
is perceiving not enough - and hence missing the important issues in a given situation rather than 
perceiving “wrong” issues. 
Overall, we posit that flexible and pluralistic value-perception is superior to rigid and singular value 
perception even if this complicates moral decision-making and behavior at a later stage. Specifically, 
we hypothesize that multiple value perception reduces the risk of moral blindness [44] and hence 
unethical behavior. Multiplicity in value recognition, however, should not be understood as a form of 
relativism. Our notion refers to other claims [44] that good decisions depend on perspective-taking 
and imagination and thus the ability of an individual to appraise multiple aspects during decision 
making. It also supports tolerance rather than fundamentalism. The development of value sensitivity 
would face dramatic barriers if assessed in a context of strict and rigid right/wrong-definitions. 
Accordingly, it will only thrive in a permissive and open environment. 
3.3. Calculating Value Sensitivity 
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Participant’s value sensitivity scores were calculated by combining both a) the number of values 
recognized in each vignette and b) the importance attributed to these recognized values 
operationalized as the number of points assigned to those selected values. In this respect, value 
sensitivity is congruent with previous definitions of moral sensitivity as containing both the 
recognition and the ascription of importance of moral-related issues (see [6, 11, 42]). In order to 
calculate participant’s value sensitivity for the three clusters, the mean number of recognized values 
for each cluster separately of the aggregated data of all five vignettes was calculated. Next, we 
calculated the total number of allocated points for each cluster and divided it by the total number of 
possible points. The mean of recognized values for each cluster was then multiplied with the 
normalized number of points allocated to the corresponding value-cluster.1 Hence, we summed all 
recognized principle-related values across all vignettes and calculated the mean which was multiplied 
by the normalized value of points allocated to principle-related values for all vignettes in order to 
calculate the sensitivity for principle-related values. We calculated the sensitivity for the other two 
value clusters in the same way. Consequently, potential differences in perception between vignettes 
carried less weight. 
3.3.1. Generalized definition of value-sensitivity computation: 
Formally, the computation of value sensitivity is as follows: Let 𝑉𝑉𝑉𝑉𝑀𝑀, 𝑉𝑉𝑉𝑉𝑃𝑃, and 𝑉𝑉𝑉𝑉𝑆𝑆 denote the value 
sensitivity for moral-related values (𝑀𝑀), principle-related values (𝑃𝑃) or strategy-related values (𝑉𝑉). 
Furtermore, let 𝑁𝑁𝑉𝑉 be the number of vignettes used; 𝐾𝐾 be the number of points that can be 
distributed to all chosen values per vignette; and 𝑁𝑁𝑀𝑀, 𝑁𝑁𝑃𝑃 and 𝑁𝑁𝑆𝑆 be the number of values per value 
group (𝑀𝑀, 𝑃𝑃 or 𝑉𝑉). Finally, let 𝑛𝑛𝑖𝑖
𝑀𝑀, 𝑛𝑛𝑖𝑖
𝑃𝑃 and 𝑛𝑛𝑖𝑖
𝑆𝑆 be the number of values chosen per vignette 𝑖𝑖 and 
group; and 𝑘𝑘𝑖𝑖
𝑀𝑀, 𝑘𝑘𝑖𝑖
𝑀𝑀, and 𝑘𝑘𝑖𝑖
𝑀𝑀 be the number of points attributed to moral-related, principle-related 
                                                            
1 To exemplify calculation: If a person has (over all 5 vignettes) in the mean recognized 2 out of 4 values of the 
moral cluster, the “recognition rate” would be 0.5. And if this person has (again over all 5 vignettes) attributed 
in total 10 out of 50 possible points (i.e., 10 possible points times 5 vignettes) to those values, the normalized 
number of points would be 0.2. Hence, the result related to the moral values for this person would be 0.5*0.2 = 
0.1.  
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and strategy-related values per vignette 𝑖𝑖. Then the generalized definition of value sensitivity is given 
as: 
𝑉𝑉𝑉𝑉𝑀𝑀,𝑃𝑃,𝑆𝑆 =  
1
𝑁𝑁𝑉𝑉 𝑁𝑁𝑀𝑀,𝑃𝑃,𝑆𝑆
∑ 𝑛𝑛𝑖𝑖
𝑀𝑀,𝑃𝑃,𝑆𝑆
𝑁𝑁𝑉𝑉
𝑖𝑖=1
 ×  
1
𝑁𝑁𝑉𝑉 𝐾𝐾
 ∑ 𝑘𝑘𝑖𝑖
𝑀𝑀,𝑃𝑃,𝑆𝑆
𝑁𝑁𝑉𝑉
𝑖𝑖=1
 
In our case, 𝑁𝑁𝑉𝑉 = 5, 𝐾𝐾 = 10 and (for example) 𝑁𝑁𝑀𝑀 = 4. Thus, the sensitivity for moral values is 
calculated as: 
𝑉𝑉𝑉𝑉𝑀𝑀 =  
1
20
∑ 𝑛𝑛𝑖𝑖
𝑀𝑀
5
𝑖𝑖=1
 ×  
1
50
 ∑ 𝑘𝑘𝑖𝑖
𝑀𝑀
5
𝑖𝑖=1
 
 
The calculation of 𝑉𝑉𝑉𝑉𝑃𝑃 and 𝑉𝑉𝑉𝑉𝑆𝑆 is analogous (𝑁𝑁𝑃𝑃 = 4, 𝑁𝑁𝑆𝑆 = 3). 
 
3.4. Results of validation study 
A Shapiro-Wilk-test analyzing normality was performed and highlighted non-normality for sensibility 
for strategy-related values. We therefore conducted a Mann-Whitney U Test as a non-parametric 
test. Statistical significance was accepted at a p ≤ 0.05 level. 
 
We compared value sensitivity of nurses and hospital managers for the three value groups (moral-
related values, principle-related values, strategy-related values) (see Fig 1). In terms of sensitivity for 
principle-related values (see Fig 1a), the group comparison yielded a significant difference with 
nurses (M = 0.39, SD = 0.12) revealing higher scores than management professionals (M = 0.32, SD = 
0.09) (U (125.00) = -1.93, p = 0.05). In terms of sensitivity for strategy-related values (see Fig 1b), we 
found another significant difference between the groups, with professionals from hospital 
management revealing higher scores (M = 0.11, SD = 0.08) than nurses (M = 0.05, SD = 0.07) (U 
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(110.00) = -2.30, p = 0.02). In terms of sensitivity for moral-related values, we found no significant 
differences between the groups (p > 0.35) (Fig 1c). Consequently, our instrument was able to 
discriminate between nursing- and management professionals as our hypothesis predicted. 
 
Next, we tested for potential gender differences. A Mann-Whitney U test yielded the following 
results: males (M = 0.11, SD = 0.09) demonstrated a significantly greater sensitivity for strategy-
related values compared to females (M = 0.04, SD = 0.06) (U (122.50) = -2.63, p = 0.01). On the other 
hand, females (M = 0.39, SD = 0.12) demonstrated a greater sensitivity for principle-related values 
compared to males (M = 0.33, SD = 0.10) (U (152.50) = -1.94, p = 0.05). There was no significant 
gender difference regarding sensitivity for moral-related values (p > 0.65). 
Finally, the analysis of the frequency of each value selected by participants across vignettes 
demonstrated only minimal differences (6 comparisons of 110 involving 3 values (cost-efficiency, 
autonomy, loyalty – one of every cluster) yielded a significant result only). This may corroborate our 
negation of “wrong” value attribution (see Supplementary Materials for a table indicating the choices 
and what was selected by each group (Table 3)). 
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4. Discussion & Conclusion 
4.1. Group Comparison & Limitations 
In the context of this research project, we were successful in executing a first trial of validity testing 
of our developed tool for the measure of context specific value-sensitivity. Significant differences 
emerged when comparing professionals from nursing compared with experts from hospital 
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management and -administration. More specifically, nursing professionals demonstrated greater 
sensitivity for principle-related values, while professionals from hospital management and 
administration revealed greater sensitivity for strategy-related values. This confirms our hypothesis. 
Finally, groups did not significantly differ on other, more general moral-related values. As outlined 
previously, we think that both groups may be faced with problems tapping into issues such as 
honesty and fairness, which might explain the indifference of the two groups.  
This study incorporates the following limitations. First, we are well aware of the fact that group 
comparisons are only one step of validating instruments. Future studies are needed to further test 
the instrument. In line with this, we are currently running studies aiming at assessing concurrent as 
well as convergent validity by comparing our instrument with other congruent or non-congruent 
questionnaires. Furthermore, we are in the process of complementing the instrument with an 
implicit measure. Hence, more research is needed for the development of an instrument that is able 
to assess value sensitivity at an individual level. 
 
Second, due to the small sample size, hospital managers and administrators used in this study might 
not be representatives of their profession. Moreover, the generally low level of strategic sensitivity 
for both groups might have been extrinsically induced by application of an unbalanced stimulus 
material: both, the moral- and principle-related value clusters are composed of 4 values each, 
whereas the strategy-related value cluster only consisted of 3 values. Hence, the pure likelihood to 
choose a strategic value was smaller. 
 
Third, one has to take into account that, based on the small sample size of at least one group and 
because of a non-randomized study design, there might be intrinsic differences between the 
individuals of the two groups related to gender. Furthermore, we are unable to fully explore the 
effects of gender detached from the domain of occupation, since gender was endogenous to domain 
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of occupation. The influence of gender on morality is controversially discussed and appears also to 
depend on age, level of education, occupation and their interrelation [45]. Whilst studies 
investigating gender differences are largely controversial, in most cases when gender differences can 
be identified, women tend to show greater levels of moral awareness, particularly when studies 
focus more closely on care-based moral convictions [29, 46]. 
 
Finally, another important point is that the increased sensitivity for strategy-related values of 
managers and the decreased sensitivity for principle-related values should not be interpreted to 
suggest that managers are “less moral” compared to nurses. We emphasize that our 
conceptualization of value sensitivity favors the notion that an increased strategic sensitivity is not 
per se ethically less desirable. Rather, professionals of a specific occupation are expected to 
demonstrate a sensitivity that aligns directly with their occupation-related values. Such a sensitivity is 
important because a manager who is not aware of concepts including e.g. cost-effectiveness, will not 
succeed in his daily work. Furthermore, an insensitivity in this respect may very well induce negative 
consequences for employees in the institution and therefore does have ethical implications. Apart 
from that, managers did not differ in their sensitivity related to other, more general moral values. It 
would therefore be desirable to have design interventions at one’s disposal for improving 
professionals’ sensitivity without compromising their occupation-related thinking. In the end, such 
sensitivities should not substitute but supplement each other. 
 
4.2. Ethical questions related to a potential deployment of an instrument of this sort 
4.2.1. Potential benefits of improving MS 
Patients and their family members are increasingly demanding empowerment and the desire to be 
involved in clinical decisions. Medical decision-making authority is being questioned, self-
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determination of patients is gaining importance and the patient is increasingly perceived as a partner 
in a shared decision making process [47]. Consequently, appropriate clinical and moral decision-
making is not performed in a paternalistic way, but increasingly demands certain kinds of sensitivities 
in pluralistic societies. As outlined previously, in such situations, healthcare providers need to 
recognize and appraise morally relevant issues immediately which requires both appropriate 
cognitive and balanced emotional processes (see Section 1). Moral sensitivity ideally would render 
agents sensitive to peculiar issues and support them in classifying their immediate perceptions. 
Supporting health care providers in coping with dilemmatic situations and vulnerable patients 
represents a primary relevant ethical duty because caring holistically for patients not only represents 
a duty-based quality but also benefits patients, healthcare providers and the clinic as a whole. Moral 
sensitivity may support the quality of caring by helping people to be better attuned to patients’ 
needs and demands. In general, agents with greater moral competences may reduce costs by acting 
swifter and in a more confident way. As such, being sensitive in the desired way and within a 
“healthy” range (see next paragraph) is certainly likely to be a desirable quality as it could improve 
clinical support and may diminish psychological stress (e.g. feelings of uncertainty) of healthcare 
professionals. Simultaneously, patients could benefit from more individualized and sensitive care. 
Moreover, incorporating values, opinions and fears of different stakeholders such as representative 
family members might prevent long-term psychosocial problems. 
In addition, organizational structures may inhibit abilities of health care providers to be sensitive to 
the moral content of everyday practice and may also evoke stress-related disorders of which many 
health care professionals suffer (be it by institutional constraints, or when professionals clash with 
legal regulations when following moral decisions) [48]. Furthermore, lack of time, skills and 
interpersonal support have been directly associated with decreased moral sensitivity [49]. If 
professionals are more clear and confident about which strategy to pursue due to greater moral 
sensitivity (e.g. following sensitivity-training), they are more likely to overcome constraints more 
easily.  
24 
 
determination of patients is gaining importance and the patient is increasingly perceived as a partner 
in a shared decision making process [47]. Consequently, appropriate clinical and moral decision-
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4.2.2. Risks of improving moral sensitivity 
While the ability of being morally sensitive to moral issues is likely to have a number of positive 
consequences, moral sensitivity might also have negative consequences. An individual sensitive to 
moral issues might be unable to act and might suffer from the psychological burden a given situation 
holds. Being morally sensitive is not per se a desirable quality. It can be maladaptive for the individual 
and society. Hence, it is not clear whether enhancing moral sensitivity should be considered desirable 
in all circumstances. Healthcare providers who demonstrate a marked sensitivity might be unable to 
comply with the economic and structural regulations that predominate within a clinic. They also 
might suffer from emotional overload or increased moral distress (i.e. the felt incompatibility to 
reconcile own moral decisions and stiff legal regulations). Furthermore, healthcare providers with 
high moral sensitivity may be subjected to more dilemmatic situations, which may hinder 
appropriate clinical acting. Alternatively, individuals who exercise marked sensitivity might be 
evaluated as behaving inappropriately due to exaggerated levels of empathy associated with being 
unable to discern privacy signals. The latter phenomenon has already been described as exaggerated 
and inappropriate approach-behaviors (i.e. hypersocial drive) in the case of disorders of 
hypersociability like Williams Syndrome [50]. It also might be problematic if nurses are completely 
honest with patients in all contexts. This is consistent with Weaver’s [10] recent criticism of bias in 
the literature in uncritically accepting moral sensitivity as having only positive consequences, while 
neglecting potential negative implications. With regard to care services, Weaver also suggested that 
negative states, such as emotional overload, exploitation or moral distress could result from a higher 
level of moral sensitivity. Similarly, Morioka [51] posited that a society with a plenty of morally 
sensitive people might be considered a good society, but people living in such a society might not 
necessarily be happy, because they worry about every immoral and unfair deed. While it is per se 
ethical to be morally sensitive, it might very well be strategically unfavourable and ultimately bad for 
the individual if one is morally sensitive in a culture which negates moral sensitivity. There is need for 
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a concise evaluation of whether and under which circumstances increased moral sensitivity might be 
beneficial at an individual compared to a societal level. Because individual values are formed through 
socialization in a context of normative beliefs, a discussion involving a distinction between the 
individual and society may also need a discussion on the relation of individual values as a reflection 
of social categories. 
 
4.2.3. Potentials and limits of instruments 
Potential fields of application include the deployment of such an instrument in the context of primary 
and continued education besides the staff-selection domain. After us, the first field of application 
appears to be more suitable whereas the latter involves a greater degree of ethical risk. As outlined 
previously, knowledge about one’s strengths and weaknesses combined with the possibility for their 
specific modulation would clearly be advantageous. Using such an instrument for personnel 
procurement purposes however, is more critical. In this context, it is important to emphasize that 
results from such instruments are generally vulnerable to error. Hence, the methodological step of 
validation is important in order to minimize the risk of misjudgment. In addition, it is difficult to make 
long-term prognoses in the context of psychological assessments mainly because a multitude of 
factors might exert modulatory influences. Instruments are typically being used in combination with 
other assessment strategies. Finally, it should be openly discussed to whom the generated data of 
the assessment belong, how and whether the data should be stored and anonymized in order to 
prevent misuse and whether such data should be made available for other organizations and 
companies (e.g. as quality assessments for teachers or medical students before entering medical 
school). To answer those questions, it will be vital to perform an in-depth analysis specifically 
addressing under which criteria and in which context privacy might overrule and prevent 
assessment-performers from disclosing data. If used as an assessment instrument for entering 
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specific occupational trainings, pressure for interested individuals might increase. Other 
consequences of such assessments are privacy concerns and the danger of stigmatizing individuals. 
 
5. Outlook & Conclusions 
Living a moral life is not simply a matter of following a set of learned moral rules and of learning how 
to apply these rules to specific situations. By emphasizing the psychological basis relevant for moral 
behavior, one (1) acknowledges the increased scientific understanding of the foundations of moral 
behavior and (2) thereby has the possibility to carve out and provide means for their specific 
modulation. In this research project, we attempted to incorporate current knowledge from social and 
moral psychology in order to develop an instrument that allows for a status-quo assessment of ones’ 
value sensitivity in the clinical care context that anticipates an additive possibility of specifically 
training the underlying competency. This idea aligns with virtue ethics by paying attention to our 
habits of character and developing these in order to act in a moral way. 
We believe that the proposed instrument provides the following advantages: (1) previous research 
suggests that value-sensitivity is domain specific (see [4]). Identifying specific subcomponents of 
value-sensitivity for different domains (e.g. values that are especially relevant for a specific domain 
solely) or semantically varying values (e.g. transparency in the economic field, honesty in medicine) 
becomes a crucial task for developing instruments aimed at assessing and increasing value-
sensitivity. (2) The instrument is thought to represent a flexibly adaptable basic module if understood 
as a loosely tool of interchangeable building blocks. This involves relevant values for the specific 
context that can be identified and enacted. The instrument can then be complemented by 
incorporating more – or simplified by incorporating less – values by adhering to our procedure. (3) 
The instrument provides a fully automated data acquisition process and could easily be extended by 
an automated analysis algorithm providing users with an instant status-quo assessment of ones’ 
moral profile. Therefore, the time consuming steps of post-coding open answers are omitted. Finally, 
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(4) we intend to complement the instrument by an implicit measure in order to further 
accommodate insights gained from psychological research. 
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Figures legends 
Figure 1: Group comparisons for moral‐related, principle‐related and strategy‐related value 
sensitivity. 
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36 
 
 
 
Table 2: demographic differences of groups 
  Nursing Management Significance level 
Number of 
participants 
37 11 
  
Mean age [years] 39 48 MW: p=0.01 
Years of employment 17 15 n.s. 
Gender‐ratio f: 30, m: 7 f: 4, m: 7 MW: p=0.005 
Time needed for filling 
out questionnaire 
[min] 
39 44 
n.s. 
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01
02
03
04
Vignette
Statements:
1
2
3
4
5
6
7
8
9
10
11
Allocate points:
2
7
9
4
1
5
Vignette presentation
Task: read situational
description
Statement presentation
Task: select those statement
which  you consider to be
associated with the previously
read situation
Allocation of importance
Task: distribute points to the
previously selected statements
After 5 vignettes:
Calculation of value
sensitivity
Calculation of Value Sensitivity:
Procedure for assessing
value sensitivity
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Table 2: distractor analysis  
Paired sample t-test of mean value statements compared to distractors. 
__________________________________________________________________________________ 
 Value group  M_stat   M_dist    p-value 
 care   5.00   4.04    p = 0.000 
 reputation  4.09   4.02    p = 0.606 
 non-maleficence 5.03   2.92    p = 0.000 
 honesty  5.22   4.08    p = 0.000 
 performance*  4.63   4.38    p = 0.038 
 cost-effectiveness 3.82   3.60    p = 0.172 
 autonomy  4.94   3.85    p = 0.000 
 respect   5.44   2.99    p = 0.000 
 loyalty   4.71   4.05    p = 0.000 
 justice   4.98   2.89    p = 0.000 
 responsibility†  x   x    x 
__________________________________________________________________________________ 
Remark: lowest mean values of value-statements (M_stat) were compared to the mean values of the 
distractors (M_dist) localized in the same value group. * indicates that the 2nd lowest M_stat was 
taken because the lowest value statement was below M_dist (see main text for explanations). For †, 
no comparison was performed because M_dist yielded the second highest value. 
 
117
Clinical & ethical aspects of modulating behaviour and affect through DBS Ineichen 2016
Ta
bl
e 
3:
 C
ho
ic
es
 a
nd
 se
le
ct
io
ns
 b
y 
gr
ou
p 
(n
ur
se
s v
s p
ro
fe
ss
io
na
ls 
fr
om
 m
an
ag
em
en
t a
nd
 a
dm
in
ist
ra
tio
n)
 fo
r e
ve
ry
 v
ig
ne
tt
e 
(V
1-
V5
) a
nd
 a
ll 
11
 v
al
ue
s (
fir
st
 
co
lu
m
n)
 w
ith
 re
sp
ec
t t
o 
th
e 
ag
gr
eg
at
ed
 n
um
be
r o
f v
al
ue
-s
el
ec
tio
ns
 (v
al
ue
s)
 a
nd
 th
e 
at
tr
ib
ut
ed
 n
um
be
r o
f p
oi
nt
s (
po
in
ts
) t
o 
th
es
e 
sa
m
e 
va
lu
es
. 
 
V1
 
V2
 
V3
 
V4
 
V5
 
 
N
ur
se
s 
M
an
ag
er
s 
N
ur
se
s 
M
an
ag
er
s 
N
ur
se
s 
M
an
ag
er
s 
N
ur
se
s 
M
an
ag
er
s 
N
ur
se
s 
M
an
ag
er
s 
 
va
lu
es
 
po
in
ts
 
va
lu
es
 
po
in
ts
 
va
lu
es
 
po
in
ts
 
va
lu
es
 
po
in
ts
 
va
lu
es
 
po
in
ts
 
va
lu
es
 
po
in
ts
 
va
lu
es
 
po
in
ts
 
va
lu
es
 
po
in
ts
 
va
lu
es
 
po
in
ts
 
va
lu
es
 
po
in
ts
 
CA
R 
28
 
25
 
8 
4 
28
 
38
 
8 
6 
37
 
91
 
10
 
12
 
34
 
40
 
9 
9 
33
 
66
 
9 
5 
PE
R 
16
 
22
 
6 
4 
10
 
5 
4 
6 
12
 
4 
6 
1 
4 
4 
4 
0 
10
 
1 
3 
1 
CE
F 
14
 
10
 
7 
9 
16
 
17
 
6 
8 
23
 
18
 
10
 
11
 
27
 
33
 
9 
13
 
29
 
33
 
10
 
15
 
RE
P 
20
 
7 
6 
8 
15
 
2 
7 
10
 
16
 
3 
7 
2 
17
 
9 
5 
4 
12
 
1 
7 
5 
AU
T 
15
 
11
 
3 
2 
30
 
61
 
10
 
13
 
35
 
90
 
10
 
19
 
33
 
58
 
8 
15
 
31
 
42
 
9 
16
 
RE
S 
33
 
69
 
10
 
30
 
26
 
43
 
7 
9 
34
 
72
 
11
 
28
 
34
 
65
 
10
 
24
 
32
 
55
 
11
 
18
 
N
M
A 
27
 
47
 
8 
15
 
32
 
64
 
10
 
16
 
22
 
20
 
8 
10
 
35
 
60
 
9 
18
 
32
 
64
 
11
 
21
 
LO
Y 
28
 
20
 
6 
8 
13
 
6 
2 
4 
9 
2 
8 
3 
12
 
1 
7 
2 
13
 
5 
7 
2 
HO
N
 
36
 
99
 
11
 
19
 
33
 
79
 
11
 
18
 
26
 
37
 
10
 
10
 
36
 
89
 
11
 
14
 
37
 
70
 
11
 
21
 
JU
S 
29
 
40
 
8 
6 
28
 
33
 
9 
15
 
22
 
24
 
8 
7 
24
 
7 
8 
11
 
31
 
27
 
9 
4 
RP
S 
19
 
20
 
5 
5 
20
 
22
 
6 
5 
23
 
9 
9 
5 
14
 
4 
5 
0 
17
 
6 
7 
2 
   
118
Clinical & ethical aspects of modulating behaviour and affect through DBS  Ineichen 2016
 
Selected vignettes (in German): 
 
Vignette 1: 
Dr. P, ein erfahrener Onkologe in der Klinik, hat in der Vergangenheit bereits mehrfach Angebote 
anderer Kliniken erhalten, diese aber aufgrund der Verwurzelung an die hiesige Klinik und seiner 
Wohnsituation wegen, immer abgelehnt. Doch seit letzter Zeit gibt es zwischen der Klinikdirektion und 
ihm als Leiter des onkologischen Zentrums Unstimmigkeiten bezüglich studentischer 
Ausbildungsmodalitäten, patientenorientierten Informationsbestimmungen und dem Einrichten einer 
Palliativstation, der Dr. P. kritisch gegenüber steht. Seit dem frühzeitigen Ableben seiner Frau ist Dr. P. 
gegenüber den Patientinnen und Patienten noch stärker engagiert, seine Skepsis gegenüber 
Neuerungen ist aber ebenfalls gewachsen, was zu Konflikten mit anderen leitenden Ärztinnen und 
Ärzten führt. Derzeit laufen Diskussionen zu diesen Punkten zwischen Klinikdirektion und den anderen 
leitenden Ärzten. Unter anderem wird erwogen, ob man sich wegen der gestörten Harmonie und in 
Konsequenz des fehlenden einheitlichen Lösungsbestrebens besser von Dr. P. trennen sollte. Wie soll 
die Klinikleitung diese Situation beurteilen? 
 
Vignette 3: 
Frau J., eine Patientin mittleren Alters, muss sich infolge einer Fussgelenksverletzung einer Operation 
unterziehen. Obgleich eine Routineoperation, wird diese infolge Versicherungsmodalitäten von der 
leitenden Oberärztin der Chirurgie durchgeführt. Am Tag nach der Operation erfolgt das 
Austrittsgespräch, bei dem die Oberärztin und ein Krankenpfleger anwesend sind. Die Oberärztin 
erklärt der Patientin die Wichtigkeit einer Thromboseprophylaxe, für die das Medikament Heparin 
subkutan mittels einer dünnen Kanüle injiziert werden muss, ähnlich wie bei der Insulin-Selbstgabe. 
Vier Tage nach der Entlassung wird die Patientin notfallmässig mit Atem- und 
Herzrhythmusstörungen eingeliefert. Sofort wird klar, dass eine Lungenembolie vorliegt. Der 
Notfallarzt vermutet eine unzureichende Thromboseprophylaxe. Nachfragen bei der Patientin 
ergeben, dass diese nicht genau wusste, wie sie bei der Heparin-Injektion vorgehen sollte. Ein danach 
anschliessendes Gespräch zwischen dem Notarzt und der leitenden Oberärztin der Chirurgie ergab 
keine Klärung der Sachlage, da üblicherweise der Krankenpfleger die Prophylaxe erklärt, im konkreten 
Fall aber die Oberärztin dies offenbar tat. Die Klinikleitung muss den Fall nun begutachten und das 
Vorgehen der Mitarbeiter beurteilen. Auf welche Aspekte soll diese dabei achten? 
 
Vignette 5: 
Im Pflegeheim der Institution ist seit einigen Wochen ein neuer Bewohner eingetroffen, ein 
exzentrischer Künstler, 65 Jahre alt, der seine Atelierwohnung aufgrund zunehmender dementieller 
Episoden verlassen musste. Bald wird klar, dass ein gewisses Bedürfnis, seine Kunst auszuleben zu 
können, weiterhin besteht. Dies wiederspiegelt sich in einem ständigen Verlangen, künstlerisch tätig 
zu sein. Der Mann stellt die Pflegenden mit diesem Wunsch sowie seiner stark ausgeprägten 
Individualität zwar immer wieder vor gewisse Herausforderungen, wird ansonsten von den 
Pflegenden als ein auf sich bezogener, einzelgängerischen, relativ ruhigen Heimbewohner 
beschrieben, der ein eher zurückgezogenes Heimleben zu führen scheint. Seit kurzem ist der Mann 
nun kaum mehr von seiner Idee abzubringen, im Hobbyraum des Pflegeheims ein kleines Atelier 
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Selected vignettes (in German): 
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unterziehen. Obgleich eine Routineoperation, wird diese infolge Versicherungsmodalitäten von der 
leitenden Oberärztin der Chirurgie durchgeführt. Am Tag nach der Operation erfolgt das 
Austrittsgespräch, bei dem die Oberärztin und ein Krankenpfleger anwesend sind. Die Oberärztin 
erklärt der Patientin die Wichtigkeit einer Thromboseprophylaxe, für die das Medikament Heparin 
subkutan mittels einer dünnen Kanüle injiziert werden muss, ähnlich wie bei der Insulin-Selbstgabe. 
Vier Tage nach der Entlassung wird die Patientin notfallmässig mit Atem- und 
Herzrhythmusstörungen eingeliefert. Sofort wird klar, dass eine Lungenembolie vorliegt. Der 
Notfallarzt vermutet eine unzureichende Thromboseprophylaxe. Nachfragen bei der Patientin 
ergeben, dass diese nicht genau wusste, wie sie bei der Heparin-Injektion vorgehen sollte. Ein danach 
anschliessendes Gespräch zwischen dem Notarzt und der leitenden Oberärztin der Chirurgie ergab 
keine Klärung der Sachlage, da üblicherweise der Krankenpfleger die Prophylaxe erklärt, im konkreten 
Fall aber die Oberärztin dies offenbar tat. Die Klinikleitung muss den Fall nun begutachten und das 
Vorgehen der Mitarbeiter beurteilen. Auf welche Aspekte soll diese dabei achten? 
 
Vignette 5: 
Im Pflegeheim der Institution ist seit einigen Wochen ein neuer Bewohner eingetroffen, ein 
exzentrischer Künstler, 65 Jahre alt, der seine Atelierwohnung aufgrund zunehmender dementieller 
Episoden verlassen musste. Bald wird klar, dass ein gewisses Bedürfnis, seine Kunst auszuleben zu 
können, weiterhin besteht. Dies wiederspiegelt sich in einem ständigen Verlangen, künstlerisch tätig 
zu sein. Der Mann stellt die Pflegenden mit diesem Wunsch sowie seiner stark ausgeprägten 
Individualität zwar immer wieder vor gewisse Herausforderungen, wird ansonsten von den 
Pflegenden als ein auf sich bezogener, einzelgängerischen, relativ ruhigen Heimbewohner 
beschrieben, der ein eher zurückgezogenes Heimleben zu führen scheint. Seit kurzem ist der Mann 
nun kaum mehr von seiner Idee abzubringen, im Hobbyraum des Pflegeheims ein kleines Atelier 
einrichten zu wollen, wo er seinem Bedürfnis, künstlerisch wirken zu können, nachgehen könnte. 
Dieses Bestreben, welches einiger Umstrukturierungen bedürfte, wird von einigen Mitbewohnerinnen 
und -bewohner unterstützt; die Mitarbeiter allerdings haben mit Blick auf Personalplanung und 
längerfristige Konsequenzen Bedenken. Wie soll die Leitung des Pflegeheims diese Situation 
beurteilen? 
 
Vignette 6: 
Prof. M. – ebenfalls Mitglied der Expertengruppe – ist eine anerkannte Forscherin im Bereich 
Migräne- und Schmerzforschung. Sie berichtet, sie habe kürzlich an einem Kongress von einer neuen 
klinischen Studie gehört, innerhalb welcher ein vielversprechender Wirkstoff getestet wird. In dieser 
Studie wurde auch ersichtlich, dass der Wirkstoff Verdauungsstörungen hervorrufen kann, die sich 
normalerweise mit einer längeren Einnahme verflüchtigen. Sie ist von den Studienerstellern direkt 
angesprochen und gefragt worden, ob Sie zusätzliche Patienten für die Studie rekrutieren könne. 
Nach der Rückkehr vom Kongress trifft sie in ihrer Sprechstunde auf Frau P., eine 45-jährige Patientin, 
sozial eingebunden, die seit ihrem 35. Altersjahr unter regelmässig wiederkehrenden Migräneanfällen 
leidet. Diese verunmöglichen es ihr zuweilen, ihren privaten wie auch beruflichen Verpflichtungen 
nachzukommen. Prof. M. informiert Frau P. routinemässig über das Studiendesign, worauf Frau P., 
von der Idee sehr angetan, sich einen Eintritt in die klinische Studie überlegt. Prof M. ist sich sicher, 
dass Sie aufgrund ihrer Kontakte Frau P. einen Platz in der Studie verschaffen könnte. Sie fragt die 
Expertengruppe, welche Informationspflichten Sie als „Schnittstelle“ zwischen Patientin und 
Studienteam habe. Auf was soll die Expertengruppe bei ihrer Antwort achten? 
 
Vignette 7: 
Für das zehnjährige ADHS-Kind Peter, bei dem eine Therapie mit Ritalin bislang kaum Besserung 
gebracht hat, gibt es die Möglichkeit eines Eintritts in eine klinische Studie, in der eine neue 
pharmakologische Substanz mit grossem Potential getestet werden soll. Das Studiendesign sieht vor, 
dass Peter regelmässig diese neue Substanz erhalten soll und im Verlauf der Studie fMRI-Scans 
unterzogen würde, um einfache Aufgaben im Scanner zu lösen. Dies natürlich nur auf der Grundlage, 
dass die medikamentöse Therapie greift, da ansonsten die 20-minütige Aufgabe im Scanner aus 
ärztlicher Sicht Peter nur unnötig belasten würde. Die Eltern werden mit folgenden Informationen 
versehen: eine Angabe über die potentiellen Nebenwirkungen der Substanz, die Freiwilligkeit des 
Eintritts in diese Studie, sowie die Möglichkeit, jederzeit und ohne Angabe von Gründen aus der Studie 
austreten zu dürfen, ohne dass ihm daraus Nachteile für die sonstige Behandlung erwachsen. Nach 
Einwilligung der Eltern und Beginn der Studie verbessern sich Peters Konzentrationsfähigkeiten. Im 
fMRI-Scan stellen die Ärzte jedoch dann eine Anomalie im Bereich des Frontalhirns fest, hervorgerufen 
allenfalls durch eine frühkindliche Hirnblutung. Nun wird diskutiert, ob Peter besser von der Studie 
ausgeschlossen werden soll, weil die Aussagekraft der Studie beeinträchtigt werden könnte. Auf 
welche Aspekte soll die Expertengruppe bei der Untersuchung dieser Sachlage achten? 
 
 
 
 
 
120
Clinical & ethical aspects of modulating behaviour and affect through DBS  Ineichen 2016
Selected Vignettes (in English; translation has not been reviewed (i.e. no back-translation has been 
performed)): 
Vignette 1: 
 
Dr. P, an experienced oncologist in hospital X has previously received several offers from various other 
hospitals. So far, he always declined these offers because of his relatedness to his hospital and due to 
his housing situation. However, for some time, internal disagreements between him, as a director of 
the oncology unit, and the clinical director, emerged. They concern student-based education 
modalities, patient-oriented information requirements and the set-up of a palliative care unit towards 
which Dr. P. has a critical stance. Since the untimely death of his wife, Dr. P. is even more engaged 
towards the patients in his unit. Simultaneously, his skepticism towards innovation increased. This 
resulted in several conflicts with other senior physicians. Negotiations with the executive board of the 
hospital and the other senior physicians regarding the mentioned issues are currently underway. 
Among other things, the clinic director is considering whether Dr. P. should be dismissed due to the 
disturbed harmony within the hospital and the lack of consensual procedures. How should the clinic 
management evaluate this situation?  
 
 
Vignette 3: 
Miss J., a middle-aged patient has to undergo surgery following ankle injury. Although being a routine 
operation, the senior surgeon is performing the surgery because of insurance modalities. The day 
after surgery, the exit interview takes place in the presence of the senior surgeon and the nurse. The 
senior physician explains the importance of thrombosis prophylaxis and the procedure of 
subcutaneous heparin-injection by means of a thin needle, similar to insulin self-application. Four 
days after having left the hospital, the patient is transferred to the hospital for emergency medical 
treatment due to respiratory dysfunction and cardiac arrhythmia. Immediately, a pulmonary 
emoblism is diagnosed. The emergency doctor assumes an insufficient thrombosis prophylaxis being 
the cause for the lung embolism. Subsequent enquiries revealed that the patient apparently was 
insecure regarding the procedure of heparin-injection. A subsequent discussion with the senior 
physician revealed no clarification of the situation. Usually the nurse explains the thrombosis 
prophylaxis. In the current situation however, the senior physician apparently has taken over this 
task. The clinic management now has to examine the case and has to evaluate the course of action of 
the personnel. On which aspects should they focus? 
 
Vignette 5: 
A 65 years old eccentric artist has been admitted to a nursing home as a consequence of increasingly 
frequent episodes of dementia. It quickly becomes clear that there is still a need for him to express 
himself through his passion for art, particularly evidenced by a permanent mentioning of his desire. 
Even though the handling of the artist often was challenging for the nurses due to his distinctive 
personality and his desire for artwork, he otherwise is described as a solitary, introverted and 
relatively calm home resident. Recently, he pushes forward the idea of establishing a studio in the 
hobby room of the nursing home in order to live out his desire for artwork. Some of the other 
residents support this idea. However, as the construction of a studio would imply several 
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Selected Vignettes (in English; translation has not been reviewed (i.e. no back-translation has been 
performed)): 
Vignette 1: 
 
Dr. P, an experienced oncologist in hospital X has previously received several offers from various other 
hospitals. So far, he always declined these offers because of his relatedness to his hospital and due to 
his housing situation. However, for some time, internal disagreements between him, as a director of 
the oncology unit, and the clinical director, emerged. They concern student-based education 
modalities, patient-oriented information requirements and the set-up of a palliative care unit towards 
which Dr. P. has a critical stance. Since the untimely death of his wife, Dr. P. is even more engaged 
towards the patients in his unit. Simultaneously, his skepticism towards innovation increased. This 
resulted in several conflicts with other senior physicians. Negotiations with the executive board of the 
hospital and the other senior physicians regarding the mentioned issues are currently underway. 
Among other things, the clinic director is considering whether Dr. P. should be dismissed due to the 
disturbed harmony within the hospital and the lack of consensual procedures. How should the clinic 
management evaluate this situation?  
 
 
Vignette 3: 
Miss J., a middle-aged patient has to undergo surgery following ankle injury. Although being a routine 
operation, the senior surgeon is performing the surgery because of insurance modalities. The day 
after surgery, the exit interview takes place in the presence of the senior surgeon and the nurse. The 
senior physician explains the importance of thrombosis prophylaxis and the procedure of 
subcutaneous heparin-injection by means of a thin needle, similar to insulin self-application. Four 
days after having left the hospital, the patient is transferred to the hospital for emergency medical 
treatment due to respiratory dysfunction and cardiac arrhythmia. Immediately, a pulmonary 
emoblism is diagnosed. The emergency doctor assumes an insufficient thrombosis prophylaxis being 
the cause for the lung embolism. Subsequent enquiries revealed that the patient apparently was 
insecure regarding the procedure of heparin-injection. A subsequent discussion with the senior 
physician revealed no clarification of the situation. Usually the nurse explains the thrombosis 
prophylaxis. In the current situation however, the senior physician apparently has taken over this 
task. The clinic management now has to examine the case and has to evaluate the course of action of 
the personnel. On which aspects should they focus? 
 
Vignette 5: 
A 65 years old eccentric artist has been admitted to a nursing home as a consequence of increasingly 
frequent episodes of dementia. It quickly becomes clear that there is still a need for him to express 
himself through his passion for art, particularly evidenced by a permanent mentioning of his desire. 
Even though the handling of the artist often was challenging for the nurses due to his distinctive 
personality and his desire for artwork, he otherwise is described as a solitary, introverted and 
relatively calm home resident. Recently, he pushes forward the idea of establishing a studio in the 
hobby room of the nursing home in order to live out his desire for artwork. Some of the other 
residents support this idea. However, as the construction of a studio would imply several 
restructuring work and due to staff planning and potential long-term consequences, the personnel is 
hesitant regarding this idea. How should the management of the nursing home evaluate this 
situation? 
 
 
Vignette 6: 
Professor M., a member of the expert committee, is a renowned scientist in the field of migraine and 
pain research. She reports that she recently attended a congress, where a new clinical study testing a 
promising drug for migraine has been presented. In this presentation of the study, it was mentioned 
that the drug might induce side-effects including digestive dysfunctions. However, these normally 
disappear during long-term use. Prof. M. has been asked by the study director, whether she would be 
able to recruit patients for the study. After the return of the congress, a 45 years old patient was 
reported to Prof. M. for consultation. Miss P., the patient, is a socially engaged person suffering since 
the age of 35 from recurrent, regularly appearing migraine. Miss P. is often unable to work and to 
take care of her personal duties due to the re-emerging migraines. Prof. M. informs the patient 
routinely about the study design. Showing great interest in the study, the patient considers entering 
it. Prof. M. is confident to be able to secure a spot in the study because of her contacts to the study 
director. She now asks the expert committee regarding her information requirements between 
patient and study-team. On which aspects should the expert committee pay attention? 
 
Vignette 7: 
Peter, a 10 years old patient suffering from ADHD for whom a therapy including Ritalin has largely 
failed, would have the possibility to enter a clinical study testing a new pharmacological compound 
with great potential. The study design envisages a regular intake of this new substance combined 
with fMRI-scans during which Peter is supposed to solve a simple task. The 20-minutes fMRI task is 
only permissible from a medical point of view, if the pharmacological therapy shows beneficial 
effects; otherwise, the procedure would be an unnecessary burden for Peter. The parents are provided 
with the following information: details on possible side-effects of the drug, the voluntariness of study 
entrance and the possibility to quit the study any time without the need of stating reasons and with 
no disadvantages with respect to other medical treatments. After parental approval the 
concentration abilities of Peter improve. In the fMRI-scan the physicians however detect a 
malformation situated in the region of the frontal brain, possibly caused by an early childhood 
cerebral hemorrhage. Now the debate concerns whether Peter should better be excluded from the 
study because of impairment of the study’s conclusiveness (significance/validity of the study). On 
which aspects should the expert committee pay attention when investigating this situation? 
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Outlook
The immense advances which were achieved in neuroscientific research and therapy together with 
the incredible public awareness of the field substantiate neuroscience as a leading discipline at the 
interface between medicine and natural science. Undoubtably, such a stance also bears the danger of 
distraction from challenges neuroscience is confronted with. Challenges include the anticipated un-
derstanding of the functioning of complex living systems together with the causes and mechanisms 
of neurological and psychiatric disorders. Given these inherent challenges and limitations, any (cli-
nical) neuroscientist knowing about the often easily and rapidly sparking euphoria emanating from 
preliminary research results or treatment successes has to be able to take both a critical and humble 
view all at once. Like in no other area of medicine, self-criticism and humility are leading personality 
traits.
Notable is one strain of research which is currently in progress. We are in the process of investiga-
ting on the electric field expansion based on a physics-informed theoretical model which takes into 
account regional anatomical and physiological characteristics. By making a statement about the gene-
ral shape and size of the electric field in tissue we claim to being able to contribute to the question of 
how to minimize side effects and complications. Hence, combined with the translation of the instru-
ment for measuring moral behavioural changes, enriched with carful normative reflection, we tackle 
the issue of behavioural and personality-related side-effects from three different angles, which again 
reflects the nature of DBS as a whole, a truly multidisciplinary journey.
At the end I hope I have succeeded in showing that in the process of evaluating interventions into 
the brain partly resulting in personality-changes, a theoretical and empirical understanding of such 
changes is indispensable. In summary, instead of metaphysical thought-experiments, more empirical 
research is required to better understand how interventions into the central nervous system can result 
in feelings of alienation, inauthenticity and complex personality changes and how one is able to help 
those patients. It is important to appreciate that deep brain stimulation is as much a therapy as a 
tool of discovery, and to secure the resources that will allow us to develop treatments and imagine 
next-generation hypotheses to serve patients now and in the future (Fins, J. J., Mayberg, H. S., & 
Schlaepfer, T. E. (2011). FDA Exemptions: The Authors Reply. Health Affairs).
I end this cumulative dissertation by quoting Montogmery (Montgomery Jr, E. B. (2010). 
Deep brain stimulation programming: principles and practice):
“At the time of neurobiological hegemony in the construction of models of neurological and 
mental disorders in particular, it may be the critique that careful analysis can bring to this 
modeling process and the refusal to abandon alternative explanatory constructs that may be 
philosophy’s most valuable contribution”.
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